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IMPORTANT CLINICOPHARMACOLOGICAL 
ASPECTS OF CAPTOPRIL
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With a brief description of the physiological role of the renin-angiotensin-aldosterone 
system in the regulation of blood pressure the most important clinicopharmacological 
aspects of the converting enzyme inhibitor, captopril, is outlined. Hemodynamic and 
humoral effects, pharmakoinetics, indications, contraindications, dosage, side effects, 
drug inractions and usage in diagnostic procedures of captopril is described. The pos­
sibility of captopril therapy in children is also discussed.
Keywords: renin-angiotensin-aldosterone system, regulation of blood pressure, 
converting enzyme inhibitor, captopril, captopril therapy in children
Captopril was the first antihypertensive agent to act through the inhibition of 
angiotensin converting enzyme (ACE) and proved to be suitable for human 
use. The role of renin-angiotensin system in the physiological and pathologi­
cal regulation of blood pressure is more or less known. Renin — a peptidase 
enzyme — is produced in several tissues (the juxtaglomerular apparatus of 
kidney, salivary gland, placenta, CNS, etc.) of the organism. In patho- 
mechanism of hypertension renin has distinguished role at two sites; i.e. 
in the kidney and in the CNS. The polypeptide angiotensinogen, synthetized 
in the liver (and also in certain cells of CNS) is converted by renin to the 
decapeptide angiotensin-I which is transformed by ACE to the effective octa- 
peptide angiotensin-IE The main effect of angiotensin-II is vasoconstriction, 
and hence increase in total peripheral resistance (TPR) and blood pressure. 
Angictensin-III (a heptapeptide) produced by angiotensinase enzyme from 
angiotensin-II has some effects similar to those of angiotensin-II since it 
significantly stimulates aldosteron production in the glomerular zone of ad­
renal gland. The reabsorption of sodium and water in renal tubuli as well as 
the absorption of sodium in the intestines is increased by aldosteron. As a 
consequence, hypervolemia develops, which, together with the positive ino­
tropic effect of Angiotensin-Ш., results in an increase of cardiac output.
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Angiotensin-П, acting on specific presynaptic receptors at noradrenergic 
synapses both in the CNS and at the periphery, increases the release of 
noradrenaline. Thus it significantly elevates the sympathetic tone which 
further augments the cardiac output and peripheral vascular resistance. 
In addition to these effects, Agil increases also the production of ACTH and 
vasopressin and water-absorption.
Thus, due to the effect of Angiotensin-II on TPR, cardiac ouput and 
plasma volume are also increased, consequently, blood pressure becomes 
elevated.
Apart from angiotensin-I, ACE exerts an effect also on the metabolism 
of bradykinin. By destroying bradykinin, it lowers the plasma concentration 
of this effective vasodilator substance. Bradykinin acts, at least partly, via 
the increase of the production of vasodilator prostaglandins (PGE2). In addi­
tion, ACE may play a role in the metabolism of certain endogenous opioid 
peptides, i.e. it may also destroy the vasodepressor beta-endorphin.
Thus, the renin-angiotensin-aldosteron-bradykinin-prostaglandin-beta-en- 
dorphin system has a profound influence on the actual level of blood press­
ure. In this system ACE plays a central role / 1, 11, 12, 16, 17, 19, 20, 21, 24, 
27, 30, 32/.
1) M ECH AN ISM  OF CA PTO PRIL ACTION
Both the hemodynamic and humoral effects of captopril can be explained by 
the changes brought about by the inhibition of ACE. TPR is significantly 
decreased while the heart rate is either not changed or decreased by captopril. 
The decrease of TPR is mainly the consequence of the decrease in the con­
centration of Angiotensin-II. both in the plasma and the tissue including 
CNS /6, 7, 8, 14, 25, 27, 29, 32, 33/.
Cardiac output is usually increased due to the decrease of “ after-load” , 
however, it may be decreased in patients with hyperkinetic syndrome /47/. 
The renal blood flow is enhanced /22/; the glomerular filtration rate is either 
unchanged or decreased. Plasma aldosteron and vasopressin levels are 
reduced plasma renin activity in enhanced /46, 47/.
Consequently, the urinary excretion of sodium is increased /41/.
Plasma concentration of bradykinin /19, 21, 30/ and that of the vasoac­
tive metabolites PGE2, /30/ are increased either directly by captopril /12/ or 
indirectly by the increased bradykinin level. The role of elevated bradykinin 
and PGE2 levels in the hypotensive effect of captopril is still under discussion 
/12, 30/.
The facilitation of noradrenergic transmission by Angiotensin-II. is 
well-known /20/. Captopril inhibits the pressor response elicited by sym­
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pathetic nerve stimulation. The pressor responses elicited by Agil and nor­
adrenaline are inhibited by chronic captopril-administration /1/. Thus, one 
can assume that pre- and postsynaptic inhibition of vascular sympathetic 
innervation may also play a role in the hypotensive effect of captopril.
It is well-documented that the effect of captopril on CNS renin-angio­
tensin system is a part of the antihypertensive effect /7, 17, 32/. The p ara ­
sympathetic tone, elevated by captopril, may also contribute to the de­
velopment of antihypertensive effect and, in some instances, to the occurrence 
of bradycardia /5, 29, 47/.
Since captopril had a favourable effect in migraine and the plasma 
concentrations of beta-endorphin were elevated by captopril, and the anti­
hypertensive effect of captopril could be inhibited by naloxone in animal 
experiments it was hypothetical that its effect on endogenous opioid mecha­
nisms may play a role alsóin the antihypertensive effect /11, 24/. However, 
the experiments carried out in hypertensive patients do not support this 
theory /47/.
Summarizing the data one can conclude that captopril potently decreases 
blood pressure both in high- and normoreninemic hypertension, and in 
some cases even in low-renin hypertension. Furthermore since its antihyper­
tensive effect does not show a strict correlation with the effect on plasma 
ACE, it is assumed that other mechanisms may also be involved in its 
beneficial effect in arterial hypertension. As possible mechanisms the 
increase of vasodilator bradykinin and PGE2 levels, decrease of noradr­
energic neurotransmission, and activation of depressor endogenous opioid 
system might be suggested. Further studies are necessary to clarify the exact 
mechanism of action.
2) PHARM ACOKINETICS OF CAPTOPRIL
In case of oral administration captopril is absorbed rapidly and almost 
completely (75%) from the gastrointestinal tract. Its 30% is bound to plasma 
proteins. The absorption is decreased after meals therefore it is recommended 
to take it before meals. The peak value of plasma concentration occurs 
30-90 minutes after oral administration.
Unchanged captopril is excreted by urine (30-50%) within 4 hours 
after the intake. The rest is rapidly metabolized in the liver (Disulfid- 
dimer, cystein-disulfid-dimer). The half-life of excretion is less than 3 hours 
in healthy subjects but it correlates well with the endogenous creatinine clear­
ance. In case of reduced renal function higher plasma concentrations have 
been observed thus the dosage should be decreased accordingly (see Dosage 
section).
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Captopril is rapidly distributed in the various tissues but it does not 
pass easily the blood-brain barrier. In small amount it is excreted with the 
breast milk and also passes the placenta-barrier /14, 33/.
3) THE IN D IC A TIO N S OF CAPTOPRIL-TREATM ENT
Both in essential hypertension (WHO grades II—III) and severe, accelerated 
hypertension the blood pressure can be effectively decreased by combina­
tions containing captopril. In these combinations captopril can be used to 
supplement the conventional double (beta-blocker plus diuretic, central 
antihypertensive agent plus diuretic, vasodilator plus diuretic) or triple (beta- 
-blocker plus diuretic plus vasodilator, central antihypertensive agent plus 
diuretic plus vasodilator) combinations as 3rd-5th step agent. In patients 
treated previously with diuretics where the renin-angiotensin system is signi­
ficantly stimulated and volume-depletion exists caution should be exercised 
due to the probably increased sensitivity to captopril; therefore, smaller 
dosage (6.25 mg) than the usual is advised with subsequent dose-elevations 
according to the necessity /41 ,43, 44, 45, 46, 47/. Its effectiveness is increased 
in renovascular hypertension, too; lower dosage (6.25-12.5 mg 3 times daily 
with dose-increases if necessary) is required also in such cases; the mono­
therapy is sufficient till the surgical intervention or for treatment of récidivé 
hypertension after the operation /47/. Favourable experiences have also 
been reported in renal-transplant recipients with hypertension /10/.
In hypertensive patients with bronchial asthma or diabetes mellitus 
captopril may substitute the beta-blockers thus it can be applied as a first- 
second choice agent; it does not induce bronchial spasm and does not 
worsen the metabolic impairment in diabetes. The blood levels of lipids are 
not influenced. In monotherapy, captopril does not cause orthostatic hypo­
tension; due to lack of this effect it could be administered in monotherapy 
in elderly hypertensive patients with favourable results /9, 41/. Since the 
antihypertensive effect of captopril appears within 30 minutes, it can be 
effectively applied in hypertensive emergency states; both oral and sublingual 
administration may be advised in a dose of 20 mg /3, 31/.
Captopril lowers the peripheral vascular resistance and the left ventri­
cular filling pressure in patients with heart failure; it can be recommended in 
cases of heart failure refractory to digitalis and diuretic combination /40/. 
It can also be administered in combination with other vasodilators (prazosin, 
dihydralazine). Due to the higher plasma renin activity, greater hypotensive 
effect can be expected in these patients; therefore smaller initial dosage 
(6.25 mg) is advised. The resulting hypotension is well tolerated by the 
patients probably due to the unimpaired cerebral flow. Heart failure caused
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by valvular dysfunction (aortic, mitral), cardiomyopathy, coronary disease 
and also by hypertension responds well to captopril treatment /36, 37, 38, 
40, 45/.
Captopril can be tried for the treatment of primary pulmonary hyper­
tension /25/.
Beside the above diseases, captopril was applied with success in the 
treatment of Raynaud'syndrome, scleroderma (even the renal impairment may 
improve, /39/, \v and idiopathic edema /41/.
4) CONTRAINDICATIONS OF CAPTOPRIL-TREATM ENT
Since captoptil passes the placenta-barrier and causes embryopathy it is 
absulutely contraindicated for the treatment of pregnant hypertensive pa­
tients. It appears also in breast milk therefore it is not indicated for the treat­
ment of lactating mothers. When its administration cannot be avoided (e.g. 
lactating mother with renovascular hypertension refractory to treatment) 
then the nursing should be stopped /14, 33/. Naturally, it is contraindicated in 
patients who are hypersensitive to captopril, in severe leukopenia, thrombopenia, 
in membranous glomerulopathy induced by captopril.
In essential hypertension a daily dose of 75-150 mg divided in 3-4 doses can 
be initiated. Since the maximum antihypertensive effect appears even after 
taking the first dose one does not have to wait for days to increase the dose; 
the requirement should be established by gradual, daily dose-elevations. 
If high renin hypertension cannot be excluded at the start of treatment or 
the patients were previously treated with diuretics then the first dose should be 
quite low (6.25 mg) with close monitoring of blood pressure the subsequent 
dose can be increased (12.5 or 25 mg).
The maximum daily dose is 300 mg; it is not advised to surpass this level 
since the hypotensive effect does not increase but the side effects are more 
frequent and more severe above this dose level.
In case of renal disease the maximum daily dose depends on the 
creatinine-clearence according to the followings:
Creatinine clearance: max. daily dose:
2.31-1.18 ml/sec 300 mg
5) DOSAGE OF CA PTO PRIL
1.15-0.61 
0.57-0.31 
less than 0.29
150
75
37-5
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6) SIDE EFFECTS OF CAPTOPRIL
The following side effects have been reported in the literature: dysgeusia 
(they appear 2-3 months after the start of treatment and disappear sponta­
neously,) allergic rashes, flush, loss of appetite, dryness of mouth, aphtous 
ulceration on the gingiva, vomiting, cholestasis, headache, dizziness, sleep- 
disturbance, paresthesias, rarely palpitation, chest pain, neutropenia, agra­
nulocytosis, thrombopenia. Although infrequently, the values of liver enzy­
mes may be increased. In patients with bilateral renovascular hypertension, 
due to the eliminnation of autoregulation an increase of creatinine level may 
appear which may have diagnostic significance /4/. In renal transplant 
recipients when the artery of transplanted kidney becomes stenotized an 
acute status-worsening may occur upon captopril administration which is 
reversible and may have also diagnostic value (4, 18/. In aldosteron-deficient 
patients captopril may induce severe hyperkalemia /34, 41/.
It should be emphasized that the side-effects appear very rarely in case of 
conventional therapeutic doses (75-150 mg a day). Their survey in the liter­
ature was based on experiences obtained upon administration of the over­
sized initial, significantly higher dosages (400-600 mg a day).
7) DRUG INTERACTIONS
Additive interaction was observed between captopril and several other 
antihypertensive agents (diuretics, adrenergic blockers, vasodilators, central 
alpha-adrenergic agonists) /41, 47/. It potentiates also the antihypertensive 
effect of nifedipine. Indomethacin and other cyclooxygenase inhibitors coun­
teract the antihypertensive effect of captopril. Combined treatment with 
aldosteron antagonists (Spironolacton, K-canrenoate) or potassium-sparing 
diuretics (triamteren, amilorid) may cause severe hyperkalemia and hypad- 
renic symptoms /41/. Symptoms relating to neurological dysfunction have 
been observed in two patients taking both captopril and Cimetidine /2/. 
Lethal Stewens-Johnson syndrome has been reported in a patient taking 
captopril and allopurinol /23/.
8) TREATMENT OF C A PTO PRIL OVERDOSAGE
Hypotension due to the overdosage should be treated with the infusion of 
physiological NaCl solution. In the most severe cases Agil infusion should 
be administered with frequent control of blood pressure. Captopril can be 
dialyzed from the circulation.
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9) DIAGNOSTIC PO SSIB IL ITIE S W ITH CAPTOPRIL
In renovascular hypertension even very low doses elicit significant hypoten­
sion due to the increased effectiveness. Following the oral administration 
of 6.25 mg single dose, blood pressure should be monitored for 3 hours by 
measuring blood pressure at half-an-hour intervals. If hypotension reaches 
or surpasses 50/20 mmHg (systolic/diastolic value) then renin-dependence 
of hypertension is likely, therefore a renovascular pathomechanism can be 
assumed. Captopril stimulates renin release thus it is supposed that if the 
ratio of the renin-activities measured in blood samples drawn from the two 
renal veins 30 minutes after taking 25 mg captopril orally is higher than 
3.0 then it enhances the probability of a succesful surgical intervention /15, 16, 
26/. The renin-stimulation produced by captopril can be demonstrated also 
in the peripheral blood /16/ of patients with renovascular hypertension but it 
cannot be used for the prediction of the success of surgical intervention.
Dynamic renal scintigraphy performed under the influence of captopril 
indicated higher difference between the sides than without treatment; this 
finding has also diagnostic significance /42/.
Primary hyper aldosteronism
In contrast to renovascular hypertension these patients have low plasma 
renin activity and Agil levels. Therefore, the hypotensive effect of captopril 
is very mild or even it cannot be demonstrated. In patients with aldostero- 
noma in the adrenal gland captopril usually does not elevate plasma renin 
activity; it does not decrease the plasma aldosteron level /13/ and does not 
change the blood pressure, either. Patients with mineralocorticoid hyperplasia 
react differently to captopril; high dose of captopril (ioomg single dose) can 
stimulate the plasma renin activity but to a smaller extent than in patients 
with essential hypertension; the developing hypotensive effect is also weaker.
In most cases the adenoma (Conn’s syndrome) and hyperplasia of ad­
renal gland /13,15) can be differentiated by the administration of high dose of 
captopril.
10) PEDIATRIC A PPLICA TIO N
In case of severe hypertension and heart failure captopril can be administered 
with extreme caution /36/. The advised daily dose is 1 mg/kg which may be 
increased to 2 mg/kg. Patients suffering from renovascular hypertension, 
high renin hypertension or a disease accompanied by sodium and volume 
depletion are more sensitive to captopril; the occurrence of the so-called
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“ first dose symptom” (profuse hypotension, collapse) can be expected due 
to the increased antihypertensive effectiveness thus the first dose (6.25 mg) 
should be very low /36/.
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DTPA functional renal camera scintigraphy (DTPA-FS) was performed in 220 
patients with moderately severe and severe hypertension after an initial 7-14-day 
Captopril+thiazide-type diuretic treatment. If, comparing it with the DTPA-FS prior 
to treatment, appearance or increase of a side difference were observed and it was 
also indicated by the clinical picture, nephroangiography was performed. Using this 
method, 15 cases of unilateral, 3 bilateral renal arterial stenoses were recognized, and 
in one case restenosis was diagnosed, in allcases of positive DTPA-FS with Captopril. 
In negative case of DTPA-FS sensitized with Captopril, there was no positive angio­
graphic finding.
The method of DTPA-FS performed under Captopril effect is considered to be 
a simple, harmless, specific out-patient examination for screening genuine renovascular 
hypertension. To perform several angiographies likely to be negative can be avoided 
by this method. The hypotensive effect of Captopril may, at the same time, be a useful 
guide in differentiating patients with renovascular hypertension being suitable most of 
all for surgical intervention or angioplasty.
Keywords: Renovascular hypertension, Captopril functional renal scintigraphy.
Since the introduction of Captopril into the treatment of hypertension, several 
attempts have been made to utilize it for the detection of renovascular hy­
pertension. The trial with the so-called single-dose Captopril has not proved 
to be specific. Atkinson et al. regard the effect of prolonged Captopril treat­
ment of renovascular hypertension as the best indicator of surgical outcome 
/1/.In bilateral renal artery stenosis or in artery stenosis of a solitary kidney, 
administration of Captopril, or particularly its combined administration with 
a diuretic, may produce reversible renal insufficiency /3, 7/.
It was observed by Wenting et al. that if DTPA functional kidney scin­
tigraphy was performed in patients with renovascular hypertension treated 
with Captopril, in one part of them the isotope activity over the kidney 
of a stenotic artery decreased considerably during Captopril treatment /9/.
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After discontinuation of Captopril treatment isotope activity could again be 
detected also in the kidney of stenotic artery.
It seemed advisable therefore to perform the basic DTPA examination in all 
patients with moderately severe and severe hypertension and, subsequently, 
to carry out a repeated DTPA-FS by administering Captopril (Thensiomin ®, 
EGIS), and a thiazidetype diuretic as an initial therapeutic attempt. The 
results of the first series of trials, the selection of patients and the method 
were reported in Orvosi Hetilap (Medical Journal, in Hungarian) /6/.
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PATIENTS AND M ETHODS
Patient were selected from begining of 1985 according to the following criteria: a,moderately 
severe or severe hypertension b,therapy-resistance c,sudden-onset hypertension or worsening of 
hypertension d, abdominal vascular bruit over the kindeys in hypertension.
The basic DTPA-FS was made without treatment or continuing the antihypertensive treatment 
prior to first examination at our outpatient hypertension clinic (considering that these drugs do not 
influence the glomerular filtration of DTPA). After the basic DTPA examination all antihypertensive 
drugs were stopped. Captopril were given all patients in a starting dose of three times 6.25 mg or 
12.5 mg daily. Besides C diuretics were given to all patients to potentiate the effect of C (Clopamid 
10 mg/day or Chlorthalidone 25 mg/day). The next days the dose of C was tailored according to its 
hypotensive effect. The aim of the treatment was possibly to normalise the blood pressure. The 
maximal dose of never exceeded three times 50 mg a day.
The second DTPA-FS was done 1.5-2 hours following the last dose of C after 14 days treatment. 
The DTPA-FS was made with 185 MBq Tc9,m DTPA, useing 9100 typ gamma-camera (GAMMA- 
Hungary) and MB9101/A typ. computer (GAMMA-Hungary). After iv. injection of T c"m-DTPA 
analoge serial scintiscans were made in the o -io th seconds (perfusion phase) and in the 3rd and 
J2th minutes (renographic phase). The first 20 pictures o f the time-activity curves were registrated 
with 0.5 second intervals then the next 50 pictures with 20 seconds intervals. The time activity cur­
ves of perfusion and secretion phase were analysed separately with ROI technic. The difference of 
amplitudes, the change of intrarenal transport of DTPA, the shift of Tmax. and prolongation of 
half-time was assesed. To eliminate the difference originating from the size-difference of the kidneys 
we calculated an activity/area time-activity curve too. Increase of side difference (i.e decrease of acti­
vity of one side) greater then 50% and shifting of Tmax to the right was considered to be positive. 
Decrease of activity and shifting to the right on both sides-concomitted with rise of serum-creatinine- 
was the signs of bilateral renal artery stenosis. In this case the C treatment was stopped.
ÿcrionephroangiographics were made by the Seldinger-method. The renal function (serum- 
creatinine) was controlled in all cases of C treatment o f the 3rd or 5th day. The patients were admitted 
to our programme protocol with their informed consent.
RESULTS
DTPA-FS sensitized with Captopril has been performed in 220 patients since 
September 1984. The results were considered to be positive with an increase 
of difference in the levels of activity shown in the analogue scintiscans or 
with the appearance or increase of side difference between the two kidneys in 
the time activity curves (i.e. decrease of activity of one side).
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Table I. summarizes the data of all patients examined and treated with 
Captopril.
Table II. shows the result of the completed examinations. Positive angio­
graphic findings were obtained in all 19 positive DTPA-FS examinations 
sensitized with Captopril.
Table 1
DTP A functional scintigraphy performed under Captopril effect
No. of patients: 220 (83 males, 137 females)
Mean age: 48.3 (17 -76 years)
Mean blood pressure 
Before Captopril:
(S.D. ±
179-7/п з .З  mm Hg 
24.4/ 13.4 mm Hg)
After Captopril:
(S.D. ±
150.8/ 93.4 mm Hg 
21.7/ 12.1 mm Hg)
Table II
DTP A functional scintigraphy with Captopril
DTPA-FS with Captopril 
n — 220
Nephroangiography 
n =  87
Positive: 19* Positive: 19*+
* 15 unilateral, 3 bilateral renal arterial stenosis, 
I restenosis
+ significant renal artery stenosis
No significant stenosis on angiograms were obtained using a negative 
DTPA-FS sensitized with Captopril.
It was also notable that the appearance or the mild degree of increase of 
a side difference sometimes observed in unilateral renal hypoplasia associated 
with parenchymal damage could be well differentiated from the fairly marked 
degree of positivity due to stenosis of the renal artery.
Side-effect appeared only in one case out of 220 examinations. The 
toxic maculopapulous skin change induced by the drug completely disap­
peared within some days after stopping the drug. Studying the blood pressure 
response during drug administration, it could be stated that the singificant 
decrease in blood pressure due to Captopril was not specific for the renovas­
cular hypertensive patients, since a considerable part of patients with essential 
hypertension showed a similarly markedly reduced blood pressure of the 
same degree in response to the combined Captopril+thiazide type diuretic 
treatment. For illustration two cases are presented.
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Figure I. shows the results of DTPA-FS examination of a 35-years-old 
female patient prior to, and during a 3-day and 14-day Captopril treatment.
In Figure 2. time activity curves were plotted which were naturally made 
parallel to the analogue scientiscans. It was revealed by both methods that 
following a 14-day Captopril treatment, the Tc” m DTPA excretion (3 min 
and 12 min) of the right kidney, decreased fairly markedly, namely it was 
practically undetectable. The perfusion (blood supply) of the right kidney is 
maintained (o-ios). The patient’s blood pressure decreased from the earlier 
fairly high level to normal following the first Captopril dose and remained 
at this level throughout the whole Captopril treatment.
Before Captopril After 3days C After Kdays C
Fig. 1. Mrs. Gy.F. 37 years old woman. Analoge scintiscans. After 14 days C treatment no isotope 
activity in the right kidney in the glomerular phase
Fig. 2. Mrs. Gy.F. Time-activity curves. After 14 days C treatment the right kidney does not excrete
DTPA
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Figure 3. shows the nephroangiogram of the same patient having con­
siderable stenosis of the right renal artery.
Figure 4 shows the analogue DTPA-FS scans of a male patient (42 years 
old), while Figure 5 the time activity curves. It is well discernible that the 
glomerular function of the right kidney -  i.e. its isotope density -  decreased 
significantly. There is no significant side-difference prior to C treatment on 
the time-activity curves of the two kidney’s. The nephroangiogram of the 
same patient is presented in Figure 6. In the right renal artery there is a 
marked stenosis. The patient’s blood pressure decreased from the earlier very 
high (190/125 mm Hg) to the normal (125/80 mm Hg) level.
Fig. 3. Mrs. Gy.F. Nephroangiography. Right renal artery stenosis
Before Captopril After Kdays C
12mm
Fig. 4. Mr. M.K. 42 years old man. Analoge scintiscans. After 14 days C treatment there is no activity 
over the right kidney in the glomerular phase
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Fig. 5. Mr. M.K. Time-activity curves. Before Captopril there is no significant side-difference. 
Tmax of the right kidney is only slightly shifted to the right. After C the right kidney does not excrete
DTPA
Fig. 6. Mr. M.K. Nephroangiography. Right renal artery stenosis
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DISCUSSION
In view of our investigations, it appears that the present examination proce­
dure helps in detecting the haemodynamically significant renal arterial 
stenosis. That means that genuine renovascular hypertension can possibly be 
differentiated from renal artery stenosis associated with essential hyper­
tension.
It can be supposed that Captopril stops glomerular function only in 
haemodynamically significant stenoses. In this case the increased tone of 
the efferent arteriola is regulated by the intrarenal renin-angiotensin system. 
It is indispensable for maintaining the effective filtration pressure, compen­
sating the poststenotic decrease of arterial pressure. Inhibition of the intra­
renal renin-angiotensin system by Captopril may thus result in a considerable 
decrease in glomerular filtration in the kidney of stenotic artery. This is 
primarily not due to the reduced blood pressure but to the inhibition of 
the intrarenal renin system /2, 4, 8/. Diuretics potentiate this effect of Cap­
topril partly by stimulation the renin system and partly by decreasing the 
angiotensin-II sensitivity of the mesangial cells.
To our opinion several days of Captopril treatment is needed to the 
assessment of C induced changes on renogramms, as it is shown on Figure 1 
and Figure 2 of our case presentation. The specific effect of C is a cummu- 
lative one on the glomerular filtration of a kidney with stenotic artery. It is 
not in contrast to the observation of Geyskes et al. /3/. The longer use 
of C makes this diagnostic test more sensitive and specific. In agreement 
with Atkinson et at. the long terms use of C in renovascular hypertension is a 
better predictor of the surgical outcome than the single dose or short-term 
treatment /1/.
Renal artery stenosis disclosed with nephroangiography together with 
negative Captopril DTPA-FS is considered not to be renovascular hyper­
tension, as it was found by some patients of Wenting et al. /9/. In this case 
essential hypertension and a given degree of renal artery stenosis is coex- 
sisting, or a former renovascular hypertension is transformed to a fixed 
accelerated hypertension. In this occassions surgical intervention or PTA will 
esrolve only the stenotic lesion but the hypertension will persist.
DTPA camera nephrography performed under the effect of Captopril 
is a relatively simple, fairly sepcific, inexpensive and well reproducible 
method imposing a small radiation load on the patient for the detection of 
renovascular hypertension. Using this method, the number of expectedly 
negative nephroangiographies can be considerably reduced in hypertensive 
patients. The examination can be carried out on an out-patient basis, too. 
It seems advisable to test and control renal functions (and to eventually 
reveal a bilateral renal arterial stenosis) before and after Captopril treatment 
is started.
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The effectiveness of captopril, the dose-response relationships, the influence of 
diuretics on the effective dose of captopril, the possible combinations of captopril 
with other antihypertensive agents as well as the clinical value of monotherapy and 
combined treatment have been investigated in 48 patients with hypertension. This 
paper summarizes the data obtained in the course of several special clinico-pharmaco- 
logical studies during a 4 year period (1982-1986). Captopril proved to be an anti­
hypertensive agent with a wide therapeutic spectrum. As a single agent it was used 
especially in geriatric cases. Of the antihypertensive agents, diuretics have been com­
bined with captopril most frequently but it has been concurrently administered with 
practically all the other antihypertensive drugs. Captopril appeared to be a safe agent 
without significant side effects. An increase in serum potassium levels by captopril 
were seen not infrequently; its advantages, disadvantages, prevention and mechanisms 
have been dealt with in detail.
Keywords: captopril, antihypertensive treatment, inhibition of converting enzyme
Captopril is a new tool in the treatment of hypertension /1, 3, 13/ and the 
prospects of its application are getting broader /4-12, 14-32/. Inhibitors 
of converting enzyme, such as Captopril can be used in the renovascular, 
malignant and accelerated “ high renin” hypertension as well as in the 
“normal renin” and “ low renin,” moderate and mild hypertension /1-32/. 
Beside broad applicability other advantage of Captopril is that it can be 
combined with almost all the other antihypertensive agents.
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PATIENTS AND M ETHODS
A total of 48 patients was treated with Captopril (Capoten, Squibb, Tensiomin EGIS) during the 
4 year period of acute and chronic studies (1982-86). Special clinico-pharmacological examinations 
were performed in all cases beside the measurement of blood pressure: endocrine changes and specific 
renal functions as well as the interaction of posture and the effects of glucose-loading were studied. 
Blood pressure was measured 10 times daily in supine and standing positions in 10 cases; in the 
other cases 3 times daily. Captopril was administered first in cases with essential hypertension refrac­
tory to the “standard triple therapy” (diuretic plus vasodilator plus beta-blocker); later in moderate 
and mild hypertension, heart failure, chronic renal failure, geriatric cases, with hypertension or 
/and edema, idiopathic edema and hepatic cirrhosis with ascites. “Follow up” studies were usually 
performed, the results of which were reported in our earlier publications /9 -26/, The daily dose 
o f Captopril was 12.5-450 mg divided in 3 doses.
In most cases 2.5-3.5 mg/kg/100 ml GFR captopril was administered but this dose could be 
reduced to one-third by the combined administration of a diuretic /13/. Extreme dosages were 
applied only exceptionally i.e. 100 mg/16 ml GFR daily /26/. As a diuretic chlorthalidon (Flygroton, 
Ciba-Geigy-Biogal) clopamide (Brinaldix, Sandoz-EGIS), dihydrochlorothiazide (Hypothiazid, 
Chinoin), muzolimine (Edrul, Bayer) and piretanide (Arelix, Hoechst) were used. Of the beta- 
blockers, metoprolol (Betaloc, Astra-EGIS) Oxprenolol (Trasicor, Ciba-Geigy-Chinoin), pindolol 
(Visken, Sandoz -EGIS) and propranolol (Stobetin, Spofa) were administerd. Clonidine (Hemiton, 
VEB, Arzneimittelwerk), hydralazine (Nepresol injection, Sandoz, Depressan, Intermed) and 
nifedipine (Corinfar, Intermed) were also administered in the combinations. Considering the various 
protocols and research purposes of our investigations performed in the last 4 years, in this paper 
the main directions of our clinico-pharmacological studies are outlined by the presentation of 
representative cases beside the summarized blood pressure statistics. Methods of blood pressure 
measurements, classification of hypertension, routine laboratory and R1A hormone examinations 
as well as of the specific renal and other studies are listed in detail in our previous publications /9-26/.
RESULTS
I. The effectiveness o f Captopril in monotherapy
First of all, the effective dose of Captopril producing a 10% decrease in 
blood pressure (BP) was established by gradually increasing the dose at 
4-5 days’ intervals. In 18 patients, the daily mean value of BP was decreased 
by 183428 mg Captopril from 181 d=5/i 15±3 mmHg to 15945/103 mmHg 
(by I i± l% ) (p less than 0.001) (Fig. 1). The heart rate was not changed at 
the same time (7542 and 77±2 beats/min).
The BP measured in supine position was decreased from 17945/11643 
mmHg to 15745/103 + 3 mmHg (p less than 0.001) at 8 a.m., from 1864=7/ 
119 ± 3 mmHg to 16145/104+3 mmHg (p less than 0.001) at 4 p.m., from 
17945/1 1443 mmHg to 15745/10243 mmHg (p less than 0.001) at ю p.m. 
The changes in blood pressure in upright position were similar; see. Fig. 2.
In some cases very high doses of Captopril were required for the effective 
reduction of the BP. In one of the cases, 300 mg daily dose of captopril 
induced an only small and transient decrease in BP. (Fig. 3). There was a 
patient whose BP was hardly influenced even by daily 400 mg Captopril;
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some effect was observed only for 6 hours out of the 24 (from 4 p.m. till 
10 p.m.) Fig. 4).
In another case the effect could be considerably increased only by 
raising the daily dose from 75 mg to 225 mg (Fig. 5). It was evident from these 
observations that the patients refractory to beta-blocker+diuretic-Fvaso­
dilator combination may also be refractory to Captopril. Apparently, in 
some cases the cessation of resistance was partly dependent on the dose of 
Captopril.
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Fig. 1. Captopril elicited statistically significant decrease in systolic and diastolic blood pressure 
Addition of a diuretic potentiated the antihypertensive effect of Captopril
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Diuretic
П Control
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Fig. 2. Diurnal variation of blood pressure in standing position (pretreatment control) and during 
the administration of Captopril without and with diuretics
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Fig. 3. Transitory small hypotensive effect of Captopril administered in daily 300 mg doses in a patient 
refractory also to the combination of a diuretic, betablocker and vasodilator. (Not indicated in the 
Figure: combination of Captopril and a diuretic resulted in a significant decrease in blood pressure
Fig. 4. The effect of Captopril monotherapy (dashed lines) and Captopril plus diuretic combination 
(drawn line) in a patient refractory to the combination of a diuretic, betablocker and vasodilator. 
Daily 75 mg Captopril administered alone is ineffective; daily 150—400 mg Captopril have some 
hypotensive effects. Daily 150 mg Captopril combined with 50 mg chlorthalidon (Hygroton) effecti­
vely decreases blood pressure. The effect is slightly more pronounced in the upright position
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Fig. 5. Treatment of a patient refractory to antihypertensive drugs with gradually increasing Captopril 
doses. It can be seen that 1. 75 mg daily dose (divided in 3 doses) is less effective than 225 mg; 
2. the effect is not more pronounced in the standing position (dashed lines) than in recumbency 
(drawn line); 3. the effect is greater in the first 8 hours than during the rest of the day
II. Increase o f the effectiveness o f Captopril by diuretics
On the basis of our preliminary experiences /13/, we used approximately 
one-third dose of Captopril in combination with diuretics. In 18 cases, BP 
measured in upright position was decreased from i50±5/i04±3 mmHg to 
141  ^ 5/96d-4 mmHg, at 8 a. in., from i52±5/i04±3 mmHg to ^ ± 5 /9 4 ^ 3  
mmHg at 4 p.m., and from 1 51 ±5/101 ±3 mmHg to i34±6/94±4 mmHg at 
10 p.m. (p less than 0.01) (Fig. 2). Although Captopril alone did not enhance 
the small orthostatic decrease in BP its hypotensive effect in combination 
with a diuretic was more pronounced in the upright than in supine position 
(Fig. 2). Diuretics may increase the sensitivity to Captopril and may suspend 
the resistance to it. In one of the cases where 400 mg Captopril was ineffec­
tive and the patient did not react to diuretics either, 150 mg Captopril 
became effective upon simultaneous administration of a diuretic (Fig. 4).
III. Combination of Captopril with diuretics and other antihypertensive
drugs
In one of our patients (Fig. 6, upper part) treated with a combination of 
furosemide, clonidine and hydralazine, hydralazine had to be withdrawn due 
to side effects. Captopril was chosen for replacement. Very low doses 
(12.5-37.5 mg daily) proved to be effective (Fig. 6, lower part). The effective­
ness of individual doses of Captopril in this case are presented in Fig. 7.
One of our young patients had “high renin” essential hypertension (the 
stenosis of renal artery had been excluded by angiography) and was refractory 
to multiple antihypertensive combinations. Although he seemed to be an 
“ uncontrollable” case, a multiple combined therapy including Captopril was
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Fig. 6. In the left upper part o f the Figure: the effect of the treatment of acute hypertensive crisis 
with the combination of furosemide+hydralazine can be seen. At the right side: the effect of triple 
combination. Lower part: the blood pressure was rapidly normalized by changing hydralazine
to Captopril
Fig. 7. Effect of 3 X 12.5 mg Captopril (c Captopril) in the patient presented in Fig. 6. (drawn line: 
in the lying position; dashed line: in the upright position)
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effective. Combination of 75-150 mg Captopril, 50 mg Hygroton, 60 mg 
Trasicor and 4 mg Minipress reduced mean BP by 25 mmHg in standing 
position. BP was decreased twice as much by 1. increasing the dose of 
Captopril to 250 mg (within the combination) or 2. by doubling the dose of 
Minipress and Trasicor (with unchanged Captopril dose of 150 mg) (Fig. 8). 
This is a good example for the utilization of dose-response relationships of 
antihypertensive drugs to suspend refractoriness.
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Fig. 8. Effect of the increase of the dose of the drug within the combination on blood pressure 
in an extremely resistant patient. [Praz=Prazosin (Minipress) CTN-chlorthalidon (Hygroton)
OXP = oxprenolol (Trasicor)]
IV. Captopril in geriatric cases
The usefulness of Captopril monotherapy in geriatric cases is illustrated by 
the data of a representative patient in whom the high blood pressure was 
reduced to normal within a few days of treatment (Fig. 9). Excellent effect 
of combined therapy with captopril is illustrated by Fig. 10.
V. Captopril in idiopathic edema
Captopril was administered in two patients with severe idiopathic edema. 
Definite diuretic and natriuretic effects were observed in both cases. The 
edema was drained of and the demand for diuretics decreased. The hyper­
aldosteronism was ameliorated (Fig. 11).
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Fig. g. Immediate effect (rapid clinical im­
provement) of low doses (2x12.5 mg) of Cap- 
ptopril in a geriatric patient
Fig. 10. Excellent effect of combined antihy­
pertensive treatment with Captopril
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Spirono­
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Fig. 11. Diuretic-abuse (furosemid + verospiron) in idiopathic edema, resulted in hypokalemic
paresis. The clinical syndrome of pseudo-Bartter syndrome appeared and was characterized by extreme 
hyperreninemia and hyperaldosteronism. Diuretic withdrawal and extreme dose of KCI infusion 
restored the normal basic state of idiopathic edema; Captopril corrected the basic abnormality
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Fig. 12. No significant clinical and laboratory effect of Captopril in decompensated hepatic cirrhosis
with ascites
Fig. 13. Endocrine effect of Captopril in hypertensive patients: plasma renin activity was elevated
and plasma aldosterone was decreased
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VI. Captopril in hepatic cirrhosis
This was the only disease where disadvantageous experiences were acquired 
with Captopril. It was applied to two elderly patients with pulmonary 
emphysema and alcoholic cirrhosis accompanied by ascites. Although a natri­
uretic effect could be demonstrated in one of the cases the diuresis was not 
changed and the ascites was not decreased, either. (Fig. 12) Captopril did not 
potentiate the effect of furosemide (Table 1.). In spite of the fact that the 
impaired renal functions were not worsened by Captopril both patients fell 
worse and the patient’s cyanosis of pulmonary origin singificantly increased 
during Captopril treatment. On the basis of these experiences administration 
of the drug was stopped.
table I
Comparison o f parameters o f ion- anil fluid balance and renal function in a case during the administration 
o f a diuretic, diuretic + captopril, or diuretic + Spironolacton
Therapy Days Urine
ml /day
G F R
ml/min
Cosm
ml/min
c HiO
ml/min
Urine Nu 
mmol/day
Urine  К  
m m o l/d ay
„  . Na 
Ur,ne к
6 4 0  m g  
F u r o s e m i d
3 3 0 6 7  ± 2 3 3 4 6 ±  8 2 .3О ± 0 . 2 0 — 0 . 1 4 ± 0 . 3 0 2 1 4 .4 4 1 4 . 5 7 0 .6 ±  1 2 .7 3 - 3 4 0 . 7
6 4 0  m g  
F u ro s e m id  +
3 7 - 5  m g  
c a p t o p r i l
2 2 3 7 5 ± 2 7 5 51 ± « 3 2 .3 7 Ü .45 -0 .7 3 i i .25 4 5 .6 ±  0 . 6 4 4 . 8  4  7 . 7 1 . 0 4 0 . 2
6 4 0  m g 
F u ro s e m id  +
5 5 0  m g  
S p iro n o la c to n
3 3 7 5 0 ± 2 6 o 5 1 ±  11 3 -0 4 ± o . i  5 — 0 .4 4 * 0 . 1 4 3 3 2 .4 4 5 8 . 2 5 0 . 0  4  3 . 6 6 . 6 4 0 . 7
DISCU SSIO N
According to our results and data from the literature Captopril has proved 
to be a broad-spectrum antihypertensive agent. It decreases the mean arterial 
blood pressure by approx. 12%; does not cause orthostatic hypotension and 
does not increase the heart rate. Its great advantage is that the physiological 
counter-regulatory systems -  first of all the angiotensin-aldosteron system -  
are not stimulated. Hypokalemia, hyperglycemia, disturbance of lipid me­
tabolism and depression are not produced. The general feeling of patients 
is not impaired by Captopril, in some cases the mood is elevated to such an 
extent that it may be regarded as euphoria contributing to the improvement 
of the “quality of life” .
Since Captopril does not induce orthostatic hypotension its usage to treat 
patients having cerebral sclerosis, coronary disease or peripheral vascular
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stenosis beside of arterial hypertension seem greatly advantageous. Therefore 
Captopril monotherapy occupies a distinct place in geriatry (Fig. 9). Although 
the captopril monotherapy is relatively safe, to predict its effectiveness is 
difficult and to “ titrate” the effective dose requires time. The application 
of dose-response relationship of Captopril is not so simple in the clinical 
practice since the development of full effect of a given dose requires a 4-5 
days’ administration. Therefore the monotherapy is less used apart the 
aforementioned geriatric cases. On the other hand, diuretics potentiate the 
effect of Captopril to decrease high arterial blood pressure and may suspend 
the resistance to Captopril. Accordingly in two series of our nongeriatric 
patient material, the daily “effective” dose of Captopril by combining it 
with diuretics could be decreased from зс>4±з8 mg to 119^20 mg and from 
210J-66 mg to 85 : 26 mg respectively. The „Captopril-sparing” effect of 
diuretics makes possible to reduce the occurence of the side-effects and to 
administer relatively large doses of Captopril relatively safely when necessary, 
i.e. in the extremely resistent cases.
Captopril may also be used to treat idiopathic edema. As the principle of 
the disease is a bizarre combination of the extreme orthostatic activation of 
renin-angiotensin-aldosterone system and the abuse of this system-provoking 
diuretics (resulting in diuretic-enhancement of the edema) it is understandable 
that the converting enzym inhibitor treatment of idiopathic odema proved to 
be effective (Fig. 1 1 ).
Hepatic cirrhosis was the only disease in which Captopril had dis­
advantageous effects. In one case the diuresis was not increased by Captopril, 
in the other one Captopril seemed even to inhibit the effects of diuretics 
(Fig. 12).
In our hands Captopril had only few side effects. Dysosmia and dysgeu- 
sia were found in 4 cases. Dermatological symptoms occurred in 2 cases. 
In one case with renovascular hypertension edema and heart failure de­
veloped. In 5 cases chronic administration of Captopril was accompanied 
with cough.
Captopril inhibits the enzyme that converts angiotensin I to angiotensin 
II. Due to this plasma renin activity is increased (Fig 13). It is certain that 
the above described mechanism plays a role in the elevation of serum potas­
sium level by Captopril /32/. During long-term Captopril-treatment prog­
ressive hyperkalemia has been observed in paralell with the decrease of 
plasma aldosteron in patients with renal disease while the renal function has 
improved /26/. However, the increase of serum potassium level is rarely 
severe /19/; and even in such cases it could be prevented by the use of the 
ion-exchanger resin (Resonium) /26/. Furthermore, mild increase of serum 
potassium could be advantageous since simultaneous diuretic treatment 
frequently induces hypokalemia /14/.
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Experience with the use of foreign (Capoten Lopirin; Squibb) and Hungarian (Ten­
siomin; EGIS) captopril preparations is reported. It was found that the first dose 
of captopril resulted in a larger blood pressure decrease in hypertensive patients with 
a high blood renin level. A linear correlation was observed between the blood renin 
level before treatment and the captopril induced blood pressure decrease following 
the first dose. Captopril monotherapy lowered the blood pressure effectively without 
significant pulse rate change in patients whose blood pressure was difficult to influence 
with combined treatment containing no captopril. This paper reports on the area of 
indications and side-effects of the drug.
Keywords: captopril, hypertension, renin activity
Captopril was the first orally administered angiotensin converting enzyme 
inhibitor used in clinical practice as a hypotensive agent /2, 4, 6/. Fol­
lowing the favourable experience with foreign drugs (Capoten, Lopirin; 
Squibb) in the treatment of severely hypertensive patients, the manufacturing 
of a captopril containing Hungarian drug, Tensiomin was begun (EGIS 
Pharmaceuticals, Hungary). The present paper reports on comparative 
studies with Tensiomin and Capoten.
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PATIENTS AND M ETHODS
In the first study, 12.5 or 25 mg Tensiomin was administered between 8 and 10 a.m. to patients 
with hypertension of various origins. Five days prior to captopril treatment, the administration 
hypotensive drugs was stopped. Before treatment, a blood sample was taken determine the plasma 
renin activity (PRA). After the administration of captopril, patients were allowed to eat and drink. 
The blood pressure was measured with a sphygmo manometer before 4 hours after captopril treat­
ment.
The next study involved hypertensive patients whose blood pressure could not be adjusted 
satisfactorily through the use of a combined hypotensive drug regimen. Seven patients received 
capoten, while 5 patients received Tensiomin, in doses such that the blood pressure did not exceed 
150/95 mm Hg. Captopril treatment was begun with a test dose (12.5-25 mg) in the clinic; the admi­
nistration of diuretic drugs was stopped at least a week previously. After the desired blood pressure 
had been achieved, the patients were discharged and were subsequently followed up on an out­
patient basis. Following adjustment, of the blood pressure the drug was administered in the same 
dose for 8 weeks, after which the two drug preparations were interchanged.
Blood pressure was measured in a sitting position. Diastolic blood pressure was taken at the 
Korotkoff phase V. PRA was determined by means of a New England Nuclear (Chicago) kit. 
Statistical evaluation was performed with the Student two-tailed t-test and regression analysis. Results 
are given as m eansistandard error (SE).
RESULTS
The results of the first study are given in Fig. 1. The patients were divided into 
two groups. Group I (n = 8) contained patients with PRA levels below 
2 ng/ml/h. The PRA levels in group II (n = 8) were higher than this. The 
patients in group II had slightly higher basal blood pressure values than 
those in group I. In group I 4 patients, and in group II 5 patients received 
25 mg Tensiomin as the first dose. All the others received 12.5 mg. Although
(F irs t  d o se  of tension)
Fig. I. Blood pressure in patients before and after Captopril treatment
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the difference was not statistically significant, it is noteworthy that the blood 
pressure decrease in responde to the first dose was larger in the group with 
the higher PRA level.
Comparison was made by giving a mean pressure (mean pressure-di­
astolic blood pressure-f pulse pressure) /3/, and calculating the percentage 
change relative to this basal value. The difference between the two groups as 
concerns the latter parameter was statistically significant.
When the correlation between the PRA and the percentage change in 
the mean pressure was examined, a significant linear correlation was detected 
both in group I (n 8 ; r +0.66; p<0.02) and in group II (n = 8; r +0.63;
P C O . 0 5 ) .
The correlation was also studied between the basal blood pressure and 
the percentage decrease in the mean pressure. A correlation was not found 
in group I (n = 8; r =+o.44; n.s.), but in group II a significant linear 
correlation was demonstrated (n = 8; r =+o.7o; p<0.05).
Data on the patients participating in the second study are given in 
Table I. In some of the hypertensive patients the treatment was started with 
Capoten, and in others with Tensiomin. So that the average starting blood 
pressures for the two groups should be similar, the data on one patient in 
group I were omitted from the comparison, though they are included in the 
Table. The results are listed in Table II. When we began to use Tensiomin, we 
observed that those patients who received earlier Capoten required more 
Tensiomin for the same blood pressure decrease to be attained.
In the second group the blood pressure adjustment was started with 
Tensiomin, which was subsequently replaced by Capoten. In this case some 
of the patients required lower Capoten doses.
At our suggestion, the manufacturer (EGIS) modified the technology, and 
recently we could find no difference between the efficacies of Tensiomin and 
Capoten. The pulse rate was not altered by Tensiomin or Capoten.
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Table I
Data on patients participating in the comparative study o f  the hypotensive effects 
o f Tensiomin and Capoten
N o . Sex
A g e
( y e a r s )
D i a g n o s i s P r e v i o u s  m e d i c a t i o n B P  ( m m  H g )  
s y s t .  d i a s t .
I . Ö 5 ' Essential Minipress, Dopegyt, 
Hypothiazid
170 — 200 9 5 - n o
2. О 4 4 Essential 
Diabetes mellitus
Dopegyt,
Minipress
180 -190 1 0 0  I I O
3 - î 3 4 Essential Viskaldix,
Sanegyt
165 — 190 100 — 115
G
ro
up
 1
4 - О 4 1 Malignant Brinaldix, Dopegyt 
Minipress
I 9 0  -  2 I 5 î 15 120
5 - ? 5 3 G lomeru lonephritis 
(membranoprolif.)
T rasicor, 
Hypothiazid
180-200 100 —IIO
6. î 4 4 Chr. pyelonephr. Brinaldix, Minipress, 
Betaloc
165 — 190 100 —115
7- о 21 Renovascular
Neurofibromatosis
Propranolol, 
Hypothiazid, Sanotensin
180—205 100 — 120
î . ? 38 Essential Brinaldix, Minipress, 
Trasicor
185 — 200 I 10 —120
2. О 4 9 Renovascular Hypothiazid, Trasicor, 
Dopegyt
175 -  200 105-125
3- 0 27 Essential Brinaldix, Trasicor, 
Minipress
170 — 200 I 10 — I 20
4- 6 4 4 Malignant Betaloc, Depressan, 
Dopegyt
180—210 110 —130
5- i 41 Essential Viskaldix, Minipress 0Os
T0Г" ОT«/->Os
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Table II
Comparison o f  hypotensive effects o f Tensiomin and Capoten
No. Initial
Initial BP 
mm Hg
1. Period BP 
m m  Hg
Dose
mg
II . Period 
mm Hg
BP Dose
mg
Syst. Diast. Mean Syst. Diast. Mean C apoten Syst. Diast. Mean Tensiom in
1. T.M. 183 IO9 1 3 3 6 144 8 9 107 .3 •50 '53 9 2 П 7-3 2 0 0
2. T.J. 185 IO9 1 3 4 3 138 91 1 0 6 .6 100 1 5 0 9 0 I 10 1 5 0
3. T.s. 178 IO4 1 2 8 138 8 4 102 75 13« 85 100 1 0 0
4 .  C s . Z s . 2O4 1 20 148 '47 9 6 " 3 2 2 5 1 5 2 9 4 " 3-3 ЗОО
Q.3
О 5 .  O  F . 188 119 142 I4O 9 4 109 .3 1 8 7 .5 I5O 9 2 109 .3 2 0 0
0
6. T.T. 177 IO9 0 3 1 . 6 132 84 100 150 148 9 0 109 .3 2 0 0
7. k . A . 199 114 143 134 8 6 102 2 0 0 146 93 I 10.6 2 5 0
Mean
SD
I893
± 10.21
" 3-5
±5.2
138 .8
±6.5
1392
± 5-7
О
 ^ 
6O
' -H
1 06 .4  
± 4 . 8
1 6 8 . 8
± 44-6
I 4 9 . 8
±2.6
91.8. 
± 1.6
110.8 
± i -7
216.7
±51.6
Tensiomin Capoten
1. H.J. 192 1 14 I 4 0 147 96 113 250 145 94 I 1 1 200
2. D.S. 187 IO9 135 U ' 92 108.3 200 137 88 1 0 4 3 ■ 87-5
• 3. D.M. 187 1 1 6 1 3 8 .6 148 94 1 1 2 200 150 96 1 И 150
C.3 4. R.J.
жОп 121 I50 152 98 I l 6 ЗОО 148 96 113-3 200
6 5. N.J. '79 IO4 129 .38 91 106.6 •.SO 135 88 103.6 100
Mean I9O.O 112.8 135-5 ' 45-2 94.2 I I 1.2 220.0 143.0 92.4 IO9.2 167.5
SD ±1 I . I ±6.5 ± 7-7 ± 5-6 ±2.9 ± 3-7 ± 57-0 ±6.7 ±41 ±5.0 ±42.9
Group I. patients received Capoten, and group II. patients Tensiomin as the initial drug.
42 S . S o n k o d i  a n d  G . Á b r a h á m
D ISC U SSIO N
It was originally believed that captopril might be effective primarily in cases 
of hypertension dependent on the renin-angiotensin system /2, 7, 8/. It is now 
known that it can be utilized in a much wider range of diseases /7, 10/. 
Although the area of indication has still not been clearly defined, there can 
be no doubt that its primary value is in cases of severe hypertension that do 
not respond (or only with difficulty to traditional treatment /1, 7, 10/. Since 
these latter cases pose considerable problems for the practising physician, it is 
praiseworthy that the Hungarian pharmaceutical industry (EGIS) rapidly 
elaborated this strong hypotensive agent, Tensiomin.
In our study, the first dose of captopril significantly decreased the blood 
pressure. It was found that the hypotensive effect of the first 12.5 or 25 mg 
dose of Tensiomin displayed a linear correlation with the pretreatment PR A 
level, independently of whether the renin level was normal or elevated. This 
observation is in accord with other reports /3, 4, 9/. It means that a better 
hypotensive effect can be expected from the drug in hypertensive patients 
with higher PR A levels. In hypertensive cases with higher PR A levels, a linear 
correlation was revealed between the basal blood pressure and the percentage 
decrease in the mean pressure. This finding is again is agreement with other 
observations /9/. This means that the higher the basal blood pressure in 
renindependent hypertension, the greater will be the blood pressure decrease 
in response to captopril.
As concerns drugs containing captopril as active component, we earlier 
acquired experience with Capoten and Lopirin, and in the past 7 years with 
Tensiomin. We have generally regarded the area of indication to be therapy- 
resistant hypertension accompanied by a high renin level, and malignant hy­
pertension. However, we have also applied the drug in other special indi­
cations.
Scleroderma is a rare disease, one of the infrequent (4-10%) complica­
tions of which is the scleroderma renal crisis (SRC). This is not to be con­
fused with sclerodermal renal disease, which occurs in 35-50% of the cases. 
SRC is characterized by a rapid increase in blood pressure, a high blood 
renin level, fundus changes of grades III and IV in the Keith-Wagener 
classification, a rapid degeneration of the renal function, and death within 
4-6 weeks. Of the 32 sclerodermal patients observed in our Department 
during the past 15 years, renal disease was found in 13 patients (10%), 4 of 
whom had SRC. Three of the latter were treated with conventional hypo­
tensive therapy, but all died within 6 weeks. A 41-year-old SRC patient has 
so far survived for 28 months under captopril treatment since the syndrome 
developed.*
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During chronic captopril treatment of several hundred cases, we have 
observed reversible dysgeusia on two occasions, and leukopenia once. On 
three occasions, patients complained of a sensation of tachycardiac dis­
comfort. In a 7-year-old boy with primary aortitis, who had severe hyper­
tension because of renal artery occlusion on one side and constriction on the 
other side /10/. Captopril (Capoten) administration was accompanied by 
renal glucosuria /11/, which disappeared when captopril treatment was 
suspended, but reappeared when the treatment was resumed. A similar side- 
effect has been described only in connection with one other converting 
enzyme inhibitor, Enalapril /12/.
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Combined Captopril treatment was applied in 61 patients with severe or moderately 
severe hypertension in patients insufficiently or not reacting to the usual combined 
antihypertensive therapy (3-7 kinds of drug). The combination included diuretics, 
beta-blockers, alpha-blockers, vasodilators, Ca-antagonists and centrally acting agents. 
Diuretics were used in all cases. Average duration of treatment was 8.2 months (i.e. 
2 40) months). Mean systolic pressure prior to Captopril treatment was 202.4 mm Hg 
(S.D. ±27.6), while the diastolic 122.0 mm Hg (S. D. ±11.3). During combined Captopril 
treatment the average values were 154.2 mm Hg (S.D. : 18.8) and 97.6 mm Hg diastolic 
pressures (S.D. : 10.7), the difference being significant (p<o.ooi). Refractory hyper­
tension occurcd int three middle-aged female patients in response to combined Cap­
topril treatments. Captopril treatment had to be discontinued for the appearance of 
side-effects (severe skin symptoms) only in a single case. A minor deterioration of 
renal functions was observed in three patients (in one bilateral renovascular, and in 
two essential hypertension). Serum creatinine value and renal functions of four patients 
showed significant improvement as a result of combined Captopril treatment. During 
combined Captopril treatments (also with a diuretic) two patients had so severe 
hypokalaemia that they needed potassium substitution or administration of a potes- 
siumsaving diuretic.
Keywords: Captopril, combined treatment, hypertension
The angiotensin-converting enzyme inhibitor Captopril (C) has been avail­
able for the treatment of hypertension since the second part of the 1970-s 
/ 1, 2/. Experiences on severe refractory hypertension and on long term 
effects of C were reported at the beginning of the 1980s /3, 5/. In Hun­
gary, Radô et al. were the first to publish their experiences with Captopril 
/4/. At our department Captopril has been used since 1982. Initially (up to 
December 1984) the original preparation Capoten® (SQUIBB), while later, 
from January 1985, the Hungarian Tensiomin® (EGIS) were employed. 
The first 25 patients receiving Capoten treatment were switched over to the 
Hungarian Tensiomin from one day to the other. During the change, an 
essential modification of the dosage did not become necessary within the 
combined treatment either for the Captopril or for other drugs.
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PATIENTS AND M ETH O D S
From 1982 onwards, patients with severe and moderately severe hypertension were selected for 
receiving combined Captopril treatment, who had been refractory to at least four but rather 
some more antihypertensive drugs used in maximal doses. The patients underwent a detailed exami­
nation for symptomatic hypertension. The following examinations were performed in all cases: 
urine analysis, serum sodium, potassium, creatinine determination, optic fundus examination and 
renal functional DTPA scintigraphy with Camera. In almost half of the cases, renin-angiotensin- 
aldosteron determinations were made and in over half ot them (i.e. 34 patients), serionephroangio- 
graphy was also performed.
Fourty-eight patients suffered from essential, 9 from renovascular, 3 from renal and one from 
endocrine (Cushing’s disease) hypertension. The data o f the patients are summarized in Table 1.
The begining dose of C was twice or three times 12.5 mg a day. We tailored always the dose, 
of Captopril in the light of the hypotensive effect. We employed always diuretic with C in the treat­
ment to reflect the strong additive-synergistic effect of the two drugs.
If no decrease in blood pressure was obtained by the combined administration of 150-200 mg 
C + diuretic, first a beta-blocker, and when contraindicated, a Ca-antagonist was applied. In lack 
of an adequate hypotensive effect of the triple combination, for a fouth drug, vasodilator, or alpha- 
blocker, a Ca-antagonist or a centrally active agent were added separately to, or together with, the 
combination. The number of the applied drug combinations before and after Captopril treatment 
is shown in Table II. Patients’ blood pressure, renal functions, blood counts, ionograms and urinary 
findings were controlled according to a previously defined scheme.
Table I
Data o f patients
No. of patients: 61 (31 females, 29 males)
Mean age: 45.9 (24 —66 years)
Distribution according to the type of hypertension:
о essential 
о renovascular 
о renoparenchymal 
о endocrine
(EH) 48 patients 
(RVH) 9 patients 
(RH) 3 patients 
(ENH) I  patient
Renal functions before C treatment:
serum creatinine < 130 //m ol/1 30  patients 
serum creatinine > 130/tmol/i :i 1 patients
Mean blood pressure before C treatment: 
202.4/122.0 mm Hg (S.D.±27.6/ ± i 1.3)
Table II
Number ( No.) o f  drug combinations prior and after Captopril ( C) treatment
a. No. of drugs used before introducing 
C treatment:
b. No. of drugs given in combination 
with C:
2 kinds of drug 5 patients 2 kinds of drug 20 patients
3 kinds of drug 13 patients 3 kinds of drug 12 patients
4 kinds of drug 19 patients 4 kinds of drug 14 patients
5 kinds of drug 12 patients 5 kinds of drug 10 patients
6 kinds of drug 10 patients 6 kinds of drug 3 patients
7 kinds of drug 2 patients 7 kinds of drug 2 patients
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RESULTS
Table III. shows the decrease in blood pressure as well as the changes in renal 
functions during combined Captopril treatment. Reduction in blood pressure 
was highly significant. Average dose of Captopril was 145.5 rng, however, 
a daily dose of 200 mg -  except in two cases -  had never been exceeded to 
avoid the increased risk of side-effects.
Table IV. demonstrates the number of drugs combined with Captopril 
according to how many times they had been used during the treatment of 
the 61 patients.
In Table V. the combination of antihypertensive drugs according to 
their mechanisms of action is shown as a function of the number of patients.
DISCUSSION
According to our experiences, in patients with moderately severe and 
severe hypertension, and in those with one insufficiently or not responding 
to therapy, combined Captopril treatment can be beneficially applied. 
Captopril could be favourable combined with antihypertensive drugs used 
so far. It can be particularly well combined with diuretics, vasodilators and 
Ca-antagonists. It can be fairly advantageously combined with betablockers 
and with various types of alpha-blockers too (peripherally and/or centrally 
acting). Sufficient care should be taken on the combined administration of 
alpha-sympatolythics and C at increased risk of orthostatic hypotension. 
We ourselves were compelled by this in one case to omit Minipress during 
combined Captopril treatment.
Treatment, due to side-effect, had to be interrupted only in one case. 
The side-effect was a severe maculopapulous rash. Despite earlier experien­
ces, hypokalaemia necessitating potassium substitution or administration 
of a potassium-saving diuretic was observed in two cases in response to 
Captopril treatment (i.e. to 150 mg and 75 mg Captopril, and to a thiazide- 
type diuretic). In the long run normokalaemia could be maintained only 
in such a way. We believe that Captopril in this case could not prevent 
hypokalaemic effect of diuretics. Prior to commencing Captopril treatment, 
both patiens were subjected to a detailed examination for hyperaldostero­
nism. The results were negative.
A genuine resistance to therapy develops when blood pressure during 
combined Captopril treatment can not be reduced even not with the maxi­
mal doses of 6-7 various kinds of antihypertensive drugs. Thus, in case of 
our three refractory patients, 300 mg Captopril, 50 mg Chlorthalidone in 
two cases and 80 mg Furosemide in the other case, 320 mg Propranolol,
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Table III
Results o f combined Captopril ( C) treatment
Captopril dose (mean) 145.5 mg (50 —300 mg)
Duration of treatment (mean) 8.24 months
(2 —40 months)
Mean blood pressure:
before C treatment: 202.4/122.0 mm Hg 
(S.D.±27.6/4= 11.3)
after C treatment: 154-2/ 96.7 mm Hg 
(S.D .± i 8.8 /± io.7) 
p < 0.001
Successful treatment 58 patient EH: 45
RVH : 9
RH: 3
ENH: I
Resistant even to C: 3 patients-EH
Omitted for side-effect I patients-RVH
Serum creatinine before treatment: 
121.75 ,«mol/i (S.D. ±56.59)
Serum creatinine after treatment: 
126.3 /«nol/i (S.D.±97.12)
Table IV
Drugs combined with Captopril
Diuret ic Beta-blocker Vasodilator  A lpha-blocker  Ca-antagonis t Cen tral ly  active
agents
Furosemide 9 Propranolol 26 Dihydralazin 25 Prazosin 7 Nifedipine 12 Bromocryptine 2
Chlorthalidone 25 Pindolol 2 Clonidine 2
Clopamide 21 Metoprolol 5 Guanfacin з
Hydrochloro­
thiazide 6
Oxprenolol 4 Methyldopa 2
Triamteren I
Total 62'к 38 25 7 12 9
* One patient received two kinds of diuretic, Hydrochlorothiazide and Triamteren
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Table V
Distribution o f patients according to drug combination 
with Captopril (61 patients)
c Captopril
D diuretic
В beta-blocker
V vasodilator
A alpha-blocker (A= peripherialy acting, 
Á =  centrally acting)
Ca Ca-antagonist
В Parlodel
C + D
C + D + B
C + D+Ca
C+D +B+V
C+D +B +A
C + D + B+Ca
C+D +B +B +A
C + D + B + A + Ca
C +D +B+V +Ca
C +D +B+B +C a+A
C+D +B +V +C a+A +Á
20 patients 
11 patients 
I patient 
11 patients
1 patient
2 patients 
5 patients
1 patient 
4 patients
3 patients
2 patients (+ transitorily H)
200 mg Dihydralazine, 90 mg Nifedipine, 18 mg Prazosin, 900 //g Clonidine 
in one case and 2 g Alphamethyldopa in the other two cases were used in 
the antihypertensive treatment. In twocases 7.5 mg Bromocryptine (Parlodel) 
were given in the antihypertensive combination too.
Moderate deterioration of the renal functions (not exceeding the double 
of the normal value) was observed in 3 patients, while in four the renal 
functions significantly improved during combined Captopril treatment pa­
rallel to the improvement of hypertension (Table VI.).
As for conclusion introduction of Captopril into antihypertensive therapy 
improved considerably the treatability of patients with moderately severe 
and severe hypertension recractory to prior treatment. Giving a dose not 
exceeding 200 mg, side-effect was only rarely observed.
Table VI
Side-effects during 61 combined Captopril treatment
Maculopapulous rash I patient
Transitory itch t patient
Hypokalaemia (combined with diuretic) 2 patients
Hyperkalaemia 0
Deterioration of renal function 
(slight increase in serum creatinine) 3 patients
Improvement of renal function 
(3 malignant EH, I malignant RVH) 4 patients
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Twenty patients with moderate (4) to severe (16) hypertension, whose blood pres­
sure (BP) could not be controlled on the previous combined antihypertensive ther­
apy, were investigated. In acute studies the first doses of captopril, 25 and 50 mg 
led to a significant drop in BP 30 min after administration. The maximum fall in 
BP was recorded at 90 120 min and this effect was maintained throughout the whole 
observation period (Shours). The fallin BP wassimilar in supine and standing positions 
and there was no change in the heart rate. During long-term (14.5 months) therapy 
only 2 out of the 20 patients exhibited continuing good BP control with captopril 
monotherapy of a maximum daily dose of 150 mg. A comparison of the acute and 
chronic BP lowering effects of captopril showed that the first dose of captopril caused 
a significantly greater decrease in BP than chronic monotherapy. However, combined 
captopril with a diuretic or with a diuretic and calcium antagonist or beta blocker 
provided a sustained BP control, significantly better than the previously used anti- 
hypertensive combinations (182±27/115± 11 mmHg vs i64±20/t04±t 1 mmHg 
p<0.05). The Hungarian captopril preparation (Tensiomin), similarly to other capto­
pril products, through its angiotensin converting enzyme inhibition, caused an increase 
in plasma renin activity and in concentration of plasma angiotensin I and a decrease 
in plasma angiotensin II. Eight out of the 20 patients developed side effects, which 
disappeared spontaneously in 4 patients within 2 14 days. Captopril was withdrawn 
in 3 patients for not achieving satisfactory BP control and/or because of side effects. 
It is concluded that captopril is safe and effective in the long-term treatment of hyper­
tension, however, majority of the patients with severe forms of hypertension required 
double or multiple combinations.
Keywords: severe hypertension, captopril, acute and long-term effects
The introduction of angiotensin converting enzyme (ACE) inhibitors repre­
sents a new principle in the pharmacological treatment of hypertension.
Captopril is the first orally active competitive inhibitor of converting 
enzyme (kininase II). This enzyme converts angiotensin I into the vaso­
constrictor peptide angiotensin II and inactives the vasodilator peptide 
bradykinin.
The major hypotensive action of the drug is the inhibition of the 
formation of angiotensin II. During the past decade captopril has been
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shown to be effective in treating hypertension of all degrees of severity. Also, 
it might be of value in the management of severe and previosuly unrespon­
sive hypertension mostly in a combination with a diuretic or with a diuretic 
and a beta-blocker or calcium antagonist for maximal effectiveness.
This study reports on the acute “ first dose” and the long-term effects of 
the Hungarian captopril preparation (Tensiomin) in patients with severe 
hypertension.
M ETHODS
Patients
Acute and chronic investigations were carried out in hypertensive patients with captopril (tabl. 
Tensiomin, containing 25 and 50 mg of captopril). Twenty patients were involved, 14 males and 6 
females with a mean age of 46 (38-55) years. Nineteen patients had essential and one patient reno­
vascular hypertension, persisting after dilatation of bilateral renal artery stenosis.
The severity of hypertension was moderate in 4 cases and severe in 16 patients according to the 
W HO criteria based on diastolic blood pressure (DBP).
The investigations were started in 13 inpatients and 7 outpatients. All but one patient received 
previous antihypertensive treatment: 2 patients received monotherapy (nifedipin and a beta-blocker 
respectively), 2 patients double combination of a beta-blocker plus diuretic or prazosin plus diuretic, 
and the remaining, 15 patients a three- or four-old combination. Eight of the 20 patients had vascular 
complications: cerebrovascular in 1 and cardiovascular in 7 cases, of which 3 patients had angina 
pectoris, 1 angina pectoris+mild left ventricular heart failure, 1 angina pectoris and atrial fibrilla­
tion, I  ventricular extrasystole, and I  patient paroxysmal supraventricular tachycardia. Five patients 
received concomitant medication, 3 with angina received short and long acting nitrate-preparations 
and two patients cardiac glycosides which could be stopped in 1 patient after the control of mild 
left ventricular heart-failure, 1 patient received it continuously for the prevention of paroxysmal 
supraventricular tachycardia.
Secondary illnesses: obesity in 7, diabetes mellitus in 6 (3 patients on oralantidiabetics), Raynaud 
syndrome in 1, hypernephroma in 1. Hypernephroma was diagnosed before starting the treatment 
and removed during the captopril therapy.
DESIGN OF THE STUDY
Antihypertensive medications used previously were discontinued 4 (2-7) days prior to the acute 
study. Blood pressure and heart rate, 10 min supine and 3 min standing, were measured. A 12-lead 
ECG was recorded for the measurements of R-R distance, PQ, QRS and QT invervals. These 
measurements were done before and 30, 60, 90, 120, 150, 180, 240, 360, 480 minutes after the admi­
nistration of 25 mg captopril. Detailed laboratory investigations (serum Na+, serum K+, serum 
bilirubin, SGOT, SGPT, alkaline phosphatase, blood urea nitrogen, serum creatinine, serum uric 
acid, blood sugar, serum cholesterol, serum triglycerid, platelet count, urin analysis) were carried 
out regularly before and during captopril therapy.
Measurement o f plasma renin activity (PRA) for the determination of renin activity 200 fil 
o f plasma was incubated at 37°C and pH 7.5 for 1 hour in the presence of disodium EDTA (3 mM), 
8-hydroxyquinolin (1.2 mM) and phenylmethylsulfonylfluorid (0.47 mM). The incubation mixture 
was diluted 1 3  with cold assay buffer and boiled immediately for 15 minutes to stop the enzyme 
activity. After centrifugation the angiotension 1 generated during the incubation was measured by 
RIA. Results are expressed in ng/ml/h (30).
Radioimmunassay o f angiotensin I and angiotensin I t  blood was collected in chilled tubes con­
taining EDTA and plasma samples were separated after subsequent centrifugation and stored at 
— 20° C until tested.
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Angiotensin 1 was separated from t .o ml of plasma using a special second antibody method; the 
residue containing angiotensin I was redissolved in 2.0 ml alcofol containingo.2M HC1. Angiotensin 
II was extracted from the supernatant with the elution of 1 ml of alcohol and 1 ml of chloroform. 
After centrifugation both supernatant were evaporated to dryness at 50° C under warm airstream. 
The residues were redissolved in 800//I assay buffer. The incubation volumes were adjusted to tooo/d 
with the labelled peptide and the antibody (dilution is 1 :20.ooo for angiotensin I and 1 :5.00c) for 
angiotensin 11 Rl A). After 24 hours incubation period the bound peptide was separated by polyethyl­
eneglycol and counted (29).
After the evaluation of the acute “first dose” effect of captopril, 25 mg, the patients received 
75 mg (25 mg t.i.d.) daily. If after a maximum period of one week this dose was ineffective, the acute 
effect of captopril 50 mg was tested, and then captopril 150 mg (50 mg t.i.d.) monotherapy, the 
maximum dose, was administered. When BP could not be controlled with captopril alone first 
a diuretic, then a diuretic plus a calcium antagonist or a beta-blocker was added.
The patients were seen weekly or biweekly during the dosefinding period of the drug-combination, 
and then monthly. Before augmenting the dose of captopril, or introducing combined therapy, the 
laboratory and biochemical tests were repeated.
For statistical evaluation of the results Student “ t”-test applied. In the acute studies the mean 
value of three consecutive blood pressure measurements were used as baseline value. Then captopril 
(25 and 50 mg) was given. In the chronic study the mean value of blood pressures measured at three 
different occasions during the previous antihypertenstive herapy served as baseline.
RESULTS
Acute studies
A significant fall of systolic blood pressure (SBP) in supine position could 
already be observed 30 min after captopril 25 mg (p<o.ooi) and BP reached 
its minimum at 90-180 min (p<o.ooi).
SBP decreased by 15% (from 178 mmHg to 150 mmHg) after 90 min 
and remained 11% lower after 480 min. The same significant change in SBP 
(standing position) was observed after 30 min, and this change was significant 
at each point of time (p<0.001-0.05). The size and time of the maximal 
effect were similar to those observed in lying position. The lying DBP went 
down after 30 min (pco.ooi), the change was most remarkable after 180 min 
(pCo.ooi) and remained significant after 480 min (p<0.05). The magnitude 
and duration of the effect on standing DBP (-13-14%) did not differ from 
those seen on lying DBP (pC0.001-0.05, Fig. 1.).
Fig. 2 demonstrates the acute antihypertensive effect of captopril, 50 mg.
The changes in SBP were significant after 30 min, and the maximum fall 
occured after 120 min, 22 mmHg (-13%, pco.ooi) in supine and 17 mmHg 
(-11%, pco.ooi) in standing position. DBP decreased by 11% both in supine 
and standing positions. These changes in standing position were significant 
at each point of time, and up to 120 min in supine position (pco .001-0.05).
Heart rate and PQ, QRS, QT intervals, as well as ST segments and T 
waves on ECG showed no change after the acute administration of 25 and 
50 mg captopril.
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Fig. I . First dose effect o f 25 mg captopril on lying and standing blood pressure
Fig. 2. First dose effect o f 50 mg captopril on lying and standing blood pressure
Chronic studies
Average duration of the treatment period in 20 patients was 14.5 months 
(minimum 6 weeks -  maximum 23 months), in 14 cases>i2 months, and in 
9 out of these 18 months. Sixteen patients are still on captopril. Captopril 
therapy was discontinued in 3 patients after 6 weeks (No 6), 2 months (No 
15) and4months(No 14) because of inadequate control of BP and side effects.
One patient did not attend the outpatient clinic after 6 months on 
captopril therapy.
In one patient captopril monotherapy, 150 mg daily was effective for 21 
months. One patient with Raynaud syndrome remained normotensive on 
75 mg captopril daily for 6 months, when guanfacin, 1 mg daily was added
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due to palpitation. In 6 other patients captopril monotherapy (75 mg daily 
in 4, and 150 mg daily in 2) was effective only for 4-8 weeks. In one of the 
4 patients increasing the dose of captopril from 75 mg to 150 mg daily resulted 
in satisfactory reduction of BP for 3 months, but then captopril had to be 
combined with a diuretic.
In 8 patients captopril was given in a two-fold combination, diuretics 
in 5, beta-blockers in 2, and centrally acting drug in 1. Ten patients received 
the captopril therapy in three-fold or multiple combination, 4 with diuretics-l- 
calcium antagonists, 4 with diuretics and beta-blockers, 1 with a diuretic and 
centrally acting drug, and 1 with a diuretic, beta-blocker, centrally acting 
drug and calcium antagonist. Potassium supplement or potassium sparing 
diuretic had to be given in 11 out of 20 patients before the introduction of 
captopril while in 4 patients during captopril administration.
Individual changes in DBP are shown in Fig. 3. Severe diastolic hyper­
tension (>115 mmHg) was observed in 10 cases before captopril therapy, 
and only in I case-during the combined therapy with captopril (pco.ooi). -  
In 7 cases borderline hypertension or normal blood pressure was seen 
(p<o.ooi).
Changes in mean BP values during chronic captopril therapy are pre­
sented in Fig. 4. As compared to the previous antihypertensive therapy 
captopril reduced supine SBP from i 82±27 to i64±20 mmHg (-10%, 
p<0.05). The fall in standing SBP (-7%) was not significant. DBP decreased 
by 10% from 115± 11 to Ю4± 11 mmHg (p<0.05), in lying position, and in 
standing position by 15 mmHg (-13%, p<0.05). No change in supine or 
standing heart rate was noted.
We compared the first dose effect of captopril, 25 mg to the effect of 
continuous captopril treatment (75 mg daily) for 3-7 days and again at the 
end of captopril monotherapy. The data of outpatients and inpatients were 
analysed together and separately in respect to the possible influence of 
bedrest on BP. In inpatients supine SBP was 16 mmHg higher (p<0.005) on 
the 3-7 days and 21 mmHg higher at the end of captopril monotherapy, 
75 mg daily, than the lowest SBP after the first dose of captopril, 25 mg.
The respective changes in supine DBP were 12 and 10 mmHg (pco.oi). 
The outpatients showed similar rise in BP, so the pooled data of inpatients 
and outpatients were also analysed. On the 3-7 days of captopril, 75 mg 
daily supine SBP was higher by 15 mmHg (p<0.005) and at the end of 
monotherapy by 20 mmHg (p<o.ooi). Increment in supine DBP was çmmHg 
(p<0.005) at both measurements (Fig. 5). The acute antihypertensive effect of 
captopril, 50 mg was also bigger than that of captopril 150 mg administered 
continuously (Fig. 6).
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Fig. 3. Changes in individual diastolic blood pressure during captopril therapy (WHO criteria)
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Fig. 4. Changes in mean blood pressure during chronic captopril therapy compared to the previous
antihypertensive therapy
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No significant correlation was found between the acute and chronic 
BP lowering of captopril. No significant change in biochemical tests or 
haemogram was observed during captopril administered alone or combined. 
A small but not significant increase in BUN and serum creatinine was found 
during captopril therapy combined with diuretics (Fig. 7).
The effect of captopril monotherapy on the plasma renin angiotensin 
system in 13 patients are summarized in Figure 8 . Average value for PR A 
in this group of patients was 1.6з±о.29 ng/ml/h. The average plasma angio­
tensin I level was 1 2 7 -! 18 pg/ml, angiotensin II level was 1 3 8 T 2 9  pg/ml. 
Following the captopril monotherapies the plasma concentrations of angio­
tensin II decreased to 130J 49 pg/ml on 7 5  mg/day and to 1 1 7 + 2 5  pg/ml on 
150 mg/day and according to the reduction of angiotensin II biosynthesis 
there was an increase in PRA values to 3 -C>3 ±  1.3 ng/ml/h on 7 5  mg/day and
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Fig. 7. Laboratory tests during captopril therapy
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to 2.16±0.42 ng/ml/h on 150 mg/day and in the concentrations of plasma 
angiotensin 1 to 220 + 70 gp/ml in both groups.
The effect of captopril in combination with diuretics and beta-blockers 
on the plasma renin angiotensin system in 10 patients are shown in Figure 9. 
There is a significant increase in the PRA from 1.8910.36 to 12.00 + 5 
ng/nl/h (p<0.05) and in plasma angiotensin I level from 127 + 21 to 348 93 
pg/ml (p<0.05) and a slight increase in plasma angiotensin И level from 
144 — 39 to 162 + 37 pg/ml in patients treated with captopril plus diuretics. 
This can be explained by the fact that the release of renin is stimulated by 
diuretics. The triple treatment with captopril, diuretic and beta-blockers 
causes a slight decrease in all the three parameters of the renin-angiotensin 
system (PR A: 1.51 ±0.35 ng/nl/h, angiotensin I 71 16 pg/ml ; angiotensin 11 :
68+16 pg/ml), beta-blockers counteract the renin stimulatory effect of 
captopril plus diuretics.
SIDE EFFECTS
During the acute study 2 out of 20 patients (No 13, 15) developed side 
effects. Blood pressure of patient No 13 showed no change after captopril, 
25 mg, while captopril 50 mg produced a marked decrease from 160/120 to 
110/86 mmHg, in supine position after 120 min dizziness and a feeling of 
fainting, therefore BP in standing position could not be measured.
After the first dose of captopril, 25 mg one patient (No 15) experienced 
numbness in tongue, which disappeared within one day. This complaint did 
not occur during the chronic captopril therapy.
During the chronic sudy 8 out of 20 patients exhibited side effects. 
Table I. shows the serial number of patients, the type, duration and outcome 
of side effects. The adverse reactions (nightmares, salty taste, itching without 
objective signs, periorbital and hand oedema) disappeared spontaneously 
within 2-14 days in 4 patients (No. 10, 11, 14, 18). In 2 patients (No 4, 13) 
additional therapy, or change of dose was necessary because of side effects. 
In one patients (No. 4) palpitation ceased adding guanfacine, 1 mg daily to 
captopril. Orthostatic hypotension occurred after augmenting the dose of 
clopamide from 10 to 15 mg in patient No 13. This symptom disappeared on 
10 mg clopamide. Captopril therapy was discontinued in 3 paients (No. 6,14, 
15) because of side effects or inadequate control of blood pressure. Patient 
No. 6 developed tachycardia (heart rate, supine, 120 beats/min and standing, 
140 beats/min) Metoprolol, 600 mg did not inhibit satisfactorily this 
symptom. Patient No. 14. felt increased tension and nervousness, and did 
not want to continue captopril therapy. Patient No. 15. developed palpita­
tion, supraventricular extrasystole and muscle cramps.
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Captopril: Captopril:
Before therapy 3 x 2 5 m g /d  3x50 mg /d
£ 7
E'  6 
o i
Ш  PRA 
1Ш Ang.l. 
□  Ang.ll.
C
■ 200 °
1
I -  100
Captopril.
Captopril: C ap topri l .  Diureticum.
Before therapy 3 x 5 0  mg/d Diureticum Betablocker
Fig. ç. Combined captopril therapy (diureticum+beta-blocker) on plasma renin activity (PRA)
angiotensin 1 and angiotensin 11 levels
Fig. 8. Effect of captopril monotherapy on plasma renin activity (PRA) angiotensin I and angiotensin
11 levels
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Tabic I
Side effects during chronic captopril therapy
S  I D E  E F F E C T S
N u m b e r T y p e  o f  C a p t o p r i l
D r u g s  c o m b i n e d  
w i t h  c a p t o p r i l  
m g / d i e
c> u  t  c  0  m  e
o f  p a t i e n t s  
N o
s i d e  e f f e c t s  m g / d i e D u r a t i o n
( D a y s )
C e a s e d
s p o n t a ­
n e o u s l y
C h a n g e  
i n  d o s e
A d d i t i o n a l
t h e r a p y
m g / d i e
C e s s a t i o n  o f  
t h e r a p y
4- Palpitation 75 0 2 No 0 guanfacine 0
6. Tachycardia 150 Clopamide 10 No 0 metoprolol yes
(120 beats/min) 600 6 weeks
10. Nightmares 150 Clopamidc 20 1 4 Yes 0 0 0
11. Salty taste 75 0 3 Yes 0 0 0
' 3 - Orthostatic 150 Clopamide 15 1 No Clopa- 0 0
hypotension mide to
14. Itching 150 Clopamide 10 3 Yes 0 0 0
Nervousness ■4 No 0 0 Yes
4 months
15. Palpitation, 150 0 14 No 0 0 Yes
supraventr. ES 
muscle cramps
2 months
18. Oedema 150
(Periorbital,
hands)
0 14 Yes 0 0 0
D ISCUSSION
In acute studies the first doses of captopril, 25 and 50 mg caused a significant 
fall in BP 30 min after administration. Maximum decrease was observed at 
90-120/min, and BP remained reduced throughout the whole observation 
period. The effect of a single dose lasts for minimum 8 hours. Similar fall in 
BP occurred in supine and standing positions. Heart rate was not affected. 
Similar decrease in BP and no change in heart rate or cardiac output were 
reported in most acute haemodynamic studies with captopril. The depressor 
effect is mediated via a decrease of systemic vascular resistance /1,14, 16/. 
Following the first dose of captopril, 25 mg the magnitude of the BP fall and 
the time course to the maximal decrease found by Walker et al. was not 
different from our data /35/.
A comparison between the acute and chronic BP lowering effects of 
captopril showed a significantly greater fall in BP after the first dose of 
captopril, than following continuing administration as monotherapy. No 
correlation could be demonstrated between the falls in BP following the 
first doses of captopril, 25 mg or 50 mg and the decreases in BP during
62 Eszter Török et al.
short-term treatment with captopril alone, 75 or 150 mg/day. Our findings 
are in agreement with those reported by Lijnen et al. /26/ and in contrast to 
Case et al. /7/, Laragh et al. /25/ who found a close correlation between the 
initial and sustained BP responses and suggested that the response to the 
first dose of the drug may have predictive value for its long-term influence 
on BP.
In our experience captopril monotherapy with a maximum daily dose of 
150 mg led to a long-term BP control only in 2 out of 20 patients with severe 
hypertension. Chronic combined captopril therapy with an average duration 
of 14.5 months, however, provided a sustained BP control significantly 
superior to that achieved with the previously used antihypertensive combina­
tion. In patients with mild to moderate hypertension the hypotensive effect 
of captopril alone or combined with a diuretic has been well documented 
/4, 5, и ,  18, 23, 26, 27, 33, 34/.
In patients with severe hypertension combined treatment with captopril 
and diuretics may produce about the same BP reduction as can be achieved 
by standard triple therapy /6, 17, 36/. Also, in patients with severe intrac­
table hypertension the combination of captopril and a diuretic might be 
effective /3/. Two-third of our patients with severe hypertension received a 
diuretic and half of them a 3rd drug (calcium antagonists or beta blockers) to 
achieve and maintain BP control. Captopril accentuates the effects of vaso­
dilators, such as calcium antagonists, direct vasodilators or alfa, receptor 
inhibitors /21/. Beta-blockers /28, 31/ or centrally acting drugs, such as 
guanfacin may be used to supress the tachycardia and to cause additional 
hypotensive effect. ACE inhibitors block the secondary hyperaldosteronism 
and resultant deficiencies of body and serum potassium associated with 
diuretic therapy /23/. In our experience potassium supplements could be 
stopped in 7 of 11 patients after introduction of captopril therapy. According 
to its converting enzyme inhibitory effect of captopril, 75 and 150 mg daily 
increased the plasma renin activity and plasma concentration of angiotensin I 
and decreased the plasma level of angiotensin II. There was no difference be­
tween the effect of the doses of 75 or 150 mg/day. The combination of cap­
topril with diuretics significantly elevated the plasma renin activity and the 
angiotensin I level in comparison to the captopril monotherapy. After the 
addition of a betablocker these increases totally disappeared. Beta-blockers 
counteracted the renin stimulatory effect of captopril and diuretics. Other 
biochemical tests, haemogram and urinalysis regularly done showed no change 
in either phase of the chronic study. First dose side effects hypotension has 
been reported when captopril therapy was initiated in patients who had 
been previously sodium-depleted by diet or diuretics /15/, and in patients 
with unilateral renal artery occlusion /2/. Following the first dose of cap-
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topril, 50 mg one of our 20 patients who had no renal impairment and 
had received no diuretics exhibited severe orthostatic hypotension.
Eight of the 20 patients developed side effects from captopril which 
diappeared spontaneously within 2-14 days in 4 of the 8. patients. Captopril 
was withdrawn in 3 patients for failure to maintain BP control and/or side 
effects. All discontinuances occurred within 3 months after starting captopril. 
No serious side effects were observed during the long-term therapy. In other 
studies, serious side effects, such as haematological disorders, reversible renal 
failure with hyperkalemia, nephrotic syndrome were found with high doses 
of captopril in patients who had impaired renal function, particularly those 
who have lupus or scleroderma /10, 20, 22, 29/.
Because of dose response in captopril therapy of hypertension, 150 mg 
captopril/day appears to be the ceiling hypotensive dose /26/ and because of 
dose related incidence of severe side effect /2/, in our long-term study 150 mg 
captopril was administered as a maximum daily dose.
It is concluded that captopril has been effective and safe in the long­
term treatment of hypertension, the majority of patients with severe forms of 
hypertension, however, required additional medications.
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Haemodynamic and humoral effects of captopril were studied in patients with essen­
tial and renovascular hypertension. Captopril decreased significantly both systolic 
and diastolic blood pressure and moderately, it reduced also the heart rate. On the 
basis of the haemodynamic effects our patients could be divided into two groups: 
in patients where the total peripheral resistance (TPR) exceeded 2000 dynxsecxcm -5 
during rest, captopril exerted its hypotensive effect by decreasing TPR. In patients 
in whom TPR was lower, the hypotensive action could be attributed to the reduction 
of cardiac output (CO).
Captopril increased plasma renin activity, and decreased the activity of angiotensin 
converting enzyme (ACE) in the plasma. In acute study captopril did not influence 
plasma noradrenaline level but increased it during long-term administration. It did 
not affect dopamine or adrenaline levels. Captopril had no effect on plasma beta- 
endorphin concentration, moreover, the opiate antagonist, naloxone, failed to anta­
gonize its antihypertensive effect. Comparing the acute effects of Capoten (Squibb, 
USA) and Tensiomin (EGIS, HUNGARY) no significant differences were found.
Keywords: captopril-hacmodynamic effect humoral effect
The aim of our study was to test the cardiovascular and hormonal effects 
of captopril (Tensiomin, EGIS) applied in monotherapy or in combination 
in patients with essential and renovascular hypertension.
The effects of Capoten (Squibb, USA) and Tensiomin (EGIS, HUN­
GARY) on blood pressure and heart rate were compared.
Detailed haemodynamic, humoral and laboratory examinations were 
performed following acute and long-term captopril administration.
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PATIENTS AND M ETH O D S
A total oi 59 patients participated in the study (mean age:48.i±2.7 years, mean weight: 74.9± 
4.9 kg). Not all of examinations listed below were performed in every patients-the actual number of 
tests in the individual study groups are presented in the following section. Patients had been diagnosed 
as having essential and renovascular hypertension of WHO grades 1 through III.
An open study was performed. Exclusion criteria were pregnancy, lactation, severe hepatic or 
renal insufficiency, disturbances of electrolyte, fluid and acid base regulation, haematological 
diseases and the lack of adequate collaboration.
A to-day drug-free period preceeded the study when the “baseline” examinations were perfor­
med. Then the patients were given captopril and acute or chronic haemodynamic, humoral and 
laboratory examinations were performed according to the protocol.
Blood pressure was measured by mercury sphygmomanometer with the auscultation method. 
The diastolic value indicated by Korotkov’s phase V. The pulse rate was simultaneously determined 
from the radial pulse.
Cardiac output was determined by radiocirculography (1113-indium) as described in details 
previously /5/. The plasma volume was calculated from the dilution of isotope, by determining 
the haematocrit the blood volume could also be calculated. The total peripheral resistance (TPR) was 
calculated from the values for cardiac output and blood pressure.
Plasma renin activity (PRA) and plasma beta-endorphin concentration (bE) were determined by 
radioimmunoassay. Plasma dopamine, adrenaline and noradrenaline levels were assessed by radio- 
enzymatic assay /5/. Plasma A C E  activity was determined by a spectrophotometric method, by detec­
ting the degradation of a synthetic substrate /2/. Since there are data indicating that upon storage 
captopril dissociates from the ACE in the plasma and it may cause false increase in ACE activity 
the analysis of blood, drawn from the patients, was started within 2 hours. Our previous results 
and data in the literature indicated that within 2 hours the ACE activity is not modified by storage 
in plasma samples of patients treated with captopril. The naloxone (an opiate antagonist) test was 
performed in the following way: 1.6 mg naloxone (NARCAN, Endo Labs., USA) was administered 
as an intravenous bolus and blood pressure and heart rate were measured 1, 2, 3, 5, 7, 10, 20, 40 and 
60 minutes after the intravenous injection. The test was considered positive if the mean blood pressure 
increased by at least 12 mmHg.
ECG examinations (12 leads) were also carried out. The following parameters were studied: 
PQ, QRS, QT Intervals, P, R. T amplitudes, ST segment, wave-form deviations.
Laboratory examinations : blood cell counts (RBC, Hb, Ht, platelet), urine analysis (protein, 
sugar, ubg, sediment), serum levels of bilirubin, SCOT, SGPT, alkaline phosphatase, gamma GT, 
urea, creatinine, sodium, potassium, sugar, uric acid, cholesterol and triglyceride determined.
The side effect were reported by the patients and recorded.
For statistical analysis of the data Scheffé's method, paired “ t” test and linear regression analysis 
were used.
RESULTS
/. Acute effects (12 patients)
Captopril, in the single dose of 25 mg, decreased blood pressure, from 
18 1 ±9/116±3 mmHg to 138±5/93±4 mmHg (mean±SEM). The effect became 
statistically significant even 15 min after the administration of the drug. The 
maximal effect appeared 2-3 hours later. The heart rate was decreased from 
86 to 73 beats/min (p<0.05) Side effects were not observed.
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2. Long-term effects (12 patients)
If the initial dose of 25 mg captopril decreased systolic blood pressure at 
least by 40 mmHg, the treatment was continued with the daily dose of 12.5 mg 
t.i.d. If the blood pressure reduction was smaller, the patients were given 
25 mg t.i.d. The dose was adjusted according to the blood pressure and the 
highest dose was 150 mg/day. The data are summarized in the (Table I.) 
Both systolic and diastolic blood pressure were significantly decreased by 
captopril treatment. The hypotensive effect somewhat sub -  sided around 
the 14th day: in most of the cases the dose had to be increased at this time.
By the end of the first week normotension could be achieved in all pa­
tients but one (in this patients blood pressure could not be decreased below 
160/90 mmHg even by increasing the dose to 150 mg daily).
Considering the data of the 2nd and 3rd week, captopril significantly 
decreased the heart rate. This bradycardiac effect seemed to be clinically 
significant on the 2nd week.
Tabic I
Laboratory examinations during captopril (Tensiomin) treatment
Baseline I 2 3
Blood pressure (mmHg)
systolic i 8 7 ± 6 141 ± 3* 154* 5* 144*3*
diastolic I I 2±5 87*2* 96*3* 86*2*
Heart rate 80 ±2 75±2 68*3 72*2
Blood picture
RBC (M) 4.71 ±0.19 4.83*0.14 4.68*0.19 4.82*0.21
Hb (mM) 8.34*0.38 9.18*0.27 8.71 ±0.34 8.79*0.36
Ht 0.42*0.02 0.41 ±0.01 О.42 ±0.01 0-42±0.0I
WBC (ioJ) 6.5 ±0.4 6.8 ±0.5 6.9 ±0.5 7.05*0.53
Thr (G) 185*16 171 ±12 163*9 168 *  10
Liver function
SeBi 17.1 ±2.0 14-4 ± 1.2 14.0*1.1 12.7*0.8*
SGOT 11.6*0.9 11.6*14 131 ±1.9 13.2*1.6
SGPT 12.6 150 - -
seAP 1 10 ±  I I 115*17 105*23 141*31
gamma GT 191 ±44 16.5*2.4 195 ± 3-9 16.3*4.0
Renal function
urea 5.75 ±0.45 5 -75 ± o .43 5.64*0.60 5.35*0.51
creatinine 78.2*5.0 77.8*2.7 77.2*5.0 75.7*4.6
Other
Na ido±o.5 i40±o.5 139 ±0.5 140*0.6
К 4.2 ±0.1 4.5 ±0.1 4.6 ±0.1* 4.6 ±0.1*
blood sugar (mM) 5.30*0.21 5.16*0.16 5.25*0.24 5.I2 ±0.21
uric acid 332*24 326*24 301 ±25 330*24
Cholesterin 6.65*0.21 6.45*0.32 7.0 ±0.33 6.03 ±0.41
triglyceride i.55±o.3 i 2.01 ±0.25 1.62*0.32 1.69*0.18
I ,  2, 3: duration of captopril treatment (in weeks) 
* significant change (p<0.05)
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J. ECG examinations (r2 patients)
Captopril had no effect on ECG parameters either during the acute or during 
the long-term administration. The only change was the increase in the R-R 
interval due to the bradycardiac effect. The PQ interval was not affected 
either.
4. Laboratory investigations (12 patients)
Data are presented in the Table I. in details. Captopril elicited no significant 
changes in laboratory parameters studied with the only exeption of the serum 
potassium level which was slightly increased within the normal range.
Table II
Changes in ECG characteristics during captoprii 
(Tensiomin) treatment
B aseline I 2 3
PQ interval o.i4±o.o3 o.i6±o.o3 O.I5 ±0.04 0.15 ±0.03
QRS 0.08 ±0.001 0.08 ±0.001 0.08 ±0.001 0.08 ±0.001
QT о.з6±о.оз 0.38 ±0.03 0.38 ±0.03 0.37±0.02
5. Comparison o f the acute effects o f Tensiomin 
(EGIS) and Capoten (SQUIBB, USA) (12 patients)
The acute effects of single doses of Tensiomin (25 mg orally) and Capoten 
(25 mg orally) were compared in a single-blind, cross-over study. After a 
30 min recumbent rest (during this period the blood pressure and the heart 
rate were measured at every 5th min) patients were randomly given either 
Tensiomin or Capoten. On the following day the alternative order of drugs 
was repeated. After the administration of the drug the blood pressure and 
the heart rate was measured at every 15th min for 2 hours and at every 
20th min for further 2 hours.
Tensiomin: The blood pressure was decreased from i 8 i ± 9 / i i 6 ± 3  to 
i38±5/93±4 mmHg, by 43±8/23±4 mmHg. The rate decreased from 
86±3 to 73±3 beats/min.
Capoten: The blood pressure was decreased from I 7 6 ± 8 / i i 6 ± 4  to 
i46±7/94±4 mmHg, by 31±5/22±з mmHg. The heart rate decreased from 
8з± з to 75±2 beats/min (Fig. 1.)
The effects of Tensiomin and Capoten were not significantly different as 
far as the maximal effects are concerned. When the time course of the hy­
potensive action was compared a more rapid onset of the effect of Capoten 
was found: the hypotensive action was statistically significant 15 min after
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taking the drug, and the effedt started to subside as early as after 3 hours. 
In contrast to this, the effects of Tensiomin was significant only after 30 min 
but it was still significant in the 4th hour of examination.
Tensiomin
Capoten
нет
80
1mg/kg b.w.
l - H  r
_L _L
30 60 90 120 150 180 210 240
min
Fig. I . The time course of the hypotensive effect of Tensiomin and Capoten
6. Hemodynamic effects (20 patients).
Both systolic and diastolic blood pressure were significantly reduced by 
acute administration of 25 mg captopril in this study. The heart rate was also 
decreased but this reducation seemed not to be clinically significant. Since 
it became evident from the evaluation of the hemodynamic parameters that 
captopril decreased total peripheral resistance (TPR) in some patients and 
cardiac output (CO) in others, the parameters of these two groups are pre­
sented separately.
In 12 patients, in which the CO was low at baseline, captopril increased 
the CO from 3.8210.24 to 4.4710.27 liter/min and it increased the cardiac 
index from 2.3210.13 to 2.7210.16 liter/min/m2. Systolic volume in these 
patients was increased from 46.9т3.0 to 58.4 ! 2.5 ml and TPR was decreased 
from 30521268 to 22831283 dyn. sec. cm“5. The blood pressure decreased 
from 18013/11815 to 16017/104 ! 5 mm Hg and the heart rate from 8212 
to 7612 beats/min.
In 8 patients, in which the cardiac output was high, captopril decreased 
CO from 6.1910.24 to 4 7510.45 liter/min and the cardiac index from 
3.5210.17 to 2.7110.28 liter/min/m2. The systolic volume in these patients 
was also decreased by captopril from 80.213.6 to 67.17.4 but this change 
was not statistically significant. On the other hand the TPR increased from 
1630163 to 22451292 dyn. sec. cm“5. The blood pressure of these patients 
decreased from 16315/10613 to 15415/10615 mmHg and the heart rate 
from 77.512 to 7212 beats/min.
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Thus our study has shown that in hypertensive patients characterized 
by high TPR captopril decreases TPR while the fall in blood pressure in 
patients with high CO is associated by the decrease in CO. The cut-off point 
between these two groups (high TPR and high CO) was found at the value 
TPR of 2000 dyn. sec. c irr5.
The hypotensive effect of captopril was more pronounced in the group 
characterized by the high TPR (Table III).
Table III
The acute haemodynamic effect o f captopril (Tensiomin)
T P R  (dyn. sec . cm -5) C ard iac o u tpu t ( i/m in )
b efo re  after 
c a p t o p r i l
befo re a fte r  
c a p t o p r i l
High baseline 
TPR (n: 12)
3052 ±268 2286*285 3.82*0.24 447 ±0.22
High baseline 
cardiac output 
n: 8
1630*63 2245*282 6.19*0.34 4.75*0.46
7. Humoral effects (20 patients)
The acute effects of 25 mg oral dose of captopril were investigated in this 
group of patients.
The plasma renin activity was increased by captopril from 1.4340.32 to 
2.0640.53 ng Agt 1/ml/hr. The converting enzyme activity (ACE) was 
decreased from 22.6242.22 to 8.8941.36 nM/ml/min, two hours after the 
administration of captopril.
There was no correlation between the baseline blood pressure and the 
baseline PRA or baseline ACE activity (r = o.i748 and 0.2667, resp., NS). 
At the same time there was a significant linear correlation between the changes 
in mean blood pressure and PRA as well as between the changes in blood 
pressure and ACE activity (r=-o.599i, p<0.05 and r-0.6607, p<o.oi). 
There was no significant correlation between the baseline PRA and ACE 
levels or between their changes in response to captopril.
The baseline plasma dopamine level and the level after captopril were 
2.5140.44 ng/ml and 2.3940.43 ng/ml respectively. The changes were not 
significant (n = 5).
The baseline noradrenaline concentration and the level two hours after 
captopril were 0.10640.034 ng/ml and 0.13040.041 ng/ml, resp. These chan­
ges were not significant either (n = 5).
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The plasma adrenaline level was not affected by captopril. The values 
before and after the treatment were 0.130:10.044 ng/ml and 0.120 0.023 
ng/ml, resp. (n 5). (Table IV.)
Table IV
The acme and subacute humoral effects o f  captopril 
( Tensiomin)
Baseline 2nd h o u r 7th day
Plasma renin 
activity
(ng) Agt/ml/h) 0.65 ±0.15 1.05 ±0.18 2.32 ±0.73*
ACE activity 
(nM/ml/h) 22.62 ±0.15 8.87 ± 1.36* 13.62 ±2.07*
Plasma dopamine 
concentration 
(ng/ml) 2.51 ±0.44 2.39 ±0.43 3.13 ±0.36
Plasma adrenaline 
concentration 
(ng/ml) O.I3O ±0.044 0.120±0.025 o.i40±o.oi8
Plasma noradrenaline
concentration
(ng/ml) 0.160 ±0.034 0.I30±0.04I o . 2 8 o ± o . o 8 2 *
Plasma beta-endorphin 
concentration (pM) 6.61 ±0.77 7-37 ±0.62 7 . i 6 ± o . 8 6
* Significant change (p<o.05)
8. Haemodynamic and humoral effects o f treatment for one week
(5 patients)
The above mentioned haemodynamic and humoral parameters were de­
termined again following a one-week course of captopril monotherapy 
(25 mg oral captopril 4 times daily) two hours after taking the last dose. 
The blood pressure of these 5 patients was decreased from the pretreatment 
value of 161 5/108:! 4 mmHg (in the 2nd hour: 1487.4/104 7) to 144 7/
104 1:7 mmHg by captopril treatment. Heart rate was decreased from 82 3 
(in the 2nd hour: 74 4) to 78+4 beats/min. The latter change was not sig­
nificant. Cardiac output values were 5.i6±o.7 1/min before (in the 2nd 
hour:5.i5 0.42) and 5.46 0.61 1/min after treatment for one week (NS). 
Cardiac index values remained also unchanged, the values being 3.08:10.42 
1/min/m2 before (in the 2nd hour: 3.093 0.24) and 3.34 ! 0.26 1/min/nV after 
the treatment (NS), resp. TPR was gradually decreased from 2125±330 (in 
the 2nd hour 11906 ±214) to I755±839 dyn. sec. cirr5 (Table V.). Plasma
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renin activity was increased from o.85±o. 15 (in the 2nd hour: 1.05 ±0.19±) to 
2.3240.73 ngAg-l/ml/h. ACE activity was 13.62i2.07 nM/min/ml. Plasma 
dopamine level was not changed by captopril monotherapy for one week:
Table V
Acute and subacute haemodynamic effects o f captopril 
( Tensiomin )
Baseline 2nd  h o u r 7th day
Blood pressure (mmHg) 
systolic 
diastolic
161 ±5 
108 ±4
14844*
i o 4 ± 7
144 ± 7 *
104 ±7
Cardiac output 
(i/min) 5.16± 5. i5±o .4 5.6440.6*
Cardiac index 
(I  /min/m2) 3.08 ±0.4 3.О9 ±0.2 3.3440.3*
TPR
(dyn . sec . crrT5) 2I25±330 I906±2i4 17554839*
* Significant change (p<o.c>5)
3-13±о.з6 ng/ml. Plasma adrenaline level was not changed either attaining
0.14040.018 ng/ml at the end of the treatment. However, plasma noradrena­
line concentration was significantly altered. It was increased to 0.28040.62 
ng/ml (Table IV.).
9. The effect o f captopril on endogenous opioidergic mechanisms
Following a one-week drug-free period 11 patients were given 1 mg/kg b. w. 
captopril orally, and blood pressure was measured every 10 min., for 2 hours. 
Blood was drawn for beta-endorphin determination in the 60th and 120th 
minutes. Naloxone-test was performed 120 min after the oral administration 
of captopril. Subsequently the patients were given 1 mg/kg b. w. captopril 
daily in three divided doses and blood was again drawn for plasma beta- 
endorphin determination and the naloxone-test was repeated on the 4th 
day (2hours after taking the first daily dose of captopril).
The baseline blood pressure was decreased by captopril from 161 =h 5/ 
90±3 to 14344/9043 mmHg (2nd hour). Blood pressure on the 4th day did 
not differ from the value of the 2nd hour: 145±4/91 1-3 mmHg. Intravenous 
naloxone did not affect the blood pressure of these patients, thus the naloxone- 
test was proved to be negative.
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The plasma beta-endorphin levels were 6.6ÜO.77 pM : 7.27±0.90 
pM : 7.37 1 0.62 pM and 7.1610.86 pM, prior to the treatment, 1 and 2 
hours after taking captoprii and on the 4th day, resp. These differences 
were not statistically significant (Fig. 2).
Fig. 2. The hypotension induced by captoprii could not be influenced by the opiate antagonist 
naloxone. Plasma beta-endorphin level was not changed either
10. Captoprii in combination (15 patients)
Favourable results were obtained with captoprii also in combination treat­
ment. Fifteen patients were treated with captoprii by supplementing the double 
or triple combinations (beta-blocker+diuretic, occasionally vasodilatator) for 
several months. As an initial dose 25 mg was given to those patients then 
the daily dose was increased according to requirements at intervals of 2-3 
days to a daily dose of 150 mg. Eleven patients suffered from accelerated 
essential hypertension and 4 from renovascular hypertension. Of the latter 
patients blood pressure was normalised in 1 case after surgical intervention. 
Three patients -  because of inoperablitiy -  have been treated continuously. 
In 9 out of 15 patients normotension could be attained in such a way that 
the dose of vasodilatator (dihydralazine) could be significantly reduced, and 
it could de even withdrawn in 3 patients. In 6 patients the blood pressure 
could not be normalised. Captoprii elicited a significant reduction in blood 
pressure even in these patients: blood pressure became stabilized at an 
„acceptable” level (systolic value: 160-180 mmHg, diastolic value: 95-105 
mmHg. (Table VI.)
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Table VT
Changes o f blood pressure after captopril { Tensiomin) 
treatment
B l o o d p r e s s u r e
systolic diastolic
BC A C BC A C
Accelerated
hypertension 2 i 8 ± 8 172± 9 * I 2 4 ± 5  1 0 3 4 4 *
Renovascular
hypertension 2 0 5  ± 6 4 3 ± 3 * 1 2 8 4 4  9 3 ± 2 *
BC before captopril treatment 
AC = after captopril treatment 
* significant change (p<o.05)
SIDE EFFECTS
Renal or haematological side effects were not observed during the study. 
Transient dysgeusia appeared in i patients which disappeared during therapy 
approximately in 2 weeks.
DISCUSSION
It was demonstrated in this study that blood pressure was significantly 
lowered by captopril treatment. Heart rate, although moderately, was also 
decreased. In patients characterized by high TPR the decrease in blood 
pressure could be explained by TPR-lowering effect. Our results were in 
good agreement with the data of others / 1,6, 10, 11/. This effect was accom­
panied by an increase in cardiac output, cardiac index and systolic volume, 
indicating a favourable haemodynamic action. According to our studies in 
patients characterized by low TPR, cardiac output and index were decreased 
by captopril, resulting in a smaller hypotensive effect. The calculated TPR 
was increased in these patients. Similarly an increase in TPR (above the 
baseline value) following a transient decrease had already been reported 
during chronic captopril treatment /11/. At the same time, we also reported 
the decrease of cardiac output. The mechanism of this phenomenon is 
unknown. To identify its cause further examinations are needed. As it is evident 
from this study it is not associated with the acute changes of plasma catechol­
amines. The plasma renin activity was increased both in response to acute and
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one-week captopril treatment. This phenomenon is well-known and can be 
explained by the decrease of thefeed-back mechanism through the juxtaglomeru­
lar apparatus. The reduction of plasma ACE activity was also a good indicator 
of the effect of captopril in our studies. The effect of captopril on PRA and 
ACE activities may be taken as an indication of the absorption of the compound. 
We could not find any data in the literature which would help explaining the 
increase in the plasma noradrenaline concentration following one-week captopril 
treatment. A change in the noradrenaline concentration of the opposite direc­
tion could be expected because of the reduction of presynaptic facilitation by 
Agi I of noradrenaline release. This finding may be relevant in context with 
the change in the TPR but these relationships need further studies. As it was 
demonstrated in the present observations plasma beta-endorphin level was not 
altered by captopril and the hypotensive effect of captopril could not be influ­
enced by the opiate antagonist naloxone. It was reported that captopril incre­
ased the plasma beta-endorphin level of patients suffering from migraine /3/. 
In animal experiments naloxone blocked the hypotensive effect of captopril /8/ 
although negative findings have also reported /7/. Our results have lent sup­
port to the latter observation and argued rather strongly against the assumption 
that captopril would activate the endogenous opioidergic mechanisms in essen­
tial hypertension.
Comparing the effects of Tensiomin and Capoten no significant differences 
were found between them.
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The renin production, angiotensin II and aldosterone plasma levels have been proved 
to occur in heart failure. This pathological abnormalities can be stopped by the in­
hibition of ACE. This action of captopril is accompanied by a favourable clinical 
effects, the improvement of the symptoms of heart failure and the increase of so­
dium and water excretion and the increase of serum potassium level.
Keywords: ACE-inhibition, captopril, heart failure
In heart failure the pump function of the heart is altered in such a way that 
the myocardium which has genetically determined properties and is influenced 
by various factors, e.g. ischemia, degenerative processes during the course of 
life, is not further able to perform its function without compensatory mecha­
nisms because of the impairment of contraction and relaxation.
The compensation may took place by two possible mechanims:
1. The first one originates from the venous side where the raised venous 
tone increases the flow into the heart and the diastolic volume of the ven­
tricles. According to the Stalling’s principle an increase of performance (systolic 
volume, cardiac output) is possible by passive lengthening of the fibers of the 
myocardium. The volume overload usually increases the left ventricular filling 
pressure and the end-diastolic pressure (increased preload).
2. The arterial system represents the other possibility of compensation 
since the low cardiac output, weak ejection force can be partly substituted 
through the increase of vascular resistance, thus the local tissue perfusion, the 
perfusion pressure should remain adequate. However peripheral vasoconstric­
tion increases the resistance to the blood flow out of heart (increased afterload), 
which might be dangerous: from a haemodynamic point of view it is a pressure­
load; it may increase the myocardial oxigén demand through the increase of 
myocardial wall-tension and endocardial pressure. /1,7/
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A. THE MECHANISM S INITIATING THE COMPENSATORY
PROCESSES
Two important factors should be mentioned. One is the activation of the 
sympathetic nervous system; The other is the stimulation of the renin-angio­
tensin-aldosterone system. As a part of the general protective mechanism, renin 
production is increased mainly due to the decrease in renal blood flow; the 
result is high plasma renin level. One of the main effects of angiotensin II is 
peripheral vasoconstriction which increases systemic vascular resistance; it also 
stimulates aldosterone secretoin thereby causing sodium an fluid retention.
High plasma renin, angiotensin II and aldosterone levels have been proved 
to occur in heart failure; an increase of plasma noradrenaline concentration as 
an indicator of increased sympathetic activity has been verified as well.
On the basis of the above-mentioned data it is evident, that high filling 
pressure of the left ventricle, increased vascular resistance, sodium retention 
and tachycardia occuring as a part of sympathetic predominance, when reaching 
a certain level, can cause further deterioration of the primary process, thus the 
perpetuation of heart failure (Table I). /7/
It seemed appropriate to stop this process at one of essential links (renin- 
angiotensine-aldosterone) by the inhibition of ACE. It has been proved also in 
heart failure that captopril decreases the plasma level of angiotensin II and 
aldosterone. This action is accompanied by a favourable clinical effect, the 
improvement of the symptoms of heart failure and the increase of sodium and 
water excretion. The inhibition of aldosterone stimulation increases serum 
potassium level, which is of practical importance in the pharmacological 
treatment of heart failure.
Table I
Perpetuation o f heart failure
angiotensinogen
angiotensin I7 angiotensin I t ---- >  vasoconstriction
ACE
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В THE HAEMODYNAMIC EFFECTS OF CAPTOPRIL
After taking a single dose (25 mg) the haemodynamic effects of captopril appear 
in approximately 30 min. attaining the maximum response in 1-1.5 hours and 
lasting 6-8 hours. Raising the dose mainly prolongs the duration of action.
a) The mean blood pressure is decreased by 7-20% in the majority of cases. 
In patients with low cardiac output systolic hypotension may cause symptoms 
forcing the physician to decrease the dose.This phenomenon should be con­
sidered with special attention in patients treated also with diuretics.
b) The effect on heart rate deserves particular attention since tachycardia 
accompanying vasodilatation does not appear as opposed to other vasodilatators ; 
moreover, there is a significant decrease (10-14% on the average) in the heart 
rate in most cases. The increase in the sympathetic tone mediated by angio­
tensin II also fails to occur, which is also favourable effect it is an important 
factor from the point of view of myocardial oxygen demand, especially in 
ischemic heart disease.
c) Total, systemic and pulmonary vascular resistance are decreased, on the 
average by 25-30%, 20-30% and 35-45%. respectively by the drug. The sys­
temic and pulmonary vascular effects of captopril are almost identical.
d.) Captopril decreases pulmonary capillary wedge pressure, the pressure in 
the pulmonary artery and in the right atrium by 35-50%, 15-30% and 25-40%, 
respectively.
e) The favourable effect on heart performance is characterised by an 
increase of cardiac output and cardiac index, by 25-30% and 14-40%, respect­
ively.
f) The non-significant decrease in coronary blood flow and the significant 
decrease in myocardial oxygen demand have been verified by invasive studies.
g) Although only cautious administration of captopril is advised in the 
case of impaired renal function, nevertheless in heart failure the renal blood 
flow may be increased in parallel with the general improvement of circulation. 
The increase of sodium excretion and potassium retention-should be mentioned, 
too. /1, 2, 3, 6, 7/
C. THE FAVOURABLE CLINICAL EFFECT OF CAPTOPRIL 
IN HEART FAILURE
The preload and afterload reducing effect of captopril results in a decrease of 
the filling pressure and an increase of the cardiac output without any signi­
ficant changes in the heart rate, or even sometimes at lower heart rates. These 
are especially favourable in heart failure accompanying ischaemic heart disease 
since myocardial oxygen demand is decreased to a significant extent.
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In recent years many papers have been published on the favourable effect 
of captopril and the first hungarian experiences are now known, too. It is 
interesting that, according to the studies, the effect of captopril is more fa­
vourable in the more severe cases with very high pulmonary venous pressure 
values, although it can be applied in all grades of heart failure. Most authors 
have administered the drug to patients of grade III and IV severity according 
to the NYHA functional classification, who were refractory to the conventio­
nally applied diuretics or the customary vasodilatators. /4, 7, 8/
The clinical condition has improved in 80-85% of the patients treated with 
captopril :
a) General health (clinical condition) of patients improved, the severity of 
symptoms of heart failure decreased or the symptoms disappeared; the patients 
usually improved by two NYHA classes.
b) Exercise tolerance improved by 30—80%; this favourable effect was 
observed already 1-2 weeks after the administration of the drug.
c) There was a decrease of the filling pressure in the left ventricle, a decrease 
of the ventricular dimensions and an improvement of the ejection function.
The immediate, rapid effect of captopril has been sufficiently proved; the 
effect is sustained and tolerance does not develop. There are no satisfactory 
data, however about the further prospects of captopril therapy (prognosis), i.e. 
the survival of patients suffering from heart failure. /5, 7/
D. DOSAGE IN HEART FAILURE
Captopril administration can be initiated in heart failure when properly app­
lied digitalis and/or diuretic treatment has no adequate clinical effect; these 
drugs should be continued during captopril treatment.
The initial dose of captopril is 25 mg three times a day, but the dosage 
should be individualised. It means that good results may be achieved by 12.5 mg 
or even 6.25 mg doses of captopril 3 time daily. The daily maximum dose is 
350-400 mg but this requires close monitoring of the patient. In the practice 
doses higher than 50 mg 3 times daily (a daily total of 150 mg) are required 
only very rarely. Most patients respond favourably to treatment within a week.
The hypotension cccuring at the beginning of treatment may be a problem 
for the patient and may require cautions dose reduction but not drug with­
drawal. Also, the dose should be increased very slowly, at intervals of 2-3 
days.
During captopril administration potassiumsparing drugs (e.g. spirono­
lactone) should not be administered and potassium substitution in patients 
receiving diuretics should be performed with continuous blood level monitoring
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since the increasing effect of captopril on serum potassium level is well-known. 
Even the previously existing hypokalaemia may be normalised by captopril 
treatment. /6/
E. CASES REQUIRING CAPTOPRIL TREATMENT
I. Primary disease
a) all kind and forms of ischemic heart disease resulting in heart failure
b) congestive cardiomyopathy
c) myocarditis resulting in heart failure
d) valvular dysfunction accompanied regurgitation (especially in mitral 
insufficiency and aortic insufficiency)
e) prosthetic dysfunction with regurgitation after mitral or aortic valves 
replacement
2. Haemodynamic state
a) high ventricular filling pressure
b) increased ventricular end-diastolic pressure
c) volume overload
d) low cardiac output
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Tensiomin (captopril) was tested in 23 patients with chronic heart failure for 7.5 
months on the average. In 9 outpatients suffering from congestive cardiomyopathy 
the effect of Tensiomin as an adjuvant to digitalis, diuretic, vasodilator etc. was evalua­
ted by non-invasive methods. During the 3-month follow-up period the heart rate was 
decreased and the PEP/LVET ratio was improved. The parameters calculated from 
the X-ray examination (cardiothoracic index, cardiac volume index) indicated the 
regression of cardiomegaly. Radioisotopic circulatory examinations (systolic volume 
index, cardiac output index) indicated an increase in cardiac performance. In addition 
to the significant changes of these parameters the patients’ clinical state was also 
improved in all cases as assessed according to the NYHA classification. Significant 
side effects were not observed during the treatment.
Keywords: heart failure, congestive cardiomyopathy, Tensiomin treatment, 
systolic intervals, X-ray examination, radioisotopic circulatory examination
The favourable clinical effect of long-term oral Tensiomin (captopril) treat­
ment in congestive heart failure as well as the improvement of cardiac hae­
modynamics and functional capacity during such treatment have been re­
garded at least comparable to that of other vasodilators. According to the 
results obtained during prolonged follow-up, the improvement seems to be 
long-lasting /1, 2, 9, 10, 14/
In the present study 23 patients were given Tensiomin at the Hungarian 
Institute of Cardiology. At the Department of Cardiology the drug was ad­
ministered to 14 patients suffering from heart failure of various origin refractory 
to other treatment and its clinical effects were evaluated. Beside this, at the 
special out-patient department for patients with cardiomyopathy prospective 
examinations with oral Tensiomin treatment were started and carried out in 
9 patients with congestive cardiomyopathy as the most severe and progressive 
form of chronic heart failure /3,5/.
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PATIENTS AND METHODS
Of the hospitalized patients treated at the Department o f Cardiology (14 patients, mean age: 
58 years, range 32-78 years) the severe heart failure was due to previous myocardial infarction in 6 
cases, systemic and pulmonary hypertension, postoperative state after the implantation of mitral 
valve prosthesis, each in one patient and in 4 patients cardiac failure was of unknown origin (COCM). 
Six patients fell into NYHA class III and 8 patients into class IV.
Tensiomin treatment was applied as a supplementary therapy; the evaluation of the effect 
was based mostly on the changes in the clinical state and the functional class of patients. Renal 
function and serum electrolytes were regularly checked; attention was also paid to the possible 
occurence of side effects.
In congestive cardiomyopathy (COCM), the prospective studies were carried out in 9 outpatients 
under the care of the special outpatient department (1 female, 8 males; mean age: 38 years range: 
17-46 years. The diagnosis was established by the case history, physical symptoms as well as by 
non-invasive examinations (ECG, phono-mechanocardiography, X-ray, echocardiography). Heart 
catheterization was performed in 4 cases together with myocardial biopsy and coronarography.
The duration of illness of the outpatients suffering from COCM was 3.8 years (range: 0.8-7 
years); they were under the supervision of the special outpatient department of the Hungarian 
Institute of Cardiology for 3.7 years on the average (range: 0.6-6 years).
The possibility of viral carditis as an etiological factor arose in 3 cases.
The treatment was indicated in the outpatients with COCM who belonged to NYHA classes III 
and IV and in whom the disease showed rapid deterioration as judged by the clinical symptoms and 
non-invasive examinations. Of the 9 patients 5 and4 patients were in NYHA classes III and IV, resp.
Prior to treatment the following studies were performed: recording of the patients’ physical 
state and heart rate, blood pressure determination of NYHA class, ECG, phono-mechanocardio­
graphy, chest X-ray examination. Of the laboratory parameters serum potassium, sodium, creatinine, 
BUN and blood picture were determined. The PEP/LVET ratio was calculated from the systolic 
time intervals according to Weissler’s method /4, 7, 13/.
On the basis of the chest X-ray, the cardiothoracic index (CTI) (normal value: ^<0.50) and the 
cardiac volume index, calculated according to Jefferson’s method were evaluated; the latter was 
calculated by the following equation:
L x B x D x K x M  
A
the longitudinal heart diameter 
the transverse heart diameter 
the maximum diameter in depth (cm) 
ellipsoid constant 
factor of magnification 
body surface area according to DuBois (m2)
550±79 ml/m2 and 5004=79 ml/m2 values of cardiac volume index were regarded as normal in males 
and females, resp.
Of the data yielded by isotopic circulatory examinations, the resting systolic volume index 
(SVI) and the cardiac output index (COI) were evaluated, the latter being calculated by the radio- 
graphic method with precordial detection following the administration of 99 m Тс-HSA as an intra­
venous bolus of 0.37 mBq dose. Follow-up examinations included all the above mentioned studies 
after the ist week and in the ist, 2nd and 3rd month. Control examinations were performed every 
other months thereafter.
Tensiomin (captopril) treatment lasted 1-27 months (mean: 7.5 months) in the 23 patients. The 
maximum and minimum daily doses o f Tensiomin were 200 mg and 37.5 mg, resp. (75-100 mg on the 
average). The hospitalized patients received digitalis, diuretic and vasodilatator treatment according 
to their clinical state. Of the diuretics, all patients were given furosemid; the mean daily dose was 
210 mg. Five subjects received daily 100-800 mg intravenously while the others took oral daily doses 
of 80-160 mg:
The 9 outpatients suffering from COCM were given regularly digitalis and diuretics (8 patients
V =
L = 
В = 
D = 
К = 
M -  
A =
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Spironolactone) while 5 patients were given also vasodilator treatment. Two patients received anti- 
arrhythmic and I anticoagulant treatment, too.
In the 3 cases where an inflammatory process could be assumed, prednisolon (40 mg daily) 
was also given. The medication was not changed during Tensiomin treatment. When the adjuvant 
therapy was given to patients with COCM at the outpatients department, the unchanged doses of the 
previously taken drugs were supplemented by a daily dose of 3 x 25-3 X50 mg of Tensiomin.
RESULTS
The adjuvant Tensiomin treatment of inpatients allowed the starting of oral 
treatment in all cases. Digitalis and vasodilator were continued in all patients; 
apironolactone treatment was discontinued in 3 patients while potassium 
supplements were withdrawn in 1 patient. Intravenous furosemid could be 
replaced by oral administration in all cases; the mean daily dose of furosemid 
could be reduced from 210 to 110 mg, while the dose had to be increased in 1 
patient.
The changes in the NYHA functional classes were as follows: before the 
treatment, 8 patients fell into class IV and 6 into class III according to the 
NYHA functional classification, whereas after the treatment 4 patients fell 
into class III and 10 into class II.
The results of outpatient investigations undertaken in the patients with 
COCM were as follows:
Heart rate: at the beginning of treatment the mean heart rate was 
ioi.09±25.i beats/min. After oneweek treatment it was decreased to 86.2±8.9 
beats/min; the difference is significant (p<0.05). The mean values in the ist, 
2nd and 3rd months were 79.9± 16.3 (p<0.05), 78.o± 11.26 (p<0.05) and 
80.5Ü 1.1 (p<o.o5); they are all lower than the baseline value.
Blood pressure: The mean systolic and diastolic values of baseline blood 
pressure were 130.67i41.22 and 87.22ii7.16 mmHg, resp. Moderate decrease
Fig. I. Changes in the heart rate and PEP/LVET ratio during the control examinations ate th out­
patient clinic
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was observed during the study; only the mean diastolic value in the 1st week 
decreased significantly (p<o.05).
Out of the systolic intervals, the PEP/LVET ratio was calculated.
The mean baseline value was o.652±o.86. Significant change did not 
occur in the first week while the mean values in the ist (0.55540.138) and 2nd 
(о,5б5±о.2б) months were significantly lower than the baseline value (p<0.05). 
The change in the 3rd month (0.601 ±0.143 was not significant.
On X-ray examination, the cardiothoracic index (0.577740.066) showed 
cardiomegaly, characteristic to the disease. The cardiac volume index can be 
considered as a more sensitive parameter; the baseline value (i044.6±299.o 
ml/m2) of the patients was approximately twice the normal value.
The decrease in the CTI was not significant in the first week; however, it 
proved to be significant in the first (0.5464.0.053), 2nd (0.56140.551) and 3rd 
(0.54340.055) months (p<0.05).
The decrease of the cardiac volume index was close to statistical significance 
(931.34111.6) and in the 3rd month (826.64 193.7 ml/m2) (p<0.05) it was already 
significant.
The SVI value (16.7848.41 ml/m2) measured by isotopic circulatory 
method showed a marked decrease of cardiac performance in our patients as 
compared to the normal value in our laboratory (45.345 ml/m2). The increase 
was significant as early at the end of the ist week (ist week: 20.5447.95; ist 
month : 21.1947.03 ; 2nd month : 22.34410.7313rd month: 23.1247.26, p<0.05).
The value o f СО I was 1.5540.63 ml/m2 at the beginning of treatment. 
It was very low as compared to the normal value (3.540.3) but it also showed a 
significant improvement already from the first week on (ist week: 1.8040.55; 
ist month: 1.7640.37; 2nd month: 1.8740.56; 3rd month: 1.9340.62 ml/m2; 
pco.05).
The clinical state of the patients was evaluated according to the NYHA 
classification.
The changes observed in the inpatients were as follows: 8 patients belonged 
to NYHA class IV and 6 to class III. After the treatment 9 patients were 
transferred to NYHA class II and 4 to class III ; 1 patient remained in NYHA 
class IV and died later.
Of the outpatients with COCM belonging to NYHA class IV, 2 patients 
were transferred to NYHA class III and 2 to class II. The clinical state of 5 
patients in NYHA class III was also improved; they moved to NYHA class II.
Considering the very favourable effect of the drug the side effects were not 
significant. In the inpatients, a moderate impairment of renal function was 
observed in 6 subjects which was only transient in 3 cases; it was accompanied 
by significant hyperkalaemia in 2 cases. In the same patients significant hypo­
tension was also observed; and in one of these, Tensiomin had to be with­
drawn for a short period. Of the above 6 patients 5 took also spironolactone.
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Fig. 2. Changes in the cardiothoracic index (CTI) and cardiac volume index (CVI) calculated on the 
basis of the chest radiogram during Tensiomin treatment
Cardiac index Stroke volume index
Fig. 3. Changes of cardiac output index (COI) and systolic volume index (SVI) calculated from
radioisotopic circulatory studies
Changes in N.Y.H.A. 
functional c la sses
□  □
Baseline After trea tm en t
Fig. 4. Changes in NYHA classes at the end of the 3rd month
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One of the inpatients with non-operated heart defect died after temporary 
improvement.
In the outpatients with COCM side effects necessitating the adjusment of 
previously established therapy were not observed. The decrease of oral po­
tassium supplementation was necessary in one patient because of the moderate 
increase of serum potassium level.
Of the COCM patients i patient died 4 months after the beginning of 
treatment due to complications associated with the primary disease.
DISCUSSION
In Hungary experiences with long-term administration of Tensiomin in heart 
failure are rather scanty. The chronic heart failure accompanying congestive car­
diomyopathy would be an attractive field of indication for this promising drug.
In this disease surgical treatment, except for cardiac transplantation per­
formed at the final state, is out of the question. Thus, improvement of the 
patients’ clinical condition and delayment of the unavoidable progression can 
be attained only by pharmacological treatment. Recently, supplementation of 
digitalis and diuretic treatment with vasodilators has been advocated but failed 
to yield really satisfactory results /6, 15/. As shown in the present study, the 
haemodynamic effects of Tensiomin exerted through the neuroendocrine system 
seems to provide a promising novel pharmacological tool in the treatment of 
patients duffering from COCM.
Due to progressive nature of the disease, the previously administered 
drugs were not withdrawn; Tensiomin was applied in combination with these 
agents as an adjuvant. According to our experiences in the outpatient clinic 
supported by the data of complex non-invasive examinations, a rapid improve­
ment of the patients’ state could be achieved in the first week after the introduc­
tion of Tensiomin. Cardiac dilatation due to myocardial damage and the 
cardiomegaly characteristic of the disease were markedly decreased. The heart 
rate was decreased during treatment; Tensiomin had a favourable effect on the 
compensatory tachycardia. Cardiac performance as characterized by the car­
diac output was increased first of all as a result of increased systolic volume. 
Irrespective of the baseline blood pressure value, hypotension necessitating 
withdrawal of the drug occurred in one patient.
Our experiences indicated that the improvement of the patients’s clinical 
condition was associated by favourable changes in the NYHA functional 
classification and this could be verified also by objective haemodynamic exa­
minations.
It is an open question whether these favourable initial results would bring 
about a delay in the deterioration of the disease.
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The aouthors have compared the short-term effect of two captopril (ACE inhibi­
tor) preparations namely the Lopirin (SQUIBB) and Tensiomin (EGIS) and dihydrala­
zine as well as placebo in 15 patients with severe heart failure (NYHA 1 1 1  IV. class). 
In case of 8 patients with NYHA IV. functional class the short-term effect of the 
combined therapy of dihydralazine and Lopirin and dihydralazine and Tensiomin 
as well dihydralazine and placebo have been compared. The underlying disease was 
dilated cardiomyopathy (DCM) and ischaemic heart disease (1HD).
At the end of the treatment with different drugs and placebo the clinical signs of 
heart failure (complaints and physical status) and the echo and mechanocardiographic 
parameters of left ventricular function were assessed. The parameters, apart from the 
clinical signs, have been evaluated in double blind fashion.
Compared to placebo all the three drugs i.e. dihydralazine, Lopirin as well as 
Tensiomin have decreased significantly the NYHA classes, influenced favorably the 
non-invasive parameters of left ventricular function and decreased blood pressure. 
As to the dihydralazine, it improved the left ventricular ejection function and the 
clinical state of the patients with DCM in a higher degree than the two ACE inhibitors 
did. The effect of Tensiomin and Lopirin was the same in every respect. Both have 
influenced more favourable the complaints and physical state of patients with IHD 
than dihydralazine has. The left ventricular filling pressure, the double product 
(heart rate x wall tension) indicating the myocardial oxygen demand were more reduced 
in their effect than in that of dihydralazine. Unlike dihydralazine both decreased 
the heart rate. Administering one of the two ACE inhibitors to the dihydralazine 
benefical additive effects have been experienced; the NYHA classes, the heart rate, 
the left ventricular wall tension and the double product diminished.
The authors, on the bases of 'he results, consider Tensiomin and Lopirin as equivalent 
in their effect. In their opinion the administration of these drugs mean a new, efficient 
way of therapy, first of all in cases of heart failure caused by IHD. In the most se­
vere cases they suggest a trial with the combined dihydralazine-ACE inhibitor the­
rapy.
Keywords: dilatative cardiomyopathy, ischaemic heart disease, heart failure, 
vasodilator treatment, ACE inhibitor treatment, non-invasive examination.
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For decades the treatment of heart failure has been an issue of prominent 
importance in clinical cardiology /6/. The disease is progressive, has a high 
mortality rate and, as a consequence, the treatment of the patients bears severely 
on the financial and organizational resources of health care /35, 36/. The appli­
cation of vasodilator agents should be regarded as the most important thera­
peutic achievement of the last decade. Their combination with traditional 
agents (digitalis and/or diuretics) may be effective even in otherwise drug- 
resistant cases; starting therapy at an early stage of the disease usually means 
that a sustained stabilization of the patients’clinical condition can be achieved. 
Their favourable effect is apparent not only acutely but also in long-term 
studies; the state of the patients and the haemodynamic parameters being 
considerably improved. These results can be achieved both with preparations 
acting dominantly at the „arterial” or „venous” side as well as with the so- 
called balanced preparations /3, 8, 22, 13, 19/. However, the results of the 
recently performed double-blind placebo-controllcd studies put a halo to the 
initial optimisme: contrary to expectations, the sustained favourable effect and 
the significantly higher survival rate could not be demonstrated /18, 24, 25, 32/.
Based on the observation that the renin-angiotensin-aldosterone system 
has a key role in the pathomechanism of chronic heart failure a novel, indirectly 
acting vasodilator therapy with multiple mechanismes of action has been 
introduced for 8 years based on the application of an inhibitor of the enzyme 
generating angiotensin II from angiotensin 1 (ACE); this enzyme inhibitor was 
captopril /10, 16/. Captopril, in addition to reducing angiotensin levels, dec­
reases the levels of aldosterone, catecholamines and vasopressin and has an 
inhibitory effect on bradykinin breakdown /28/. The extensively documented 
therapeutic effect suggests that captopril is an important tool in the treatment 
of heart failure; thus, the attractive theoretical considerations appear to be 
supported also by clinical experience /28/.
At our department, vasodilator agents, initially dihydralazine and nitrates 
/2, 11/ have been applied in the therapy of congestive heart failure since 1976. 
The first experiences with the therapeutic application of captopril were obtained 
in 1984 when we started administering Lopirin (SQUIBB). Tensiomin (EGIS) 
was first given at the beginning of 1985. The studies to be presented below were 
aimed at comparing the effectiveness of the two ACEI preparations with each 
other as well as with that of dihydralazine which is known to reduce primarily 
the arteriolar resistance. The side effects as well as the development of tolerance 
to these preparations were also compared.
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SUBJECTS
Consecutively admitted 21 patients (18 males and 3 females) with heart failure 
of NYHA classes III and IV were enlisted. Of them 13 had DCM and 8 IHD. 
The age of patients varied from 30 to 73 years; the mean age was as high as 
53 years. In 12 patients significant mitral insufficiency was revealed; one had 
also functional tricuspidal insufficiency. All patients had sinus rhythm. Ventri­
cular extrasystoles were seen in 7 cases; their incidence did not interfere with 
the evaluation. None of the patients with IHD had unstable angina or had 
any history of myocardial infarction within six months prior to the study. None 
of the patients had hypertension or chronic renal disease. The severity of heart 
failure as assessed according to the NYHA criteria was approximately identical 
in the patients with DCM and IHD. At the same time, however, similarly to 
our earlier observations /12/, IHD patients had more markedly elevated left 
ventricular filling pressure and a slighter impairment of the ejection function as 
compared to the DCM group. The treatment of the patients, save for the 
compounds to be evaluated and only minor adjustment in the dose of diuretics 
according to the demands, remained unchanged throughout the trial.
The course o f the trial
Patients were informed about the aims and the course of trials; after having 
given their consent they were enlisted.
The first phase of the trial consisted of a 7-day stabilization period. In this 
phase the previously given vasodilator agents (nitrates and, in 12 patients di­
hydralazine) were omitted, the digitalis and/or diuretic (Henle-loop diuretics, 
ethacrinic acid or furosemid) therapy was optimized and the abnormalities in 
electrolyte levels were also normalized. In 7 cases, mexiletine was adminis­
tered to control ventricular extrasystolia. At the end of this period the parame­
ters to be detailed below were assessed.
In the second phase the short-term effects of the drugs and placebo were 
evaluated and compared. The patients, in different order, received Tensiomin, 
placebo, dihydralazine, placebo and Lopirin. The drugs or placebo were ad­
ministered orally in 3-4 divided daily doses for 12-16 days (the captopril pre­
parations were given for at least 14 days). The starting daily dose of dihydrala­
zine was 4 times 12.5 mg which was gradually increased to daily 4 x25-4 x 50 mg. 
The mean daily dose was as high as 150 mg.
The initial daily dose of Lopirin and Tensiomin was 3 X25 mg; the dose of 
the diuretics was for a few days reduced prior to this treatment. If the systolic 
blood pressure was low (100 mmHg or below) the starting dose was 12.5 mg 
3 times. The dose was increased daily or every other day until a daily total of 
100-150 mg (mean; 143 mg) was reached.
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The dose of Lopirin and Tensiomin was identical in the same patient. The 
clinical symptoms of heart failure and the parameters of left ventricular function 
were evaluated at the end of each treatment period. The application of the drug 
and the evaluation of the clinical picture was performed in an open fashion. 
When making this choice we considered that we were treating patients with 
severe heart failure whose state, according to our previous experience, could 
be affected favourably by vasodilator administration. At the same time, howe­
ver, with the exception of the patients’ complaints, the data of the physical exa­
mination and blood pressure measurements, all other parameters were evalua­
ted in a blind manner; moreover, the patients were unaware which preparation 
they were actually receiving.
The comparison of the short-term drug effects could be completed in 15 
(10 with DCM and 5 with IHD) out of the 21 patients. These 15 subjects cons­
tituted Group 1. In 6 out of the 21 patients (3 with IHD and 3 with DCM of 
NYHA class IV) there was a worsening of the clinical condition in the course 
of the placebo period and their response to dihydralazine treatment (the 3 
IHD patients) or to the administration of one of the captopril preparations 
(the 3 DCM patients) proved to be unsatisfactory. In these cases theoretical 
considerations, data from the literature /21/ and our previous, favourable 
experience prompted us to decide a combined treatment with dihydralazine 
and Lopirin or Tensiomin. To assess the potential advantage, the effectiveness 
of the dihydralazine-Lopirin and dihydralazine-Tensiomin combinations was 
compared not only to each other but also to that of the dihydralazine-placebo 
combination: thus, the combined drug treatment periods of varying order were 
spaced by a dihydralazine-placebo treatment period. In addition to the 6 pa­
tients mentioned above a treatment schedule of similar design was applied in 
2 further patients with DCM, whose heart failure had worsened during a pre­
vious phase of sustained therapy when one of them was receiving dihydrala­
zine and the other Tensiomin. These 8 patients (5 with DCM and 3 with IHD in 
NYHA functional class IV) constituted Group 2. In this group the different treat­
ment periods lasted 8-12 days; at the end of these periods, with the exception 
of the assessment of the clinical picture and the measurement of blood pressure, 
the evaluation was performed in blind fashion, as well.
Upon completion of the short-term studies the treatment that had been 
found as most favourable was given for a longer period; the results of this 
treatment will be presented in a separate report.
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METHODS
The following parameters were recorded : i ., heart rate (HR) which was determined from the ECG 
and phono-mechanochanocardiographic records, 2., mean arterial BP (MABP), for the assesse- 
mciit of left ventricular ejection function 3., the PEP/EP values calculated from the intervals measured 
by, ECG and phono-mechanocardiography and 4., the linear ejection fraction (dD%) determined by 
M-mode echocardiography, to characterize left atrial and left ventricular filling pressure 5., the 
preisovolumetric contraction periodfisovolumetric relaxation period (P/VCP/IVRP) quotient obtained 
by phono-mechanocardiographic method, 6., end-systolic was tension (ESW T), an M-mode écho­
cardiographie parameter to assess the afterload obtained by multiplying systolic blood pressure with 
the end-systolic left ventricular cavity diameter /wall diameter ratio. Its calculation was as follows:
systolic arterial pressure x/end-systolic left-ventricular cavity diameter x z '
(end-systolic left ventricular septum +• posterior wall diameter) x 2"1
7., double product, the product of heart rate and the above wall-tension parameter (ESWT) to charac­
terize myocardial oxygen demand, the clinical signs o f heart failure and the patients’ complaints which 
were evaluated by determining, 8., the NYHA class. The changes in the latter parameter during 
a given period was determined mostly on the basis of the reports given by the patients themselves.
The échocardiographie measurements were carried out by a one-dimensional device (Picker 
Echoview 80 C type). The measurements were carried out on records making correct evaluation 
possible. The records were taken at the level of the mitral valve, at 25 or 50 mm/sec chart speed. 
The polycardiographic recordings were made on a 6-channel direct recorder (Heilige EK-21 type); 
the records were evaluated at too mm/sec paper speed. Both the echo- and polycardiographic para­
meters represent the mean values resulting from at least 3 consecutive cardiac cycles. The differences 
between placebo and drug effects were evaluated by group comparisons. At the end of the respective 
treatment periods the mean and SD values were calculated; the differences between groups were 
evaluated by analysis of variance. The data obtained in the two placebo (P, and P2) and ACEI 
periods (Lopirin and Tensiomin) were pooled: for further comparisons they were considered as 
single homogenous groups. The pooling of data was statistically justified because the values of 
variables obtained in the two placebo or ACEI periods were similar and no significant differences 
were found between the groups to be pooled. The statistical calculations were performed on a “ZX 
Spectrum” personal computer, using the relevant statistical program.
RESULTS
The mean and SD values of various parameters obtained in the different drug 
and placebo periods, as well as the results of statistical comparisons are pre­
sented in tabulated form. Table 1 contains the data for the Group 1. of pa­
tients, whereas the statistical comparisons are given in Table II.
The mean arterial blood pressure was reduced significantly by dihydrala­
zine and the two captopril preparations; the reduction produced by the ACEIs 
tended to be slightly greater although the difference did not attain statistical 
significance. Tensiomin and Lopirin decreased significantly the heart rate as 
compared to the values obtained in the placebo period whereas during dihydra­
lazine treatment it did not change.
As demonstrated by the results of the echo- and polycardiographic mea­
surements, the most prominent improvement in left ventricular ejection function 
was produced by dihydralazine as compared to the placebo period; the two
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Table 1
Parameters o f non-invasive measurements at the end o f the various treatment periods
(Group I ,  15 patients)
P E R I O D D i h y d r a l a z in e P la c e b o  I . L o p i r i n ' P l a c e b o  2 . T e n s io m i n
PARAMETER
MBP, mmHg 86±8 95±io 84 ±9 9б±ю 85 ±8
HR, beats/min 94±9 95 ±8 82±7 9б±9 83 ±8
PEP/EP 0.58 ±0.092 0.77 ±0.123 о.б7±о.юз o.77± o .i24 О.б7± 0.П 2
PEP/EPI о.зб±о.043 0.48 ±0.062 0.41 ±0.041 о.4б±о.054 0.42 ±0.052
A D  % 16.1 ±4.01 I0-3±3.20 13-2± 3-5i 11.1 ± 3-43 i 3-4 ± 3-2i
Pl VCP/1VRP 0.67 ±0.103 o.79±o.i24 o . 5 8 ± o .o 8 i o.8o±o.i33 o . 5 4 ± o .o 82
end-systolic 
wall tension, mmHg 294 ±27.3 369 ± 44-4 268 ±27.1 358 ±47-1 274± 28.9
Double product, 
mmHg/min 27874± 2оз8 36104 ±4098 22408±1841 348 i o ±3872 23579 ±2208
NYHA class 2.47±o.5i6 3.6o±o .507 2.53 ±0.516 3-53 ±0.516 2.57 ±0.507
Table II
Comparison o f parameters measured and calculated during the virus treatment periods
(Group I, 15 patients)
P A R A M E T E R
M B P
m m H g
H R
b e a t s / m i n
P E P /E P
P E P /E P I
a D %
E n d - s y s to l ic  
P I V C P / I V R P  w a ll t e n s io n  
m m H g
D o u b l e
p r o d u c t
m m H g /m in
N Y H A
c la s s
Difference 
between D 
and P
p <0.02 NS
P<0.01
Pco.oi P C O . O I P<o.o5 P<0.01 Pco.oi Pco.ooi
Difference 
between D 
and C
NS P<0.01
Pco.05 
P<o 05 P<0.05 P<0.05 NS P <0.02 NS
Difference 
between T 
and L
NS NS NS NS NS NS NS NS
Difference 
between C 
and P
P<0.01 Pco.ooi
P <0.02 
P<o.o5 P<0.05 P<0.001 P<0.01 P<0.001 Pco.ooi
Difference 
between P] 
and P2
NS NS NS NS NS NS NS NS
Abbreviations: D dihydralazine; L = Lopirin; T = Tensiomin; 
C = Tensiomin and Lopirin drawn together;
P = Placebo I  and placebo 2 drawn together
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ACEls caused a slighter although statistically still significant amelioration of 
this parameter. In Figure i a characteristic captopril effect is demonstrated as 
evaluated by M-modeéchocardiographie method: the significant shortening of 
end-diastolic diameter is accompanied by a moderate (from 9 to 11%) impro­
vement in the linear ejection fraction (Figure 1). The left ventricular filling 
pressure as characterized by the PIVCP/IVRP quotient was reduced most 
markedly by the two AGEIs whereas the effect of dihydralazine was weaker 
(Fig. 2).
The reduction in the end-systolic tension i.e. in the left ventricular afterload 
was of similar extent during Fopirin, Tensiomin and dihydralazine treatment.
The indicator of myocardial oxygen demand, the double product was 
decreased most prominently by Tensiomin and Lopirin; the effect of dihydra­
lazine was less (Fig. 3).
The clinical signs o f heart failure, the complaints, i.e. the NYHA class was 
affected to a similar extent by all three drugs, as compared to the placebo: 
the improvement was approximately one NYHA class. Dramatic improvement 
by two NYHA classes was produced by both ACEls in two patients with IHD. 
In 4 out of 5 IHD patients of the group the improvement was more marked 
upon ACEI treatment; one patient responded similarly to both dihydralazine 
and the captopril preparations. Dihydralazine ameliorated more effectively the 
clinical signs in6DCM patients characterized by severe impairment of the pump 
function and significant mitral regurgitation whereas in one patient the ACEls 
proved to be more effective; 3 patients with DCM responded similarly to 
ACEls and dihydralazine. As to the response to Lopirin and Tensiomin it was 
found to be identical in all but one patients. Death did not occur during these 
treatment phases.
Table III contains the data and statistical comparisons for Group 2 of the 
patients who have received combined treatment (Table III).
As compared to the dihydralazine-placevo period, the heart rate was sig­
nificantly reduced by dihydralazine-Lopirin and dihydralazine-Tensiomin com­
bination. The mean arterial pressure tended to be lower upon the addition of 
ACEls to dihydralazine although this fall attained statistical significance only 
in the case of the Lopirin-dihydralazine combination. The ejection function, as 
it was demonstrated by both parameters used for its characterization, was not 
affected by the addition of captopril preparations to dihydralazine treatment. 
The left ventricular filling pressure as characterized by the PIVCP/IVRP 
quotient was significantly decreased by combined treatment with ACEls and 
dihydralazine.
The values for end-systolic tension and the double product during drug 
combinations are presented in Figure 4.
It is apparent that there was a favourable identical change in both para­
meters when either Tensiomin or Lopirin was added to dihydralazine therapy.
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C O N T R O L T E N S I O M I N
Fig. I. Changes in left ventricular dimension ; moderate increase of linear ejection fraction in response 
to Tensiomin. Left side : before Tensiomin administration Right side : duringTensiomin administration
Dd “end-diastolic diameter of left ventricle 
Ds “ end-systolic diameter of left ventricle
?
E
?<_>
Q.
E
-*=p<0.05 **-=p<0.01 -***= p< 0.001
Fig. 2. The effect of drugs and placebo on calculated left ventricular filling pressure in Group i. 
On the vertical axis the P1VCP/IVRP values, and the corresponding mean pulmonary wedge 
pressure values are presented. The level of significance of differences are shown too. Abbreviations: 
T = Tensiomin, P = placebo; D-= dihydralazine; L= Lopirin; mPCW' mean pulmonary wedge
pressure
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Table III
Parameters o f  nan-invasive measurements at the end 
o f treatment periods 
(Group 2, 8 patients)
P E R IO D Dihydralazine 4- 
Lopirin
Dihydralazine +  
Placebo
Dihydralazine 4 
Tensiomin
PARAMETER
MBP, mmHg 8 o ± 7 89 ±9 8 2 ± 8
HR, bcats/min 86±9 96± to 88±9
PEP/EP
AD".,
0.84 ±0.091 
14 ± 3-4
0.89 ±0.101 
13 ±2.6
0.82 ±0.084 
i5± 3-3
Pl VCP/1VRP o.7o±o.io 0.93 ±0.13 o.66±o.09
End-systolic
wall tension, 
mmHg
385±4' -6 478 ±48.3 367 ±36.1
Double product, 
mmHg/min 34320±3i23-8 46752 ±4306.3 326o8±32o8.8
NYHA class 3.25 ±0.463 3.87±o.353 3.25 ±0.463
Table IV
Comparison o f parameters calculated during the various treatment periods 
(Group 2, 8 patients)
P A R A M E T E R MBP
m m Hg
H R PEP/EP
PEP/EPI . lD°0 PI V C P / I V R P
End-systolic 
wall tension 
m m Hg
Double
product
m m H g /m in
N Y H A
class
PERIOD
Difference 
between D + L 
and D ±P
P<0.05 p <0.02 NS NS p <0.02 P<0.01 P<0.001 P<0.01
Difference 
between D+T 
and D + P
NS P<0.05 NS NS p <0.02 P<0.001 Pco.ooi P<0.01
Difference 
between D+T 
and D + L NS NS NS NS NS NS NS NS
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Fig. g. The effects of various drugs and placebo on the double product (heart rate x end-systolic wall
tension) in patients of Group i .
The crosses between the columns indicate the level of significance of differences 
Abbreviations: T Tensiomin; L Lopirin; P »placebo; D-dihydralazine
Fig. 4. Effects of various drug combinations and dihydralazine + placebo on end-systolic wall- 
tension (left side) and on the double product (right side) in patients of Group 2.
The level o f significance of differences is also presented 
Abbreviations: ESWT«end-systolic wall-tension;
D  +T = dihydralazine+Tensiomin 
D  + P dihydralazine + placebo 
D + L = dihydralazine + Lopirin
The clinical symptoms of heart failure were improved in 6 patients; the 
NYHA class became lower by one unit upon the addition of either Tensiomin 
or Lopirin to dihydralazine therapy. Out of the 5 patients with DCM and 3 
with IHD the clinical condition of only 2 patients (one with DCM and one 
with IHD) showed no improvement. No death occurred in these phases of 
trial.
When comparing the effects of the dihydralazine-Lopirin and dihydrala- 
zine-Tensiomin combinations, there was no significant difference in any of the 
observed parameters.
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LABORATORY TESTS
The BUN, serum creatinine, К and Na levels, the white blood cell count, 
urine sediment and protein content were determined before and once a week 
during the treatment with ACEIs. No significant alterations were found. The 
decrease in the white blood cell count was only moderate : in the case of Lopirin, 
from an initial mean of 6800/mm3 to a mean of 5900/mm3 by the end of treat­
ment; for Tensiomin, the value fell from 7100/mm3 to 6300/mm3The BUN and 
serum creatinine levels became moderately elevated usually by the end of the 
first week of the treatment ; at the end of the second week the values approached 
the initial figures and in 6 well-responding cases the values fell below the ini­
tial level. The favourable responses to dihydralazine treatment were characterized 
also by a fall in the BUN values.
SIDE EFFECTS
Transient fall of blood pressure occured in 5 patients; it was accompained by 
dizziness and, in one case, collapse. Of these patients, one received Lopirin, one 
Tensiomin, two the dihydralazine-Tensiomin and one the dihydralazine-Lopirin 
combination. Of the 3 patients who were receiving combined treatment 2 
responded with rapid normalization of blood pressure upon an elevation of the 
legs in the supine position and both drugs were discontinued for a brief period, 
whereas in the rest transient dose reduction proved to be sufficient.
At the beginning of dihydralazine treatment or upon increasing the dose 
of the drug 2 patients developed significant tachycardia; this tachycardia, which 
became subsequently reduced, provoked angina pectoris in one patient with 
IHD. Headache was apparent in 6 patients in the first few days of dihydralazine 
administration; in one case it persisted throughout the treatment period.
None of the side effects necessitated the permanent discontinuation of 
treatment.
DISCUSSION
The effect of vasodilators and ACEIs could be assessed by evaluating the 
changes in left ventricular function during the treatment. Other parameters 
such as the levels of hormones and endogenous vasoactive substances correlate 
rather weakly or ambiguously with the therapeutically relevant drug effect; 
sonsequently, their value in assessing and comparing the effectiveness of drugs 
is rather doubtful /28/.
In this study left ventricular function was evaluated by non-invasive 
techniques, mostly by echo- and mechanocardiographic methods. In addition
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to the well-known advantages of the non-invasive techniques, there were some 
other, special factors which prompted us to choose these methods for the present 
study. Some data in the literature /20, 29, 34/ and, incertain aspects our 
previous findings /14/ and clinical experience demonstrated convincingly that 
these methods are suitable for assessing both the systolic and diastolic func­
tions of the left ventricle, and also for the reliable evaluation of their changes, 
these are suitable for assessing and comparing pharmacological effects. More­
over, recent findings have cast some doubt as to the value of the invasive met­
hods in the evaluation of vasodilator treatment /27, 28/.
When analyzing the effects exerted on the different parameters it should 
be pointed out that the reduction of the heart rate by ACEIs and the absence 
of its change on the effect of dihydralazine is a known reaction in patients with 
severe heart failure /21, 26/. Lowering of the heart rate and, consequently, 
prolongation of the diastole, by all probabilities result in a reduction of myo­
cardial oxygen demand and an improved myocardial blood supply. At the same 
time, the heart rate lowering effect partly abolishes the favourable effect 
exerted on cardiac output.
When analysing the almost identical decreases of mean arterial pressure in 
response to the two ACEIs and dihydralazine it is important to note that the 
identical values mean higher systolic and lower diastolic blood pressure i.e. 
greater pulse amplitude under the effect of dihydralazine. This can be explained 
by the more pronounced decrease in arteriolar resistance and the higher car­
diac output caused by dihydralazine /26/.
For the assessment of the effects of the drugs on left ventricular ejection 
function, two methods, the échocardiographie linear ejection fraction and 
the polycardiographic PEP/EP quotient were used. To exclude the effects of 
any significant changes of heart rate in Group 1 the PEP/EPI value was also 
evaluated. Both methods are extensively applied for the assessment of pump 
function /20, 23, 30, 37/. The disturbing phenomenon that both parameters 
correlate only moderately with the ejection fraction determined by ventriculo­
graphy in the case of segmental wall movement abnormalities is partly com­
pensated by the fact that most patients had dilated cardiomyopathy characte­
rized by diffuse hypokinesis of the ventricular wall. Another important point 
is that our main object was not to assess the absolute values but rather to 
observe the changes of the ejection function. In agreement with data in the 
literature/26/we found that the greatest improvement in the ejection function 
was induced by dihydralazine while the effect of ACEIs was more moderate in 
this respect. Our observation that the subjective wellbeing of the patients with 
DCM related to heart failure were ameliorated more frequently and to a gre­
ater extent by dihydralazine may be partly explained by this favourable effect 
on the ejection function. It is well known that the dominant pathophysiological 
abnormality in this disease is the failure of the pump function. This insuffi­
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ciency is correlated not only with the degree of reduction of contractility, but 
according to recent data, also with the disproportionally high afterload in 
some cases (so-called afterload mismatch) /17/. Further explanation for a 
more favourable effect of dihydralazine in patients with DCM may be the 
better ejection function of patients with IHD belonging to the same NYHA 
class /12/.
However the opposite is true in case of the diastolic function, the increase 
of filling pressure dominating in IHD while being less prominent in DCM 
/12, 17/. In our patients the mean pulmonary capillary wedge pressure was in 
fact found to be higher in patients with IHD than in patients with DCM 
belonging to the same NYHA class.
The decrease of the filling pressure to a certain level is one of the main 
aims of treatment in patients with heart failure. In accordance with the results 
of other investigators /26/ in the present study both Tensiomin and Lopirin 
lowered the assessed value of this parameter to a greater extent than dihydrala­
zine. This difference can partly explain the more favourable effect of ACEIs on 
the subjective symptoms in patients with IHD. The more marked lowering 
effect of ACEIs on the filling pressure in cases where it was only moderately- 
increased, that was characteristic for patients with DCM, may result in normal 
or nearly normal end-diastolic pressures that may be unfavourably low from 
the point of view of an optimal ejection function. As in Group 1 the filling 
pressure was lowered by ACEIs by 14 mmHg it is evident that such an un­
favourable situation might have developed in several patients with DCM of 
this group. In this disease any substantial decreases of filling pressure are often 
unnecessary, moreover, unfavourable, and the less favourable effect of ACEIs 
on DCM may be explained by this effect. In our study the left ventricular 
filling pressure was measured by a polycardiographic method which proved to 
be reliable to the estimation of the mean pulmonary wedge pressure /14/. The 
value of its echo-phonocardiographic equivalent has been reported by several 
research teams and has been considered suitable for monitoring drug-effects
/1, 29/.
The main determinant of myocardial oxygen demand, in addition to 
contractility and heart rate, is left ventricular wall-tension. Its high level is one 
of the factors contributing to the progression of heart failure /17, 33/. To 
decrease it without deteriorating left ventricular function, moreover, even 
to improve the function is an important, longterm aim of the treatment of 
heart failure that may delay or even stop progression /13, 33/. Benjamin et al. 
/5/ based on pathological examinations, introduced a quotient by dividing the 
diameter of the left ventricular wall by that of the ventricular cavity, the 
decrease of which correlated significantly with the severity, progression and 
mortality of heart failure.
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The left ventricular wall tension can be measured by several non-invasive 
methods. We applied the M-mode échocardiographie method recommended by 
Quinones et al. /31/; the values and changes of the end-systolic wall tension cha­
racterizing the afterload were evaluated. This parameter considers, in addition 
to the size of the left ventricular cavity and the wall diameters, the other im­
portant component of tension, the systolic blood pressure too. The values 
correlate well with left ventricular peak tension measured by invasive methods. 
The parameter is complex indicates the ejection function of the left ventricle 
too, containing end-systolic diameters. This complexity can explain that its 
correlation with the patients’ complaints and the progression of the disease is 
possibly closer than any of the partial parameters. In line with their favourable 
effect on the afterload both ACEIs and dihydralazine significantly decreased the 
degree of end-systolic tension. The similarity of the effects of ACEIs, though 
decreasing less markedly the arteriolar peripheral resistance, to that of di­
hydralazine may be explained by their more favourable effect on end-diastolic 
diameters.
The other possible explanation is that ACEIs decrease the systolic blood 
pressure more markedly.
When considering the heart rate, the other main determinant of myocar­
dial oxygen demand, and calculating a version of the double product that involves 
the wall tension instead of blood pressure, mirroring the afterload in a more 
reliable way, the more favourable effect of ACEIs becomes unequivocal. This 
finding is in agreement with the results of direct measurements made by 
Chatterjee et al. /9/, which have shown that captopril significantly decreases 
myocardial oxygen consumption and demand while dihydralazine has no sig­
nificant effect on it. On the basis of these observations it can be concluded that 
the effect of ACEIs is especially favourable in heart failure caused by IHD. In 
such cases it is essential that a drug improve left ventricular function and at the 
same time decrease myocardial oxygen consumption. Indirectly the latter effect 
can further ameliorate the left ventricular function. The lowering of catechol­
amine level is also likely to be favourable first of all in IHD.
What is more important than the effect on any of the haemodynamic pa­
rameters is how the treatment influences the patients’ subjective well-being. 
It is all the more important to emphasize this circumstance since there is only 
a weak correlation between the effects on various parameters of left ventricular 
function and the patients’ complaints. Frequently, the significant favourable 
change in the haemodynamic data is followed by the improvement of the pa­
tients’ well-being and capacity to work only with a delay of several days or even 
weeks. The subjective component of the clinical picture thus is not directly 
correlated with the changes of the left ventricular functional parameters but is 
the result of complex processes, i.e., the improvement of peripheral perfusion 
and peripheral oxygen consumption too.
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In our study, by determining the NYHA classes, the complaints characte­
ristic of heart failure were evaluated numerically. Their decreases were almost 
identical in response to the two ACEIs and dihydralazine, however a more 
pronounced improvement of less patients with 1HD during the administration 
of ACEIs, merits attention.
It is important to note that, due to the short observation period, the fa­
vourable effect of captopril preparations might have been underestimated in 
some cases, since there are data indicating a delayed increase of their effect /7/. 
The response observed during short-term treatment should not be considered to 
be unambigously valid for the results of a long-term treatment.
The experiences obtained during combined treatment indicate that in 
cases refractory to one or the other drug their combination may have favourable 
effect. In our study we examined the response to captopril being supplemented 
to dihydralazine. Changes in case of dihydralazine supplementation to captopril 
are expected to be different. Massie and his co-workers examined the latter 
form of combination in 8 patients with heart failure /21/: the most important 
result was the further significant improvement in the ejection function when 
dihydralazine too was added. In our study by supplementing dihydralazine 
with ACEIs the ejection function was not significantly improved, however there 
were important favourable effects, i.e. the decrease of the heart rate, left 
ventricular filling pressure, end-systolic wall tension, double product and NYHA 
class. These changes, particularly those of the tension and the double product 
raise the possibility of long-term effects delaying the progression of the di­
sease, at least in cases where treatment is initiated well before the final stage of 
the disease. In this respect we should like to stress that it seems to be unambi­
gously reasonable to start the treatment soon, in NYHA class II, as opposed 
to the conventional indication when the disease is advanced, frequently intrac­
table. This is true first of all for captopril or dihydralazine monotherapy. 
At the same time, the advantage of combined treatment is emphasized by the 
circumstance that the late tolerance to dihydralazine can be explained, at 
least partly, by the activation of the renin-angiotensin-aldosterone system /22/. 
Thus, simultaneous administration of captopril may be expected to prevent 
this tolerance.
Considering the results o f the chemical and laboratory examinations they 
support the opinion that side effects rarely occur if the daily dose of captopril 
is not higher than 150 mg /28/. A rise in serum potassium level was not observed 
during the study, nevertheless aldosteron antagonists were withdrawn when 
administration of the ACEIs was started and potassium supplements were also 
discontinued or reduced to 1-2 g daily in cases where high doses of diuretics 
were used.
The most important side effect of ACEIs, especially in combination 
with dihydralazine, was the marked hypotension causing transient dizziness
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in some patients. This observation emphasizes that lower initial doses should 
be applied, the dose of diuretics should be reduced on the preceeding day 
and patients should be closely monitored for 0.5-1.5 hour after taking the 
first dose. These precautions are especially important in the treatment of pa­
tients with severe heart failure. When emphasizing the potential danger of 
hypotension we also report that most patients tolerated fairly well the fall in 
blood pressure to a systolic value between 80-90 mmHg induced mostly by 
ACEIs. This can be explained by the favourable effect of captopril on brain 
blood flow, as a consequence of which the cerebral perfusion is not decreased 
in spite of the significant fall of blood pressure /4/.
Similar mechanism ensures renal function to be unchanged despite the 
reduction in blood pressure apart from the cases with renal artery stenosis and 
renal insufficiency. Dihydralazine induced more side effects than the captopril 
products; the importance of individual treatment based on the diagnosis is 
indicated also by the observation that even angina pectoris was provoked by 
dihydralazine in IHD.
In our study we aimed at comparing the effects of the drugs and the 
conclusions we can draw are as follows: Lopirin and Tensiomin have identical 
effects, i.e. the treatment with either of them, compared to dihydralazine, 
results in a decreased heart rate, a more marked decrease of left ventricular 
filling pressure, a decrease of myocardial oxygen demand (double product), a 
less pronounced increase in ejection function. On the other hand similar 
effects could be recorded on mean arterial blood pressure and end-systolic wall 
tension. A favourable additive effect was found in several cases betwene 
dihydralazine and ACEIs.
Our results suggest an individual pharmacologic treatment of heart failure 
according to the underlying disease often characterized by special haemodyna­
mic fault. However, because of the low number of patients, first of all with 
IHD, we are not authorized to draw definite conclusions. Nevertheless, we 
think that the data presented are worth giving an impulse to further examination.
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The effect of oral Tensiomin treatment, 53.4 mg daily in 29 patients suffering from 
congestive heart failure associated with acute of chronic forms of ischaemic heart 
disease, e.g., recent and/or advanced myocardial infarction, aneurysm etc. was studied.
The acute and long-term beneficial haemodynamic effects were verified in 4 
patients by thermodilution Swan-Ganz catheterization as well. The parameters of ejec­
tion function improved moderately, while left ventricular filling pressure (PCW) dec­
reased significantly.
The balanced vasodilator effect was not accompanied by an increased myocardial 
oxygen demand. The “double product” was lowered in response to Tensiomin.
During the clinical follow-up (from 6 days to 2 years) there was an improvement 
in the NYHA functional class by an average of t.2 however 4 patients died in spite of 
combined vasodilator and dobutamine treatment.
Owing to the improvement of regional blood flow to the brain and the kidney Tensio­
min seems to be well-tolerated in patients with low arterial blood pressure. In pts with 
acute myocardial infarction and angina the critical fall of blood pressure and that 
of the coronary blood flow should be avoided by giving the drug in appropriately 
titrated.
Side effects were observed only with higher doses ofTensiomin in a small number 
of patients, i.e., transient worsening of renal function in 3 patients and dysgeusia in 2.
Our data indicate that Tensiomin treatment is effective and safe in patients 
suffering from all kinds of congestive heart failure complicating ischaemic heart 
disease.
Keywords: vasodilator treatment, -  effect on regional circulation, myocardial 
oxygen demand, acute myocardial infarction, ischaemic cardiomyopathy
It is general belief that heart failure refractory to conventional treatment is 
prognostically as bad as acute leukaemia /27/.
The use of vasodilators in the treatment of heart failure has in recent 
years provided significant results: it has improved the quality of life and the 
exercise tolerance of the patients. However, survival could not be so definitely 
influenced /25/. While treatment is effective it is palliative of nature. The
Correspondance should be adressed to 
Ádám Sz é k e ly
Department of Anaesthesiology and Intensive Care Unit Postgraduate Medical University 
H-1135 Budapest, Szabolcs u. 35., Hungary
Akadémiai Kiadó, Budapest
2 Á. Székely et al.
importance of primary and secondary prevention, the necessity of avoiding 
the development of congestive heart failure can not be sufficiently emphasized, 
especially, in the case of heart failure developing as a result of ischaemic 
heart disease. Fibrinolytic treatment and other pharmacological manipulations, 
by decreasing the size of the infarction, and also surgical interventions (revas­
cularisation, coronary angioplasty) may contribute to better results in this 
field.
In addition to the conventional vasodilator drugs, e.g., nitroprusside, 
prazosin or nitrates, Ca-antagonist, hydralazine, phentolamine, applied in the 
treatment of heart failure associated with ischaemic heart disease (IHD) the 
angiotensin converting enzyme inhibitor captopril (Tensiomin, EGIS) has been 
administered at our Department since September, 1984.
Our aim was to establish whether it is useful in the treatment of heart 
failure accompanying acute and subacute myocardial infarction. To test 
whether there was an acute haemodynamic improvement, in some patients 
a right-side heart catheterization was performed at the bedside.
M ETHODS
Twenty-nine patients (23 males, 6 females; mean age: 65.3 years; range: 49-83 years) with heart 
failure accompanying IHD have been treated with captopril at our Department since September 29, 
1984. The study was performed in the acute phase of IHD in more than half of the patients (acute 
myocardial infarction (first occurence) in 10 cases and recurrent transmural myocardial infarction 
in 6 cases) In the rest of the patients (previous infarction in 9 and ischaemic cardiomyopathy in 4 
cases) no actual ischaemic abnormality could be demonstrated.
Acute or protracted left ventricular failure was indicated also by malignant, severe arrhythmias 
refractory to therapy (ventricular ectopy in 7 and supraventricular arrhythmia in 4 cases) and by 
the findings of the physical examination (rales on both bases audible at least up to the apex of the 
scapula) and the chest X-ray examination. Clinically significant hypertension was associated with 
IHD in 7 patients; the other patients were normotensive.
The average daily dose of captopril was 54.3 mg.
Table 1
The applied doses o f captopril (Tensiomin, EGIS)
D o s e  o f  c a p t o p r i l N o  o f  P T S
2 X  12.5 = 25 mg/die 3
3 X  12.5 = 37-5 mg/die 10
2 X  25 = 50 mg/die 7
3 X  25 75 mg/die 7
4 X 25 IOO mg/die I
3 X  50 150 mg/die 1
mean = 54.3 mg/die 29
X = mean daily dose
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In patients with clinical signs of left ventricular insufficiency the treatment was started even 
during an acute ischaemic event. Doses of 6.25-12.5 mg were given initially. When the desired 
decrease in systolic pressure failed to ensue the dose was repeated within 2-3 hours. The changes 
in blood pressure (systolic, diastolic, as well as mean arterial pressure= MAP), heart rate and the 
so called “double product” ( heart rate x MAP) were measured in 20 patients at the peak effect of 
captopril (usually 3-5 hours after taking the first dose).
Thermodilution by Swan-Ganz catheterization was performed (using Edwards Fr. 7 catheter, 
Gould apparatus for the determination of cardiac output and Siemens Sirecust electromanometer). 
The filling pressure of the left ventricle and the ejection function were characterised by the pulmonary 
wedge pressure (PCW) and the so-called “stroke volume index” (SVI -cardiac index/heart rate, 
in ml/min) resp. The values determined at rest during the drug-free period 2 hours after the placement 
o f the catheter were considered as baseline values. The measurement was repeated 3 hours after 
taking 12.5 mg captopril orally. The determinations of cardiac output were repeated at least three 
times for each measurement; the values obtained were averaged when the difference of the individual 
determinations did not exceed ±15%.
In 29 cases the clinical condition of the patients was followed according to the NYHA (New 
York Heart Association) classification /11/ for 6 days to 2 years.
RESULTS
In Fig. I. the changes in the heart rate (HR), systolic (BPS) and diastolic 
(BPd) blood pressure, mean arterial pressure (MAP) as well as the “double 
product” 2-4 hou's after taking 12.5-25 mg Tensiomin are presented (acute
Doubts
product n = 20
B asal Peak effect
HR 92± 21 81 ♦ К p<001
MAP 9 8 í W 88* 11 p<0.01
BPS 129 i  21 114» 16 p <0 01
Bpd 82 î  12 75 ± 10 0 01 < p<0 05
Fig. i. The acute effects of captopril on basic circulatory parameters 
Abbreviation: MAP mean arterial pressure
BPSX = systolic, BPd = diastolic blood pressure 
HR = heart rate 
Double product = HR x MAP
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response). The mean heart rate and MAP were decreased from 92 to 81 beats/ 
min and from 98 to 88 mmHg, resp. (pco.oi). Accordingly, the double product 
(heart rate x MAP) wich has been shown to be correlated with myocardial 
oxygen demand /20/ was decreased from 9.1 x io3 to 7 x io3 (p<o.oi). More 
significant decreases in systolic blood pressure (to 80-90 mmHg) occured in 4 
patients; the heart rate was decreased even in these cases. These patients 
reported on the worsening of anginal symptoms; the cerebral perfusion 
remained at a satisfactory level in 3 out of 4 patients in spite of the low systolic 
blood pressure whereas the drug had to be temporarily withdrawn in one 
case because of confusion and cerebral hypoperfusion. Occurence of new 
arrhythmia or the aggravation of the existing one was not observed.
The well-balanced vasodilator effect i.e. the decrease of both the preload 
and afterload which is well-documented in the literature /1, 5, 6, 7, 8, 10, 13, 
16, 17, 19, 24, 25, 26, 28/ were proved by thermodilution Swan-Ganz catheri- 
zation in 4 cases.
After taking 12.5 mg Tensiomin orally the right and left-side filling pressure 
(central venous pressure or diastolic pressure in pulmonary artery and the 
PCW  pressure) decreased. The cardiac index and SVI were increased; systemic 
vascular resistance (SVR) was decreased considerably while pulmonary vascular 
resistance remained essentially unchanged.
The changes in the filling pressure (left ventricular end-diastolic pressure = 
LVEDP) and “stroke volume index” (SVI) of four patients are presented 
in Fig. 4. The left ventricular filling pressure was decreased from 29.8 to 19.2 
mmHg (—34.2%) on the average while the SVI was increased from 21.7 to 
3 1.2 ml/min (+43.8%). The decrease in the filling pressure and the improvement 
of ejection fraction dominated in 3 cases and 1 case, resp.
The NYHA functional state was improved by 1.2 classes on the average 
during the clinical follow up (5 days to two years) (Figure 5.) 8 out of the 9 
patients in functional state II at the start of the study were transferred to state II 
while one remained unchanged. Of the patients in class IV 7 were transferred 
to class II and 9 to class III, resp. Of these patients with severe condition 4 died 
in spite of the combined parenteral inotropic therapy applied, due to the 
persistent circulatory insufficiency refractory to therapy on the 6th-2 ist days 
of observation.
Of the side effects transient deterioration of renal function was observed 
in three cases, wich improved on dose-reduction. All the three were above 
75 years of age and had hypertension. The significantly decreased systemic 
blood pressure, not sufficient to sustain the renal perfusion, could provoke 
the symptoms. Dysgeusia occured in 2 patients treated with higher doses 
(100 or 150 mg daily) permanently (at least for 6 months): in the first case 
the symptom was moderate and the treatment was continued. In the other the 
dysgeusia was improved on dose-reduction.
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236/85. S A 38years 10mm/s 10mm r  20mmHg
B asa l 3h 72h
AP: 70 /  38/55 
CVP : 14 
Cl 1.75 
SVR : 2133
AP: 60/24/40 
CVP: 9 
Cl : 2 23 
SVR : 1817
AP: 60 /24 /40  
CVP 10 
Cl 2 86 
SVR: 1817
PCW 22
Fig. 2. The acute (3 hours) and short-term (72 hours) effects of 12.5 mg and 3 X25 mg Captopril resp. 
Abbreviations: AP = pressure in pulmonary artery (mmHg)
CVP = central venous pressure (water cm)
Cl = cardiac index (1/min/m2)
SVR = systemic vascular resistance (dyn x sec x cm-5)
PCW pulmonary capillary wedge pressure (mmHg)
1Л
Êи1Л
c 200
СИ
210 231
£  180 1 _____I_
Fig. 3. The acute changes of the haemodynamical parameters of a patient in response to 12.5 mg oral
captopril
Abbreviations: see Fig. 2.
SV1 = stroke volume index = С1/ heart rate, (ml,/min)
PVR = pulmonary vascular resistance (dyn. sec. cmA5)
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Fig. 4. The changes of filling pressure (LVEDP) 
and stroke volume index (SVI) in 4 patients 
controlled haemodynamically after taking 
12.5 mg Captopril
Abbreviations: LVEDP = left ventricular end- 
diastolic pressure = PCW
N.Y.H.A. functional sta te  
Before After C aptopril
Mean : 3.6 Mean . 2.4
' И □
Fig. 5. Changes in New York Heart Associa­
tion (NYHA) functionalclasses [12] after Cap­
topril treatment. (Follow up for 6 days to 
2 years)
In the acute cases there were considerable changes in serum electrolytes. 
Serum potassium levels of hypokalemic patients who have been treated pre­
viously with high doses of diuretics became normalized soon on Tensiomin- 
treatment. Hyperkalaemia (5.8 mmol/1) was observed in one case treated with 
the combination of Tensiomin and aldactone. It was an interesting observation 
that, when using the combination of Tensiomin and furosemide, serum sodium 
level was also normalized without sodium substitution in 4 patients with 
dilution hyponatraemia.
DISCUSSION
Since the first report of Gavras et al. /19/ a bulk of data, subsequently also 
confirmed by haemodynamic measurements, has accumulated on the benefits 
of the captopril treatment in heart failure refractory to conventional treatment 
/ 1, 5, 6, 7, 8, 10, 13, 16, 17, 19, 24, 25, 26, 28/. As an acute effect the left ventri­
cular filling pressure is decreased, the ejection function is improved and the 
cardiac output is increased; these changes result in a rapid improvement of 
the clinical symptoms. The increase in the cardiac output is due almost exclu­
sively to the increase of regional blood flows to the kidney and the brain, 
/15, 29/ therefore patients with relatively low blood pressure can also tolerate 
captopril. It is particularly favourable that the well-balanced effect, i.e. reduction 
of both the preload and the afterload is not accompanied by any increases in 
myocardial oxygen demand, in the double product wich is directly proportional
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to it /7, 20, 30/ or in myocardial oxygen consumption. The haemodynamic 
effects of hydralazine, prazosine and captopril and the changes in oxygen 
consumption were compared by Chatterjee et al /7/. Of the three vasodilator 
drugs, captopril produced the greatest reduction in myocardial oxygen con­
sumption (approx. 20%) wich was directly proportional to the decrease of 
oxygen demand, i.e., the double product. The coronary blood flow was pro­
portionally decreased along with the reduced demand. While the level of 
circulating catecholamines is elevated by other vasodilators it is significantly 
decreased (by approx. 30%) by captopril /5, 8, 9, 16, 23, 24, 26, 30, 31/. There 
is no rebound effect on captopril withdrawal /26/.
These unique regional myocardial effects which are more favourable than 
those of the other vasodilators allow the heart failure associated with acute 
myocardial infarction to be treated with captopril /3, 4/. The haemodynamic 
improvement is not accompanied by aggravation of the anginas and arrhyth­
mias. It is a promising experimental finding that captopril decreases the size 
of infarction in animal experiments /14/.
Combining captopril with dobutamine up to a dose of 5 //g/kg b.w./min 
may further improve the haemodynamic parameters; at higher inotropic doses 
oxygen demand is also increased, thus angina and arrhythmia may ensue /22/. 
The acute and chronic responses to captopril have been classified by Packer et 
al. /28/.
Permanent improvement can be achieved in 50% of the patients; the long­
term result is satisfactory after a transient decline of the therapeutic response 
in 15% of the patients (so called triphasic response). If the acute response 
is proper, permanent, improvement can be expected in the majority of cases; 
the appearance of late tolerance can be expected in 15% of all cases. The remain­
ing 20% respond poorly even at the beginning of treatment.
The lasting favourable haemodynamic changes, demonstrated also by 
catheterization, are accompanied by an increased tolerance to exercise and a 
considerable improvement of the NYHA functional class /1, 2, 5, 6, 8, 10, 13, 
16, 18, 24, 26, 28, 30, 32/ although mortality improves only moderately /11, 26/ 
during long-term observation.
Captopril may be effective for the treatment of heart failure refractory to 
other vasodilators /2, 18/. Due to the mechanism of action of angiotensin 
converting enzyme inhibitors, the secondary aldosterone overproduction which 
is one of the factors causing tolerance to other vasodilators does not develop /2/.
This aldosterone effect explains the positive potassium balance. Due to 
the risk of hyperkalaemia captopril in combination with potassium sparing 
diuretics should be given only with caution. Captopril normalizes the low 
sodium level in dilution hyponatraemia by more complex mechanisms /13, 
16, 21/.
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The most serious side effect is extreme hypotension occuring especially 
after the first dose. Such a response can be expected in patients who had been 
treated previously with large doses of diuretics and have relative hypovolaemia 
and may have hyponatraemia. To avoid this side effect low initial doses 
(6.25 mg), cautiously repeated according to the requirements, are advised. 
The maintenance dosage is lower than the usual doses applied in the treatment 
of hypertension: it rarely exceeds 100 mg daily in heart failure (In our cases 
the average daily dose was 54.3 mg).
Our patients improved by 1.2 classes on the average according to the 
NYHA classification. This is significantly higher than the pooled data of 
C.M.R.G. (Captopril Multicenter Research Group /6/) where an average 
increase of 0.5 class has been found as compared to placebo. The difference 
can be explained by the fact that in more than half of our patients the primary 
disease was an acute ischaemic event and the spontaneous improvement of 
pump function also contributed to the improvement of our patients’ classes. 
Further examinations in a larger number of patients would be neccesary to 
ascertain whether early vasodilator treatment improves the pump function 
also in the postinfarction period.
The present results indicate that captopril can be safely administered in 
the treatment of heart failure occuring during an acute ischaemic event. The 
balanced vasodilator effect verified also by right-side catheterization was not 
accompanied by any increases in myocardial oxygen consumption. The inci­
dence of side effects could be reduced to minimum with correct indication and 
cautious dosage.
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Chronic effects of captopril were studied in 29 patients (age, 4 months to 16 
years; mean, 6.9 years) suffering from digitalis and diuretic resistant congestive heart 
failure (CHF) or hypertension of different etiology. Twenty two patients with CHF 
(13 dilated, 4 restrictive cardiomyopathy, 5 congenital heart defects) and 7 cases 
with hypertension were treated for 1 to 31 months (mean, 9 months). The dose of 
captopril varied from 1 to 3 mg/kg/day (mean, 2.2 mg) in CHF and from 1.1 to 6.8 
mg/kg/day (mean, 3.7 mg) in hypertension. In CHF digoxin therapy was maintaned 
while the dose of diuretics could be reduced or discontinued. In 4 severely hypertensive 
patients the addition of a diuretic or beta blockers was necessary. In C H F clinical 
improvement was observed in 13 patients (59%), while there was no response in 4 
and 5 patients died. The survivors exhibited a significant decrease of the cardiothoracic 
index (p<0.05), the PEP/LVET ratio (p<0.05) and an increase of the echocardiograp- 
phic linear ejection fraction (p <0.001 ). If hypertension was present, blood pressure 
decreased in all patients (p<0.05). Captopril was well tolerated by all patients except 
one who developed anaemia. This side effect disappeared after having discontinued 
the drug.
These findings suggest that captopril is of benefit in controlling chronic CHF. 
Captopril alone or in combination with other drugs is effective in the management of 
severe hypertension.
Keywords: congestive heart failure, cardiomyopathy, hypertension, renal artery 
stenosis
The new vasodilator agents developed in the recent years have gained a 
significant role in the treatment of congestive heart failure and hypertension. 
Due to their site of action they can be applied rationally according to the 
haemodynamic state /4/. Captopril, the inhibitor of the enzyme converting 
angiotensin I to angiotensin II proved to be a potent vasodilator agent and 
was shown to be eifective even in the treatment of cases refractory to other 
vasodilators /2, 6/. There are however a few data about its pediatric appli­
cation, indications, dosage and long-term effect /1, 11/.
The aim of our study was to establish the efficacy of captopril during long­
term administration in congestive heart failure (CHF) refractory to digitalis
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and diuretic treatment and in systemic hypertension of various origin, to 
establish the effective dosage which can be well tolerated and to observe the 
side effects.
Captopril tablets of 25 mg (Tensiomin) produced by EGIS Pharmaceuticals 
were administered. The infants were treated by a powder prepared from the 
tablets.
PATIENTS AND M ETHODS
The patients were divided into two groups
1. Patients suffering from congestive heart failure of various origin
2. Patients suffering from systemic hypertension of various origin.
The distribution according to diagnoses and age of the patients is presented in Table i.
Table 1
Distribution according to diagnosis and age
D iagnosis N A ge (year) M ean (year)
DCM 13 0 . 5 - 16 7
RCM 4 6 - t6 10.3
Congenital 
heart defect
5 0 . 3 - 6 3 - 9
Hypertension 7 2 , 5 - 15 7 - 2
Total 29 0 . 3 - 15 5 - 5
Male / Female = 1.23
DCM = dilated cardiomyopathy
RCM = restrictive cardiomyopathy
In heart failure captopril was administered only in cases which were refractory to digitalis 
and diuretics, as a second choice drug. All the patients suffering from dilated (DCM) and restrictive 
cardiomyopathy (RCM) were chronic cases; subjects with acute myocarditis were not included. 
The diagnosis of cardiomyopathy was established by the clinical symptoms, ECG, X-ray examination, 
mechanography, M-mode, two dimensional and Doppler echocardiography. Of the 17 patients 10 
underwent heart catheterization an angiocardiography and in 7 patients endomyocardial biopsy was 
also performed. In 5 patients with DCM the biopsy specimen showed chronic myocarditis and myo­
cardial fibrosis. In 2 patients with RCM endocardial fibroelastosis was established by biopsy and 
later on at autopsy as well.
Of the 5 patients with congenital heart defect and CHF a four month old infant had ventricular 
septal defect and pulmonary hypertension; two little girl o f five and six years suffered from left 
ventricular dysfunction following the operation of Fallot’s tetralogy and double outlet right ventricle, 
respectively. Two little boys had congenital mitra| incompetence.
The hypertensive group included 7 patients; 3 patients had renovascular hypertension, 2 had 
generalized disease of the small arteries and 2 patients had persistent hypertension after having 
been operated on with coarctation of the aorta (Table II). Haemodynamic studies and angiography 
were performed in all patients.
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According to the hitherto published data /5, 13, 15, 16/ the administration of captopril may 
be deleterious in patients with impaired renal function, haematological disorders and hepatic dys­
function; such abnormalities were cautiously excluded. Baseline and control laboratory examinations 
were as follows: urinalysis, blood picture, serum potassium, sodium, creatinine, BUN, GOT, GPT, 
LDH, and cholesterol levels. These parameters were checked in the Arts week of treatment, then every 
other week, in case of long-term treatment once a month, then every other months. The treatment 
was always initiated during hospitalization.
Table II
Hypertensive group
;e N o A se 
(year)
Blood pressure D o se
Cas D iagnosis at the 
start
du rin g
th e rap y
m onths
m g /k g
daily
I 7-5 unilateral stenosis of renal 
artery
150/100 120/80 31 3-5
2 9 bilateral stenosis of renal 
artery
240/140 150/80 1-5 4-5
3 6.5 bilateral stenosis of renal 
artery
140/90 110/70 12 . . .
4 2-5 autoimmune arteritis 240/160 140/80 20 6.8
5 7 unknown (Recklinghausen’s 
disease)
190/115 125/80 12 5.0
6 15 postoperative state 
(coarctation of the aorta)
170/95 140/80 l 6 3-0
7 3 postoperative state 
(coarctation of the aorta)
160/120 110/70 3 1 -7
X = 7.2 pco.oi ~x = 13.6 X -  3-7
Blood pressures in mmHg
The initial dosage of captopril was 0.5 mg/kg a day divided into 2-3 doses. At the start o f treat­
ment blood pressure, heart rate and ECG were checked hourly. When the decrease of blood pressure 
in normotensive patients did not exceed 10 mmHg and dizziness, orthostatic collapse or other side 
effects did not occur, the dosage was increased every other day. The final dosage which varied in the 
different groups was reached in 7-10 days depending on the development of the desired effect. 
In hypertension an initial daily dose of 1 1.5 mg/kg was administered and the dosage was increased 
according to the level of blood pressure (Table III).
In the decompensated group the improvement of complaints, general state and exercise tole­
rance, the decrease or cessation of systemic and pulmonary congestion,the decrease or disappearance 
of the mitral or tricuspid insufficiency, the possibility of reducing the dosage of the diuretic were 
evaluated to establish the eficacy of captopril. As non-invasive parameters the changes of the cardio- 
thoracic index (CT1), the PEP/LVET ratio and the échocardiographie linear ejection fraction (EF) 
were determined. In hypertension the decrease of blood pressure was the decisive indicator. The data 
were statistically analyzed by Student’ paired “t”-test.
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Table III
The dosage o f  captopri!
D i a g n o s i s N m g / k g  d a i ly m e a n
DCM. 1 3
0 r*->1 2 . 2
RCM 4 1 . 5 - 3 - 0 2 . 6
Congenital 
heart defect
5 b 1 U> b 1 - 7
Hypertension 7 1 .1  - 6 . 8 3 - 7
RESULTS
The improvement of subjective complaints and the clinical state is presented 
in Table IV.
Five patients died due to intractable heart failure; three suffered from 
endocardial fibroelastosis and two from myocardial fibrosis. Their treatment 
lasted from 3 to 4 months, only one patient with RCM survived for 16 months. 
He presented a transitory improvement during captopril therapy.
The data of the non-invasive investigations of the 24 survivors were 
evaluated. In CHF the favourable effect could be observed after treatment for 
I or 2 weeks, however significant improvement was observed only after several 
month’s treatment.
The decrease of the CTI was significant (p<o.05). In the RCM cases this 
was not apparent; they were characterized mainly by disturbances of distensi- 
bility as well as by systemic and pulmonary congestion and not by cardiomegaly
(Fig- 0 -
Figure 2 shows the significant decrease of the PEP/LVET ratio in 16 
patients (p<0.05). In two small children the baseline values are missing because 
of technical difficulties.
Table IV
The result o f captopril treatment
D ia g n o s is N I m p r o v e d  U n c h a n g e d D i e d F o l lo w  u p  m o n t h s
DCM i j 8 2 3 3 - 2 4  
X =  7 . 5
RCM 4 I I 2 3 - 2 0  
X =  9 - 5
Congenital 
heart defect
5 4  I I — 1 0
X =  5 - 6
Hypertension 7 7 ' • 5 - 3 '
X =  1 3 6
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Fig. I. Changes of the cardiothoracic index (CTI) in patients with CHF Diff. x = — 0 . 0 4 3 ; P < 0 . 0 5
Fig. 2. Changes of the PEP/LVET ratio in patients with CHF Normal value for children is 0.31
Diff. x — 0 .0 6 3 ; P < o . 0 5
Figure 3 presents the échocardiographie EF values. The improvement 
was strongly significant (pco.ooi). In three patients the values could not be 
calculated because of the paradoxical septal movement. In some congenital 
heart defects (mitral incompetence, ventricular septal defect) and in the initial 
stage of RCM the EF can be normal in spite of the forward failure, but its 
increase is in agreement with the clinical improvement. That was observed in 
our four cases.
The patients with hypertension responded unambigously well. The 
decrease of systolic and diastolic blood pressure was significant (p<0.05 for 
both) (Table II). In three milder cases captopril alone proved to be sufficient; 
in four more severe cases combined therapy was necessary. The therapy was 
supplemented with a diuretic in three cases and diuretic+beta blocker in one 
case.
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Fig. 3. Changes of the échocardiographie linear ejection fraction (EF) in patients with CHF. Normal 
value for children is 0.34 DifT. x - 0.098 pco.ooi
Fig. 4. Effect of captopril in a case of renovascular hypertension and hypertensive encephalopathy
see text)
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In Fig. 4 the effect ofcaptopril in renovascular hypertension is demonstra­
ted in a 9 year old male patient with bilateral renal artery stenosis. He had not 
been treated previously with antihypertensive agents. Soon after his admission 
a blood pressure of 240/140 mmHg and severe hypertensive encephalopathy 
was recorded. Although intravenous nitroprusside-Na and the subsequent 
labetalol treatment were effective, the blood pressure could be stabilized only 
with captopril. The initial daily dose was 4.5 mg/kg. The dose of furosemide 
could be decreased simultaneously by 60%. Since then the patient undervent 
successful operation.
Side effect was observed only in one patient who developed progressive 
anaemia during three months’ treatment. This side effect disappeared after 
the drug having been discontinued. The gradually increased doses were well 
tolerated by each age-group. In normotensive patients the fall in blood pressure 
did not exceed 10 mmHg. The laboratory examinations showed normal 
values throughout the study; proteinuria, reduced renal function, leukopenia 
did not occur.
DISCUSSION
The mechanism of action of captopril is complex /3, 5, 16/. As the inhibitor 
of ACE its effect is exerted partly through the renin-angiotensin-aldosterone 
system. It decreases the angiotensin II production and as a consequence, 
aldosterone secretion is also reduced. The converting ezyme is identical 
with the kininase II which catalizes the degradation of bradykinin. Thus the 
inhibition of ACE facilitates the activity of prostaglandins, too. Due to the 
decrease of angiotensin II levels, sympathoadrenergic activity is also reduced. 
All these changes contribute to the marked peripheral vasodilation.
Captopril exerts its effect mostly on the arteriolar system (decrease of 
afterload) but it acts also on the venous side (decrease of preload). Its favourable 
effect is manifested especially in the decrease of peripheral vascular resistance, 
the increase of the ejection fraction and cardiac output, as well as the reduced 
pulmonary capillary pressure /1 ,4, 6, 8, 10/. Due to the decrease of aldosterone 
production, sodium and fluid retention is less pronounced which is favourable 
both in congestive heart failure and hypertension.
Captopril has been found to be effective also in adult cases of heart 
failure refractory to other vasodilators. Tolerance does not develop /2, 6/. 
The drug has been shown to favourably influence the regulation of regional 
blood flow. The blood flow to the kidney and brain is increased by captopril, 
while this is not apparent in the vascular system of the liver and the limbs /8/. 
However the results of acute pharmacological studies are not always in agree­
ment with the long-term effects /9, 10/. Occasionally, the favourable effect
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appears only after treatment for several months. The increase of exercise 
tolerance, the decrease of cardiomegaly and the improvement of the clinical 
state are regarded as best indicators of success in long-term therapy /6, 9, 12/.
In the present study the long-term effect of captopril was analysed; we, 
too, found that the above mentioned parameters were the most characteristic 
indicators of therapeutic benefit. The usually modest improvement of pump 
function in our patients is explained by the very severe, sometimes premortal 
disease.
The hypertensive patients responded invariably well to the treatment. 
In more severe cases, instead of raising the dosage of captopril adjuvant 
diuretic or beta blocker treatment was administered as it has been recommended 
for adults /13, 15, 16/. Renal insufficiency caused by captopril has also been 
reported in renovascular hypertension /7/; however, its administration is 
considered to be favourable by others /3, 14/. In our three cases satisfactory 
clinical response was observed; there was no indication of drug-induced 
impairment of renal function.
The side effects are mostly dose-dependent; when using lower doses 
(below 150 mg in adults) they are infrequent and, if present, they disappear 
on dose-reduction /4, 13, 15, 16/.
The question arises as to the proper timing of the initiation of vasodilator 
treatment. According to observations in humans and data of animal experiments 
vasodilator treatment may induce regression of myocardial hypertrophy and 
result in a sustained favourable effect through the reduction of tension of the 
left ventricular wall /5/. It is possible that, when having more experience with 
this therapy, we shall administer it more frequently and at earlier stages.
Comparing our experience with the data in the literature on the pediatric 
applications of captopril /1, 11/ it appears that the administration of this drug 
is reasonable in the following cases: acute and chronic myocarditis, dilated 
cardiomyopathy, severe mitral and aortic regurgitation, congenital heart 
defects with large left-to-right shunt and postoperative left ventricular failure; 
thus in general, low cardiac output syndromes with normal blood pressure 
(increased peripheral resistance) and the combination of low cardiac output 
with pulmonary congestion. It is also indicated in hypertension of various 
origin.
One has to keep in mind that captopril influences only the course of the 
disease, therefore the possible causal therapy should not be delayed.
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The effect of captopril treatment on natural killer activity and mitogen-induced 
lymphocyte blastogenesis was studied in man. No significant change in immune reacti­
vity was found either in short term (one hour after ingestion of 25 mg) or long term 
(after two weeks, 50 mg daily) treatment.
Keywords: captopril, NK-cell activity, mitogeninduced blast transformation
Captopril, an inhibitor of angiotensin converting enzyme, affects the kal- 
likrein-kinin-prostaglandin system /10, 13, 15/, thus influencing inflammatory 
processes. The molecular structure of captopril is similar to that of penicillamine, 
a drug with known antiphlogistic properties. Although D-penicillamine has 
been used for many years in the treatment of rheumatoid arthritis, the mecha­
nism of its action remains obscure /3/. Both compounds influence mitogen­
induced blastogenesis in vitro /4, 7, 11/. D-penicillamine — by means of its 
thiol group —scavenges free radicals produced by phagocytes /1, 12/; a possible 
mechanism of action of captopril may also be suggested.
Captopril, similarly to penicillamine, has been shown to be effective in the 
treatment of rheumatoid arthritis /9/. In scleroderma renal crisis, captopril 
was found to be beneficial /8, 14, 16, 17/.
We studied the immunosuppressive effect of captopril in vitro and in
vivo.
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MATERIALS AND METHODS
Patients
Four patients with progressive systemic sclerosis were treated with 50 mg captopril (2x25 mg) 
daily. Blood was drawn immediately before starting therapy, and after 2 weeks. Twelwe healthy 
subjects were involved in another study. Their blood was drawn before and after 1 h of ingesting 
25 mg captopril.
Lymphocyte proliferation assay
Mitogen-induced lymphocyte blastogenesis was performed using the “whole blood assay” , as 
described earlier /2/. The 3H-thymidine incorporation of cells was measured after 72 h in culture, 
and was expressed as counts per minute (cpm). The mitogens, phytohaemagglutinin (PHA; Leukoag- 
glutinin, Pharmacia), and concanavalin A (Con A, Pharmacia) were used in concentrations of 2, 10, 
and 25 ug/ml.
Natural killer (NK) cell activity
NK cell activity was measured according to the method of Jondal and Pross /5/ with minor modi­
fications /61 using 51Cr-labelled K.-562 targets and 50:1 and 25:1 effector to target cell ratios in a 4 
hour assay. Cytotoxicity was expressed as citotoxicity index (Cl%)
RESULTS AND DISCUSSION
There was no significant change in mitogen-induced blastogenesis after the 
oral intake of 25 mg captopril (Table I). Similarly, there was no change in 
NK activity or blastogenesis after 2 weeks of treatment (Table II). In these 
tests no immunosuppressive effect of captopril was demonstrated. A more 
detailed study, including its free-radical scavenging potential, is required to 
elucidate its exact immunological mechanism of action.
Table 1
Effect o f  captopril on lymphocyte transformation 
( I h; mean cpm + /— SEM )
M ito g e n
T a k i n g  t h e  d r u g
b e f o r e I h  a f t e r
2/ig/mI PHA 3850+/-7 9 0 4420+/—980
10 /ig/ml PHA 6230+/—1120 8160+/—1340
25 /ig/ml Con A 2810+/—865 3980+/—1019
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Table II
Effect o f captopril treatment ( j о mg daily for 
two weeks) on NK activity and lymphocyte 
transformation (mean+j — SE M )
T e s t
2  w e e k s  o f  t r e a t m e n t
b e fo re a f t e r
NK activity (CI%)
(25:1) 6.8+/—2.1 6 .3 + /-1 .7
NK activity (CI%) 
(50:1) 11.9+/-2.3 16.2+/-3.7
Lymphocyte transformation (cpm) 
2|Ug/mlPHA 5520+/—1237 
iO|Ug/mlPHA 11456+/ —2322 
25 |Ug/ml Con A 7824+/ —2089
4830+/—1786 
11 г 23 + /—3562 
7410+/-2546
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TENSIOMIN®
12.5 , 25, 50 and 100 mg in tablets 4051/8/A
The renin-angiotensin system plays an important role in the regulation 
o f blood pressure. Its dysfunction contributes to the development and 
maintenance o f hypertension of various etiology. The activity o f this 
pressor system is significantly lowered by the inhibitors o f angiotensin 
convent ing enzyme such as the active substance o f Tensiomin, capto prit, 
which inhibits the conversion o f angiotensin / to angiotensin II and thereby 
prevents the formation o f the most potent vasoconstrictor substance o f  
organism.
It can be combined andventageously with other antihypertensive agents. 
Unlike the other vasodilators, it does not cause volume retention or 
tachycardia. In certain forms o f hypertension (e.g. renovascular hyper­
tension, renal crisis o f scleroderma) it is the first choice agent.
A CT I V E  S U B S T A N C E :  12.5, 25, 50 
and 100 mg captopril in tablets
I N D I  C ATI O N S : - essential hyperten­
sion (even the forms resistant to other anti­
hypertensives); malignant hypertension
- renovascular hypertension (in inoperable 
cases alone or in combinations especially 
with Ca-antagonists, beta-blockers or diure­
tics)
-  in emergency cases of hypertension if 
nifedipine is not available or is not effective 
enough, sublingual Tensiomin (chewed) may 
be administered
- renal crisis of scleroderma
- in elderly hypertensives or hypertensives 
with bronchial asthma it is the first or se­
cond choice agent
-  in hypertensives with diabetes mellitus it 
is the first or second choice agent
-  heart failure (cases refractory to digitalis + 
diuretic)
-  in certain form of cardiomyopathy (con­
gestive cardiomyopathy)
- as diagnostic tool in renovascular hyper­
tension and Conn syndrome.
C O N T R A I N D I C A T I O N S :  Absolute: 
pregnancy, lactation (if the administration 
can not be avoided the lactation should be 
discontinued)
Relative: leuko- and thrombopenia
A D M I N I S T R A T I O N :  It should be in­
dividualized.
Hypertension : Usual dosage for adults: initial 
dosage 12.5 mg 3 times daily. If the decrease 
of blood pressure is not satisfactory after 
2-day’ treatment the dosage may be raised 
to 50 mg 3 times daily. For further reduction
of blood pressure thiazide type diuretic, 
beta-blocker and/or other vasodilator (Ca- 
antagonist, prazosin, dihydralazine) may be 
administered.
The incidence of side effects is significantly 
increased over a daily dose of 300 mg but 
the blood pressure lowering effect is not 
increased thus is not recommended to ex­
ceed this dose-level.
Renovascular and renoparenchymatous hyper­
tension : 6.25—12.5 mg 3 times daily.
The maintenance dose may be gradually 
increased to 25 mg 3—4 times daily; doses 
higher than that are rarely required.
In case of reduced renal function, the maxi­
mum daily dose;
C r é â t n i n e  c l e a r a n c e Dose
mgml/min/m2 ml/sec /m2 ml/sec*
80-41 1 .33— 0.68 2 .31- 1.18 300
40-21 0 .66- 0.35 1 .15— 0.61 150
2 0 - 1 1 0 .33— 0.18 0 .57— 0.31 75
10 0.17 0.29 37.5
* The value calculated on the  averave adul t body surface (1.73 m 2)
Heart fa ilure: Initial dosage: 6.25 mg 3 times 
daily; it should be increased gradually.
In pediatry: It should be used in well-es­
tablished cases (especially in renovascular 
and renoparenchymatous hypertensions). 
Recommended daily dose; 1—2 mg/kg body 
weight.
The tablets should be taken 1 hour before 
meals. The therapy should be started by a 
specialist of internal medicine in hospitali­
zed patients, if possible.
When treating out-patients, the effect of 
the first dose (6.25 or 12.5 mg) should be 
measured: blood pressure should be me­
asured at 30—minute’ intervals for 3 hours. 
Thereafter, a rather frequent control of 
patients is needed in order to establish 
the adequate dosage.
The doses of other drugs administered in 
combination should be adjusted individu­
ally.
S I DE EFFECTS:  In case of usual dosage 
(50—150 mg a day) the incidence of side 
effects is very low. Higher doses do not 
increase the effectiveness but the side 
effects become more frequent.
The potential side effects are as follows:
-  proteinuria which may be accompanied 
by membranous glomerulopathy; nephrosis 
syndrome
- neutropenia/agranulocytosis due to mye­
loid hypoplasia with secondary infections
- rash, rarely angioneurotic edema, flus­
hing
-transient, more severe hypotension es­
pecially in patients with heart disease 
treated previously with diuretics.
Very rarely tachycardia, chest pain, palpita­
tion (especially in volume depleated pa­
tients)
-  loss of appetite, dry mouth, metallic, salty 
taste (it disappears spontaneously in the 
2nd and 3rd month of the therapy), aphtous 
ulcers on the oral mucosa, nausea, vomiting, 
peptic ulcer, cholestasis, abdominal pain, 
diarrhea, constipation.
- headache, dizziness, sleep disturbances, 
paresthesia
- increase of hepatic enzyme, blood urea 
nitrogen, creatinine and potassium values in 
the serum, false positive urine keton-test. 
The side effects are more frequent in pa­
tients with autoimmune discorder therefore 
the regular control of blood picture and 
renal function is recommended.
D R U G  I N T E R A C T I O N S :  Concomi­
tant administration with drugs increasing 
the serum potassium level (e.g. potassium 
sparing diuretics such as spironolactone, 
amiloride, triamterene) should be avoided 
(risk of hyperkalemia).
It can be combined with caution 
-  with diuretics in volume depleted pa­
tients or in the presence of Ca-antagonists 
its effectiveness is increased.
T R E A T M E N T  O F  O V E R D O S ­
AGE:  The hypotension can be treated 
with intravenous infusion of normal saline. 
Captopril can be removed from the circu­
lation by hemodialysis.
WARNINGS:  In case of more severe 
renal impairment the dosage should be 
started with lower doses (6.25 mg 3 times a 
day) and the increase should be carried out 
with caution.
Prior to therapy then once a month protein 
excretion should be determined. If the pro­
tein excretion exceeds the value of 1 g/day 
or it is increasing the continuation of the 
treatment should be considered. (The 
appearance of proteinuria may be expected 
in the first 8 months of the therapy, thus 
from the 9th month the urinary protein 
should be checked only in every third/ 
sixth month).
Salt and/or volume depleted patients should 
be treated with extreme caution since the 
hypotensive effect is enhanced because of 
the increased renin-release. During the
initiation of treatment hypotension occurs 
more frequently in patients with heart 
failure following the first doses so the initia­
tion should be performed in hospitalized 
patients. In patients treated previously with 
diuretics the recommended initial dosage is 
6.25 or 12.5 mg 3 times a day. White cell 
count should be checked once a month in 
the first 3 months of the therapy then in 
every third month. In patients with auto­
immune disorder white cell count should be 
checked in every second month.
When the white cell count is below 4x10’/l 
(4000/тт3) differential counts should be 
performed. It the number of neutrophils is 
lower than 1 x10’/l (1000/mm3) the therapy 
should be discontinued.
If the first symptom of infection appears 
blood count should be checked at once.
If hypotension occurs during surgery it 
should be corrected by volume expansion. 
The patient should be informed:
-  when edema or infection occurs the pa­
tient should consult a physician.
- t o  warn the patient against the disconti­
nuation of treatment without the physicians 
advice
-  to avoid extreme physical effort or in­
creased dehydration (perspiration, vomit­
ing, diarrhea).
EGIS PHARMACEUTICALS, Budapest, Hungary
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